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 Protein folding is an essential  molecular process for cellular function, and protein misfolding is 
associated with a large and increasing number of human diseases. A hallmark of many protein 
conformational disorders is the appearance of insoluble protein aggregates or inclusions, also referred to 
as amyloid, as occurs in Alzheimer’s disease, Parkinson’s disease, Huntington’s diseases, amyotrophic 
lateral sclerosis and ataxias. Although the initiating aggregation-prone protein for each disease differs in 
sequence, function and expression pattern, the appearance of aggregates represents an early event 
associated with an imbalance in protein homeostasis, or proteostasis, and cellular toxicity. Despite great 
advances in the genetic  and patho-physiological characterization of these diseases, the cause of toxicity is 
still not entirely understood. In particular, whether protein aggregates are directly pathogenic, incidental, or 
protective has become a topic of great interest. While many studies have indicated a correlation between 
aggregates and toxicity, others have suggested that large inclusions correlate poorly with onset and 
severity of neurodegeneration and could have a protective function.
 Upon protein misfolding, the strategy employed by the cell  to restore balance invokes many 
processes to alter expression, concentration, conformation, activity, and localization of proteins, 
readjusting “the innate biology of the cell” through the activation of stress responses. Genetic  screens 
performed in model organisms have identified a large number of modifier genes of protein aggregation, 
including molecular chaperones, proteasome subunits, components of the autophagy machinery, and the 
stress-induced regulators DAF-16 and HSF-1. Nearly all  studies to date have focused on genetic modifiers 
that enhance aggregation, leading to the discovery of processes that maintain protein homeostasis. Rather 
than focusing on the cause of toxicity for a specific  disease, or on the cellular components responsible for 
protein folding and clearance, the studies presented in this thesis took a distinct and novel approach. The 
tractable genetic model organism Caenorhabditis elegans, expressing aggregation-prone YFP-tagged 
polyglutamines (polyQ), was employed to perform a genome-wide RNA interference (RNAi) screen for 
suppression of protein aggregation. The purpose of this screen was to identify genes that, when knocked 
down by RNAi, enhanced the cellular capacity for protein folding, leading to suppression of aggregation 
and toxicity.
 In Chapter I, an overview of the literature relevant for these studies is described, including a 
description of the quality control  machinery and stress response pathways employed by the cell to combat 
protein misfolding and toxicity. An introduction to diseases of protein misfolding and aggregation, model 
organisms used in the study of disease, and genetic screens for modifiers of protein homeostasis, are also 
included. Finally, a brief commentary on the current advances in the field of genetics and chemical  biology 
for the development of therapeutics is presented.
 Chapter II describes the genome-wide RNAi screen performed in C. elegans for suppression of 
polyglutamine aggregation, to identify new modulators of proteostasis. The results revealed that 
aggregation suppression could be genetically uncoupled from the effect on toxicity. A set of secondary 
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screens was then strategically carried out to identify the genes that represented the most robust modifiers 
of homeostasis maintenance. That is, genes that when downregulated activate protective cellular 
processes that enhance the capacity for folding and suppress misfolding, aggregation and toxicity, of both 
heterologous proteins, as well as endogenous metastable proteins. The gene-modifiers identified, not 
previously linked to quality control, revealed new genetic mechanisms to restore cellular proteostasis.
 Chapter III introduces one of the genes identified in the screen, encoding GEI-11. This work 
explored the relevance of neuronal  signaling on post-synaptic protein homeostasis, in particular how 
cholinergic  signaling can be modulated to produce opposite effects on post-synaptic muscle protein 
folding. This study demonstrated that within a defined range of signaling modulation, increase in neuronal 
cholinergic  stimulation of muscle cells can activate the transcription factor HSF-1 and expression of 
chaperones, through a calcium-dependent mechanism, restoring folding and muscle function. The 
neuronal  cell non-autonomous regulation of proteostasis is relevant for many diseases of neuro-muscular 
dysfunction.
 Chapter IV integrates the results described in the previous chapters, and also results presented in 
the appendices. It is also discussed how the approach taken and the results obtained contribute to the 
understanding of the cellular processes that maintain proteostasis and that can be modulated/targeted in 
disease scenarios. Finally, it is discussed how the combination of genetic  and chemical  (small  molecules) 
modifiers of proteostasis and stress responses is relevant for the development of therapeutics.
 The appendices included in this thesis describe (I) the development of fluorescence correlation 
spectroscopy tools to analyze the biophysical  properties of soluble oligomeric and insoluble aggregated 
protein species formed in vivo; (II) the new proteostasis modulator LET-607, a new modifier of ER and 
cytosolic stress responses; and (III) a small  molecule screen for proteostasis regulators, validated in cell 
and animal models of diseases of protein conformation.
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‘Genetic Screens in C. elegans for 
New Modulators of Protein Homeostasis, with Relevance for 
Conformational Diseases’
SUMMARY
 Protein folding is an essential cellular process, required for proper molecular and cellular function. 
The cell  has evolved as a sophisticated machinery that ensures the quality and stability of the proteome. 
The network of cellular processes that coordinates protein synthesis, folding, trafficking and clearance, and 
determines the fate of proteins that do not acquire a native conformation, is responsible for maintaining 
protein homeostasis (proteostasis) and is referred to as “the proteostasis network” (PN). The key 
components of the quality control system are molecular chaperones that ensure proper folding under 
physiological and stress conditions. To restore homeostasis, the PN also relies on stress sensors and 
inducible pathways, such as the heat shock response (HSR), the unfolded protein response (UPR) and the 
oxidative stress response. How a protein folds and acquires its native conformation is a matter of high 
medical relevance since a large number of human diseases are associated with protein misfolding. These 
conditions are broadly classified as conformational disorders, and they are caused either by genetic 
mutations that cause protein misfolding and premature degradation (e.g. Cystic Fibrosis and Gaucher’s 
disease); or by the accumulation of misfolded, aggregated and/or fibrillar protein inclusions that are toxic to 
the cell. In particular, the phenomenon of protein aggregation is a hallmark of a large number of 
neurodegenerative diseases (e.g. Alzheimer’s, Parkinson’s and Huntington's diseases and several 
ataxias), muscular dystrophies, metabolic disorders and certain types of cancer. Considerable efforts have 
been directed at dissecting of the mechanisms of protein aggregation and toxicity, but the full extent of 
events leading to cell  dysfunction is still unclear (Chapter I). The unifying aspect of conformational 
disorders is, however, the inability of the PN to respond efficiently to misfolded and aggregation-prone 
proteins so as to prevent cellular toxicity. Therefore, it is urgent and relevant to multiple diseases to identify 
genetic modifiers that enhance proteostasis function and consequently prevent protein aggregation and 
toxicity. Research has benefited from powerful model systems that recapitulate important aspects of the 
human disease. In particular, the nematode Caenorhabditis elegans (C. elegans) is a tractable genetic 
model organism that combines sufficient complexity so as to allow research on both cellular and 
organismal  (including behavioral) phenotypes, with simplicity that facilitates rapid, high‐throughput testing 
of hypotheses (Chapter I). Genetic  screens performed to date have identified the network’s protective 
components which, when knocked down or deleted, lead to enhanced aggregation and/or toxicity. These 
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include molecular chaperones, proteasome subunits, components of the autophagy machinery, and the 
stress-induced transcriptional regulators FOXO/DAF-16 and HSF-1. 
 The work described in this thesis is novel as it focuses on the opposite side of the PN, i.e., the 
pathways that when down-regulated lead to enhanced folding capacity. We established a screening 
strategy in C. elegans using RNA interference (RNAi) to identify genetic modifiers that suppress protein 
aggregation and toxicity of multiple disease-related proteins (Chapter II). Our goal  was to identify genes 
that, when downregulated, enhanced the functional properties of the proteostasis network and restored the 
folding environment. We thus identified 63 genetic modifiers that suppressed both polyglutamine (polyQ) 
and mutant superoxide dismutase I (SOD1) aggregation, of which only 23 also suppressed the toxicity 
phenotype associated with aggregation. This was an important finding as it demonstrated that aggregation 
and toxicity can be genetically uncoupled. From the initial  hits, 9 modifiers systematically reduced the 
misfolding of endogenous metastable mutant proteins, suggesting a general improvement of the folding 
environment. We postulated that this effect could be a consequence of activation of the heat shock stress 
response and chaperone expression by the modifiers. Although, we found that 5 improved folding in a 
HSF-1/chaperone dependent manner, the remaining modifiers improved folding by altering metabolism 
and RNA processing functions. Overall, this study introduced new genetic modifiers that promote alternate 
cellular folding environments broadly protective against misfolding events. 
 We then characterized further the genetic  modifier gei-11, a negative regulator of the L-type 
acetylcholine receptor (AChR) at the neuromuscular junction, to determine the mechanism of proteostasis 
enhancement (Chapter III). Downregulation of gei-11 increased cholinergic  signaling and calcium flux into 
the cytoplasm of muscle cells, via activation of the voltage-gated calcium channel, EGL-19, and the 
sarcoplasmic reticulum ryanodine receptor, UNC-68. This resulted in selective activation of HSF-1 and up-
regulation of cytosolic  chaperones that restored the post-synaptic  folding environment. Earlier work had 
identified a loss-of-function deletion mutation in unc-30 that regulates GABA expression in C. elegans 
neurons, and resulting in enhanced polyQ aggregation in post-synaptic muscle cells (Garcia et al. 2007). 
Notably, enhanced aggregation occurs when GABAergic signaling is completely inhibited, resulting in 
maximum cholinergic  overstimulation of muscle cells, whereas suppression of aggregation results from a 
moderate increase in cholinergic  signaling. The effects of increased AChR expression are not the same as 
complete inhibition of GABA signaling, in part because the signaling response (and degree of stimulation) 
occurs at an intermediate level through a titrated response and waves of Ca2+ release. Therefore, the 
effect on post-synaptic protein aggregation is a consequence of the degree of imbalance generated 
between ACh and GABA, with an apparent range for folding improvement by cholinergic  signaling. We 
propose that altogether these studies underscore the importance of the balance between cholinergic and 
GABAergic signaling as a mechanism for non-autonomous neuronal regulation of proteostasis in post-
synaptic  cells, and provide compelling evidence that will  lead to a better understanding of the control of 
stress responses through tissue signaling events, which is very relevant for a number of neuromuscular 
disorders.
 We have also initiated the characterization of the hit gene let-607 (Appendix II). This gene is 
predicted to encode the C. elegans ortholog of CREBh, an ER regulated transmembrane protein (RIP) 
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bZIP transcription factor that maintains sterol homeostasis in the liver and mediates UPR. Downregulation 
of let-607  in C. elegans led to an improvement of proteostasis function through activation of the HSR, up-
regulation of molecular chaperones and consequent suppression of protein misfolding, in an HSF-1- and 
XBP-1-dependent manner. UPR induction was found to be epistatic  and required for HSR activation by 
let-607 RNAi. This is not observed for other UPR inducers, revealing specificity of “crosstalk” between the 
two stress responses through let-607. Currently, we are further characterizing the role of let-607 on UPR 
and the mechanism involved in UPR-mediated activation of the cytosolic HSR.
 The studies presented in this thesis emphasize the value of genetic  screens and model organisms 
for the identification of genes and pathways that maintain protein homeostasis and are compromised in 
disease. Our screening strategy and triage hypotheses revealed novel genes/pathways that can be 
modulated to improve the PN capacity and help resolving the issue of protein aggregation-toxicity. Even 
greater value is offered by complementation of these genetic studies with small  molecule screens to 
ultimately identify the suitable targets for therapeutics. This is highlighted in the work on “Chaperone 
Therapeutics: Small Molecule Proteostasis Regulators of the Heat Shock Response for Protein 
Conformational  Diseases” (Appendix III). In this work we describe the results of a ~900,000 small molecule 
screen that identified small  molecule proteostasis regulator compounds (PRs) that induce HSF-1-
dependent chaperone expression and restore protein folding in multiple conformational  disease models. 
The enhancement of proteome stability by the PRs is mediated by HSF-1, DAF-16/FOXO, SKN-1/Nrf2 and 
the chaperone machinery, through mechanisms that are distinct from current known small  molecule 
activators of the HSR. Together, genetic  and chemical modulation of the PN reveal new candidates and 
new mechanisms to be targeted by PRs, establishing promising therapeutic  approaches for a variety of 
protein conformational diseases.
KEY WORDS: 
Protein Misfolding; Neurodegenerative Diseases; Proteostasis; Stress Response; Chaperones
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 O folding proteico, processo pelo qual proteínas adquirem a sua conformação correcta, é 
essencial para o bom funcionamento molecular e celular. Assim, as células possuem um sofisticado 
mecanismo de controlo de qualidade do proteoma (i.e., a totalidade das proteínas da célula num dado 
instante). O conjunto de vias celulares que coordena a síntese, o folding, o tráfego e a degradação de 
proteínas, e que determina o destino de proteínas que não adquirem a conformação correcta, é 
responsável  por promover e manter a homeostase proteica celular ("proteostasis network" ou PN). Os 
componentes principais deste sistema de controlo de qualidade são os chaperones moleculares, 
responsáveis pelo folding de proteínas quer em condições fisiológicas quer sob stress. A PN utiliza 
sensores e vias induzidas por stress para restabelecer a homeostase, como é o caso da heat shock 
response (HSR), da unfolded protein response (UPR) e a resposta ao stress oxidativo. O processo de 
folding, e o modo como cada proteína adquire a sua conformação nativa funcional tem uma enorme 
relevância clínica uma vez que existe um elevado número de doenças provocadas por misfolding proteico. 
Estas patologias são genericamente designadas por ‘doenças de conformação proteica’, e podem ser 
causadas por mutações que impedem uma dada proteína de adquirir a conformação correcta, o que leva 
à sua degradação prematura (ex: Fibrose Quística e doença de Gaucher); ou então podem ser a 
consequência da acumulação e agregação de proteínas na forma de inclusões ou fibras amilóides que 
são altamente tóxicas para a célula. O fenómeno de agregação proteica é característico de doenças 
neuro-degenerativas (ex: doenças de Alzheimer, Parkinson e Huntington e várias ataxias), distrofias 
musculares, doenças metabólicas e certos tipos de cancro. Têm sido desenvolvidos esforços 
consideráveis na investigação dos mecanismos responsáveis pela agregação, toxicidade e sintomas 
clínicos destas doenças, no entanto ainda existem muitas questões em aberto (Capítulo I). O aspecto 
comum entre as doenças de conformação proteica é, no entanto, a incapacidade das células ou da PN de 
resposta eficiente face à presença de proteínas com tendência para agregar, de modo a evitar a 
respectiva toxicidade. Assim, uma alternativa para fins terapêuticos à identificação da causa de toxicidade 
em cada doença em particular, poderá ser a identificação de moduladores genéticos que alteram e 
principalmente que melhoram a capacidade funcional da PN, consequentemente prevenindo agregação e 
toxicidade. Este tipo de trabalho tem tido imenso sucesso através da utilização de organismos modelo que 
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apresentam fenótipos relevantes para estas patologias. Particularmente, o nemátode Caenorhabditis 
elegans (C. elegans) oferece inúmeras vantagens em termos de facilidade de manipulação genética, 
estudo de fenótipos celulares e organismais (incluindo comportamentais), e possibilidade de ser usado em 
high-throughput screens genéticos (Capítulo I). Os screens genéticos executados até a data identificaram 
já os principais componentes da PN com função protectora os quais, aquando se reduz a sua expressão, 
levam ao aumento de misfolding e agregação proteícos e/ou toxicidade. Tais componentes da PN incluem 
chaperones, componentes das vias de degradação, como o proteasoma e autofagia, e os factores de 
transcrição FOXO/DAF-16 e HSF-1 que participam na resposta a stress celular.
 O trabalho descrito nesta tese é inovador pois foca numa outra vertente da PN, ou seja, os 
componentes cuja redução da expressão leva a uma melhoria do folding global. Assim, foi estabelecida 
uma estratégia de screening em C. elegans, utilizando RNA de interferência (RNAi) para identificar 
moduladores genéticos que reduzem a formação de agregados e a toxicidade de múltiplas proteínas 
(Capítulo II). O objectivo deste trabalho foi  identificar novos factores que, quando negativamente 
regulados por RNAi, melhoram a função da PN e consequentemente aumentam o folding. Foram 
inicialmente identificados 63 moduladores/RNAi  que reduziram o fenótipo de agregação no modelo de 
expressão de poliglutaminas (polyQ) e da superóxido dismutase 1 mutante (SOD1). Destes, apenas 23 
moduladores genéticos reduziram o fenótipo de toxicidade. Este resultado demonstra que os processos 
de agregação e toxicidade não têm de estar necessariamente acoplados. Por último, pusemos em 
evidência que 9 destes moduladores corrigiram dum modo consistente o folding de várias proteínas 
mutantes endógenas, extremamente susceptíveis a misfolding, sugerindo que os genes identificados são 
moduladores gerais do folding proteíco. Propusémos entāo que este efeito seja uma consequência da 
expressão de chaperones e outros componentes do controlo de qualidade celular que promovem folding. 
 De facto, o efeito de 5 destes genes parece ser dependente do factor de transcrição HSF-1 e do aumento 
da expressão de chaperones. Os restantes parecem afectar o folding através de alterações metabólicas e 
de processamento de RNA. Em conclusão, este trabalho identificou novos moduladores de homeostase 
proteica, os quais actuam de forma a promover um novo “ambiente celular” que propicia uma maior 
capacidade de folding.
 De seguida, caracterizou-se o mecanismo pelo qual o modulador genético gei-11 melhora a 
capacidade de folding (Capítulo III). Mostrámos que a redução da expressão do gene gei-11, descrito 
como sendo um regulador negativo do receptor de acetilcolina tipo-L (L-AChR) na junção neuro-muscular 
de C. elegans, aumenta o sinal colinérgico nas células musculares, activando os canais de cálcio na 
membrana (EGL-19) e o influxo do cálcio para o citoplasma através do retículo sarcoplásmico. 
Subsequentemente, verificou-se que ocorria a activação da HSF-1 e a expressão de chaperones que, por 
sua vez, assistem o folding de proteínas e minimizam agregação. Por ouro lado, tinha já sido descrito que 
a deleção do gene unc-30, que regula a via de síntese e secreção de GABA em células neuronais de C. 
elegans, intensifica a agregação de poliQ nas células musculares (Apêndice II). De notar, é o facto do 
aumento da agregação ocorrer apenas quando o sinal GABAergico é completamente eliminado, o que 
resulta em estimulação colinérgica máxima das células musculares. Por outro lado, a redução no número 
de agregados resulta dum “aumento intermédio” de actividade colinérgica. O aumento de expressão de 
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AChR através do gei-11/RNAi não é assim equivalente à total inibição do sinal GABAérgico, uma vez que 
no primeiro caso o efeito é de nível intermédio e com oscilação nos níveis de cálcio. Assim, a alteração 
dos níveis de agregação e uma consequência do grau de desequilíbrio entre ACh e GABA, com um 
aparente limite para efeito positivo no folding proporcionado por ACh. Deste modo, s duas componentes 
deste trabalho revelam que o equilíbrio entre o input neuronal GABAérgico e colinérgico é essencial para 
regulação da proteostase no músculo, e aparentemente revelam um limiar para a melhoria do folding por 
parte da sinalização colinérgica. Estes resultados também revelam assim duma forma clara as vias de 
comunicação entre o sistema nervoso e muscular, que se reveste de extrema relevância para um conjunto 
de doenças neuromusculares.
 No Apêndice III são também brevemente descritos os resultados da caracterização do modulador 
genético let-607. Prevê-se que este gene codifique o ortólogo do gene humano CREBh, um factor de 
transcrição associado à membrana do retículo endoplasmático (RE) e responsável pela regulação dos 
níveis de esteróis no fígado, bem como pela regulação da UPR. Observou-se que a redução da 
expressão de let-607 conduz à activação da UPR e da HSR, à expressão de chaperones dependentes de 
HSF-1 e XBP-1, e consequentemente uma melhoria do folding proteico. De notar que a UPR ocorre de 
forma epistatica relativamente à HSR, sob a acção do RNAi  contra o gene let-607. Os resultados sugerem 
uma especificidade de comunicação (“crosstalk”) entre as duas vias de stress UPR e HSR, que é regulada 
pelos níveis de let-607. Presentemente, a função do let-607 na UPR e o mecanismo de activação da HSR 
pela UPR estão a ser caracterizados.
 O trabalho apresentado nesta tese sublinha o valor dos screens genéticos em organismos modelo 
para a identificação de novos factores e vias que contribuem para a homeostase celular. A estratégia de 
screening e o método de triagem aqui aplicados revelaram componentes específicos da PN que podem 
ser modificados com o objectivo de reduzir o fenótipo de agregação e toxicidade proteíca. Estes estudos 
genéticos podem ser complementados por screens de pequenas moléculas (“small molecules”) para 
identificação de compostos que sirvam de base para o desenvolvimento de novas terapêuticas. Este é o 
foco do trabalho publicado no artigo “Chaperone Therapeutics: Small Molecule Proteostasis Regulators of 
the Heat Shock Response for Protein Conformational Diseases” (Appendix IV). Nele é descrito o resultado 
dum screen de ~900.000 moléculas, a partir do qual foram identificados novos reguladores de proteostase 
(PRs) que activam a HSF-1 e a expressão de chaperones. A exposição de modelos celulares e animais de 
doenças de conformação proteica a estes PRs reduziu o misfolding de múltiplas proteínas e as 
respectivas consequências fenotípicas. Verificou-se que o melhoramento da capacidade de folding é 
regulado por HSF-1, DAF-16/FOXO, SKN-1/Nrf-2 e chaperones. No seu conjunto, este estudo revelou 
novos moduladores genéticos e químicos das vias de proteostase, os quais apresentam potencial 
terapêutico (por exemplo, os PRs) para várias doenças causadas por proteínas com conformações 
prejudiciais à célula/organismo.
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1. PROTEIN FOLDING 
 Proteins are conformationally complex and versatile macromolecules, responsible for the majority 
of cellular functions. It is therefore not surprising that cells have evolved an elaborate machinery to ensure 
the quality and proper function of the proteome. Protein folding is a multi-step physical process by which a 
polypeptide chain acquires its native and functional  three-dimensional structure, according to the 
information contained in the amino acids sequence, and partly dictated by attractive and repulsive forces 
between neighboring amino acids [1-4]. The energy component of protein folding can be illustrated by a 
funnel-shaped landscape representing the multitude of conformations populated by a given protein en 
route to the native state, via intra-molecular interactions (Figure 1). The free energy decreases as the 
native folded state is acquired, towards a minimum global energy and higher thermodynamic stability [3]. 
There are multiple energetically accessible paths going downwards the folding funnel, some with local 
energy minima that can trap the protein in kinetically stable “off-pathway” conformations that can drive 
inter-molecular interactions and formation of amorphous aggregates, or instead, ordered cross-β-sheet 
fibrillar structures, called amyloid (Figure 1) [1-3,5-7]. To prevent these events, protective mechanisms are 
in place to assist in the proper folding or degrade misfolded proteins [1,8]. Together with the synthesis and 
clearance machinery, molecular chaperones are the central  components of the cellular quality control  (QC) 
system that preserves protein homeostasis under normal and stress conditions (Figure 2). How proteins 
fold into a native and functional  structure is a matter of great medical relevance, as protein misfolding can 
lead to a growing number of human diseases. Likewise, the mechanism by which misfolded proteins are 
Figure 1: Energy landscape of protein folding 
and aggregation. A folding ‘funnel’ landscape 
depicts the number of energy pathways and 
intermediate conformations allowed to a given 
protein, en route to the lowest minimum energy and 
highest stability native state. Alternatively, due to 
aberrant but stable intermolecular interactions 
between unfolded intermediates, aggregation can 
occur. The width of the funnel represents entropy of 
molecular interactions, and the depth represents 
energy (adapted from [1]).
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recognized, processed and ultimately degraded by the cell to avoid toxicity and disease are a topic  of 
extensive research.
1.1. Quality Control Machinery
 To ensure fidelity of gene expression at the post-translational level, the cell possesses a stringent 
QC system that ensures the coordination between gene transcription, protein synthesis, folding, trafficking 
and repair. To surpass all QC checkpoints, a protein must reach the correctly folded state. When proteins 
fail  to attain their native conformation or damage occurs, a triage system comes into place to repair and 
refold proteins, or to promote degradation and avoid accumulation of misfolded and potentially toxic 
proteins (Figures 2 and 3). Furthermore, the cell employs folding sensors and enzymes that covalently tag 
proteins with molecules such as glucose, mannose or ubiquitin, for recognition by the folding and 
degradation machinery, respectively [9]. 
 Cytosolic Molecular Chaperones
 Surveillance of protein conformation is the primary function of molecular chaperones that ensure 
proper folding under normal physiological  conditions and under cellular stress. Molecular chaperones are 
highly conserved proteins ubiquitously expressed in all cell  types and cellular compartments that, by 
definition, interact with and assist a non-native protein to acquire its native conformation, without being 
present in the final functional structure (Figure 2). Notably, most molecular chaperones were first identified 
as genes induced by stresses that alter protein stability, such as exposure to elevated temperatures (heat 
shock), being therefore referred to as heat shock proteins (Hsps) [10]. Chaperones are grouped into 
families according to molecular mass (KDa) and sequence homology, and include Hsp100, Hsp90, Hsp70, 
Hsp60, Hsp40 and small  Hsps (sHsp). Each chaperone family varies in size, substrate specificity, 
distribution into subcellular compartments, and cohort of co-chaperones that modulate chaperone-
substrate specificity. Protein folding in the cytosol  relies on a group of ribosome-associated chaperones 
that stabilize nascent polypeptide chains to initiate folding, the primary “control check-point”, and then on a 
second group of chaperones that complete the folding process [4,11]. Ribosome-associated chaperones 
include the bacterial  trigger factor (TF), and the eukaryotic ribosome-associated complex (RAC) and 
nascent-chain associated complex (NAC) [1]. Other chaperones recognize and bind to the yet unfolded 
polypeptides to continue proper folding, assist in intracellular trafficking, or direct proteins to proteolytic 
degradation [1,10,11]. The Hsp70 family members participate in protein co- and post-translational folding 
and translocation [1,10]. Hsp70 chaperones, both constitutive and stress-inducible, ensure proper folding 
through cycles of substrate binding and release in an ATP-dependent manner [1,10]. Co-chaperones and 
nucleotide exchange factors (NEFs) act in concert with the Hsp70 machinery to increase substrate-binding 
efficiency, specificity, and release, by modulating various steps of the ATPase cycle and interactions with 
other QC components [1]. Hsp40s are a family of chaperones with a signature J domain related to the E. 
coli  DnaJ protein, that function as Hsp70 co-chaperones to stimulate ATP hydrolysis and stabilize Hsp70-
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substrate binding. Chaperonins, such as Hsp60, the E. coli  GroEL, and the eukaryotic  TRiC (TCP-1 ring 
complex) or CCT (chaperonin containing TCP-1), are large double-ring multimeric  complexes that 
encapsulate protein substrates (cage-like structure) to substantially accelerate the rate of folding through 
ATP-regulated cycles [1,4,10]. The Hsp90 chaperone is fundamental  for the structural  maturation of 
specific client proteins involved in signaling processes (e.g. glucocorticoid receptor), transcription and cell 
cycle control  [12]. The Hsp100 family is a large family of ATPase Associated with diverse Activities (AAA+) 
chaperones, described to associate with proteases or with Hsp70, to assist in protein disaggregation and/
or degradation [10,13-15]. The sHsps are chaperones of molecular masses ranging from 15 KDa to 40 
KDa, with a conserved α-crystallin domain, that bind as dimers to misfolded proteins to prevent 
aggregation, without requiring ATP. 
 The Endoplasmic Reticulum Folding Environment
 The endoplasmic reticulum (ER) has many functions, including lipid storage, calcium (Ca2+) 
homeostasis, biogenesis of organelles, protein folding and QC, and protein degradation [9,16]. 
Chaperones operating at the ER have an essential role in the maturation of proteins destined for the 
Figure 2: Molecular chaperones and the quality control machinery. Molecular chaperones facilitate protein folding 
and prevent misfolding. Chaperones are represented in all cellular organelles, and in addition to folding reactions, 
regulate other cellular processes, such as autophagy, vesicle fusion, signal transduction, apoptosis and proteasomal 
degradation. AIF, apoptosis-inducing factor; ER, endoplasmic reticulum; ERAD, endoplasmic reticulum-associated 
degradation; HSF1, heat shock transcription factor 1; HSP, heat shock protein; LAMP, lysosomal-associated membrane 
protein; ROS, reactive oxygen species. Figure from [308].
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secretory pathway. The milieu of the ER differs from that of the cytosol  in respect to ions, redox conditions, 
complement and concentration of chaperones and folding enzymes, providing an optimized environment 
for folding efficiency, disulphide bond formation and multi-domain protein assembly [9,16,17]. The ER 
chaperones include the Hsp70 family members BiP and Grp170 (Glucose-related protein); Hsp40 family 
members (ERdj1-5); one Hsp90 family member Grp94; and the lectin chaperones calnexin (CNX) in the 
ER membrane and calreticulin (CRT) in the ER lumen that assist the folding of proteins carrying 
monoglucosylated N-linked glycans. In addition, thiol-disulphide oxidoreductases and peptidyl-prolyl 
isomerases (PPIases) enzymes catalyze oxidation, isomerization and reduction of disulphide bonds 
[9,16,17]. The ER QC is a “retention-based system”. BiP, CNX and CRT, among other chaperones, serve 
as retention anchors, inhibiting the secretion of incompletely folded or misfolded proteins. If a protein is 
permanently misfolded or if it stays bound by chaperones for a prolonged time, it is targeted for ER-
associated degradation (ERAD) and retro-translocated back into the cytosol for degradation by the 26S 
proteasome (Figure 2) [9,16-18]. This type of quality control is problematic when mutant, yet (partially) 
functional, proteins are retained and degraded because of (minor) structural defects, failing to reach their 
proper cellular location, leading to disease. Proteins that leave the ER enter vesicles for protein export into 
the Golgi complex and secretion. ER resident proteins  that escape this secretory route contain an ER-
retention signal at the C-terminus, such as the KDEL sequence (lysine-aspartate-glutamate-leucine). 
 Protein Clearance
 The proteolytic  machinery manages the clearance of misfolded, damaged and aberrant proteins. It 
also contributes to replenish the intracellular reserve of free amino acids to sustain protein synthesis 
(Figure 3) [8,19]. Protein degradation in eukaryotic  cells is carried out by two major proteolytic  systems: the 
ubiquitin-proteasome system (UPS) and the lysosomal  system [19]. The proteolytic process occurs in a 
sequence of common steps: cargo selection and tagging, cargo recognition and delivery to the proteolytic 
entity, and degradation. Proteins destined for degradation by the UPS are first tagged by covalent 
conjugation of multiple molecules of ubiquitin (Figure 2) [20]. The conjugation of ubiquitin is orchestrated 
by the activity of three enzymes: E1, the ubiquitin-activating enzyme; E2, the ubiquitin-conjugating 
enzyme; and E3, the ubiquitin-ligase. E3 ligases can function in cooperation with the Hsp70 or Hsp90 
chaperones to facilitate recognition of misfolded client proteins [8,19]. The 26S proteasome is a highly 
conserved multi-catalytic  ATP-dependent protease complex with two main subunits: the catalytic  20S core 
particle (CP) and the regulatory particle (RP: 19S and 11S). Substrates are recognized via ubiquitin 
receptors, de-ubiquitinated by specific  enzymes (DUBs), and then unfolded for threading through the 
narrow barrel-like proteolytic chamber [8,19]. 
 Lysosomes are the main components of the autophagy proteolytic  machinery. These single 
membrane vesicles contain a variety of proteases, lipases, glycases and nucleotidases in an acidic lumen 
environment that facilitates unfolding of proteins and proteolysis [8,19]. Macroautophagy participates in 
degradation of both cellular organelles and proteins, under basal or stress conditions. Cytosolic  cargo is 
sequestered into autophagosome vesicles that fuse with lysosomes where degradation of the cargo 
occurs. In turn, microautophagy is characterized by direct sequestration of cytosolic cargo by the 
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lysosomes. Finally, chaperone-mediated autophagy (CMA) of cytosolic  proteins requires the recognition of 
the target substrate by a cytosolic  chaperone, complete unfolding and subsequent targeting to a surface 
receptor on the lysosome. CMA is mostly activated in response to stress. 
 The chronic  expression of misfolded proteins, often associated with conformational disorders, 
leads to saturation of the QC and degradation machinery and results in accumulation of insoluble, 
aggregated and potentially toxic  species (Figure 3). Aggregates of certain pathogenic  proteins, although 
positive for ubiquitin and cargo recognition molecules, still  fail  to be recognized by the autophagy or 
proteasome machinery, which suggests failure in the clearance function as a possible contributor to 
pathogenesis [8,21]. In certain situations however, cells seem to recruit misfolded species into large 
protein inclusions as a protective mechanism against aberrant interactions with other cellular components, 
and to facilitate autophagy-mediated clearance [21-23]. The degradation of aggregated proteins by 
macroautophagy has been shown to be protective in cell and mouse models of Parkinson’s and 
Huntington’s diseases [19,21,24-27].
1.2. Cell Stress Responses
 ‘Stress’ is defined as a noxious factor that causes harmful alterations in the cellular environment, 
triggers a series of molecular events and ultimately affects protein homeostasis. Acute forms of stress 
include environmental fluctuations in temperature (heat or cold shock), osmolarity, hydration and nutrient 
availability; chemical insults, such as oxygen free radicals and heavy metals; bacterial  and viral infections, 
ischemia, or injury. Alternatively, protein homeostasis is perturbed by a chronic form of stress consisting of 
persistent expression of mutant, misfolded and/or aggregated proteins (Figure 3). Aging is also considered 
Figure 3: Protein folding homeostasis. Protein homeostasis is maintained by a delicate balance between proper 
folding of proteins and efficient removal of damaged proteins. Under certain conditions, proteins misfold and adopt 
alternate intermediate conformations. Molecular chaperones recognize non-native states and assist in (re-)folding. 
The proteasome system degrades both normal short-lived and abnormal misfolded proteins. Impairment in protein 
folding homeostasis, due to genetic mutations/perturbations or environmental stressors, leads to increase in 
misfolding events and accumulation of aggregates, leading to cellular toxicity. Adapted from [10].
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a form of chronic stress that results from a gradual accumulation of deleterious modifications in nucleic 
acids, proteins, lipids and carbohydrates. The increase in Hsp levels during aging, without any other 
source of external  stress, is an indication of intrinsic  age-related stress [28]. Little is still known about the 
differences between molecular mechanisms that sense and respond to acute vs. chronic stress. In 
general, activated stress responses up-regulate chaperones for restoration of protein homeostasis, mainly 
by facilitating refolding, preventing accumulation of misfolded and toxic proteins, and by promoting 
degradation [1,21]. The folding environment is monitored within each compartment through specific 
pathways [29]. Whereas stress perturbation of the cytosolic  folding environment selectively activates 
cytoplasmic chaperone expression, interference with ER or mitochondrial folding preferentially activates 
expression of ER- and mitochondria-localized chaperones, respectively. 
 The Cytosolic Heat Shock Response
 The heat shock response (HSR) was discovered in 1962 by Ferruccio Ritossa, who reported a 
puffing pattern in polytene chromosomes of the fruit fly Drosophila buschii upon heat shock [30]. A decade 
later it was established that this pattern corresponded to the activation of genes encoding heat shock 
proteins [30]. The heat shock family (HSF) of transcription factors mediate both basal  and stress-induced 
expression of chaperones. Whereas S. cerevisiae, D. melanogaster and C. elegans have one HSF, 
vertebrates have multiple and, in particular, humans have three: HSF1, HSF2 and HSF4 [31-34]. HSF 
family members are comprised of an amino-terminal  helix-turn-helix DNA-binding domain (DBD), an 
adjacent coiled-coil  trimerization domain responsible for activation-induced trimerization, and a regulatory 
domain (RD) that together with the transactivating domain is essential for responsiveness to stress [34,35]. 
HSF1 is constitutively expressed in most tissues and cell  types, is the main transcriptional regulator of 
chaperone expression and the only HSF known to be active during stress [31,36,37]. Transcriptional 
activation of human HSF1 has been well  characterized (Figure 4). Briefly, under physiological conditions 
HSF1 is predominantly localized in the cytoplasm in a monomeric inactive form, and interaction with Hsp70 
and Hsp90 has been proposed to maintain HSF1 in a repressed state [38-40]. Upon stress stimuli, Hsp70 
and Hsp90 are recruited to interact with misfolded proteins, releasing HSF1. Then a rapid cascade of 
events takes place, starting with HSF1 translocation to the nucleus, trimerization and binding to consensus 
sequences named heat shock elements (HSE) in heat shock gene promoter regions, and transcriptional 
activation of chaperone expression to combat protein misfolding (Figure 4) [34,35,41-43]. In mammalian 
cells, post-translational modifications of HSF1 are a determinant for transactivating potency and later 
repression of HSF1 activity, and include acetylation, phosphorylation and sumoylation (Figure 4). HSFs 
also participate in development, differentiation and growth [35]. The non-stress related roles of HSF1 
include maintaining the stability of the proteome during cell cycle, embryonic  development, cellular 
differentiation, cell growth, and spermatogenesis (reviewed in [34]). Of particular interest is that elevated 
levels of HSF1 have been detected in several  types of human cancer, such as breast cancer and prostate 
cancer, probably as a consequence of high proteotoxicity and and demand for chaperone function in these 
cells [35]. Moreover, the stress response may also be somewhat cell-type specific, as studies have 
identified disparate sequence of events leading to activation of HSF1, specifically in neurons. Levels of 
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HSF1 expression, activity, and Hsp expression are reduced in certain neurons in comparison to other cell 
types, which may be related to the apparent susceptibility of neurons to the expression of aggregation-
prone proteins and neurodegenerative disease incidence [10,44]. 
 ER and Mitochondria Unfolded Protein Responses
 Accumulation of unfolded and/or misfolded proteins in the ER lumen causes a homeostatic 
imbalance and ER stress. A signal transduction pathway transmits information about the folding status in 
the ER to the nucleus for expression of ER-resident chaperones and other QC genes, in a process 
referred to as the ER unfolded protein response (UPRER) (Figure 5) [45-48]. In eukaryotes, the most 
immediate response to ER stress is the reversible and transient attenuation of mRNA translation to reduce 
the protein load that enters the ER. Then, as general  translation repression is relaxed, signal  transduction 
pathways are set into motion to mediate expression of ER chaperones, by UPR executors IRE1 (inositol-
requiring protein-1), PERK (protein kinase RNA-like ER kinase) and ATF6 (activating transcription factor 6) 
(Figure 5). IRE1 is the most conserved branch of the UPR [47], and encodes a type 1 ER transmembrane 
protein with a lumenal and a cytoplasmic domains, with a Ser/Thr protein kinase and endoribonuclease C-
terminus domains. The most recent studies on IRE1 activity propose that, under physiological conditions, 
BiP binds to IRE1 in the ER lumen and maintains the protein in an inactive monomeric state. Upon stress, 
BiP is recruited to misfolded proteins and releases IRE1, leading to its dimerization, cluster formation and 
activation (Figure 5). Direct interaction of unfolded proteins with the IRE1 stress-sensing domain in the ER 
lumen may also be involved in IRE1 cluster formation [46,47,49]. IRE1 trans-autophosphorylation triggers 
IRE1 RNase activity, which undertakes the unconventional splicing of the mRNA encoding the basic 
leucine-zipper (bZIP) transcription factor XBP1 (X-box binding protein 1 in mammals and metazoans) or 
Hac1 (homologous to ATF/CREB1 in yeast) (Figure 5) [45]. The spliced form (sXBP1) translocates to the 
nucleus and activates gene transcription by binding to UPR-specific  promoter sequences (UPRE/ERSE) 
on genes involved in protein folding and ER QC [45,46]. ATF6 is an ER transmembrane bZIP transcription 
Figure 4: HSF1 activation and attenuation 
cycle. Under normal conditions, HSF1 is a 
monomer in both the cytoplasm and nucleus and 
it interacts with Hsp90 (and Hsp70). Upon stress, 
Hsp90 dissociates from HSF1, allowing 
trimerization and binding of HSF1 to HSEs in Hsp 
genes. Phosphorylation (P) and sumoylation (S) 
are involved in regulating the transactivation and 
transcriptional capacity of HSF1. Attenuation 
involves negative feedback from HSPs, which 
represses transactivation, and inhibition of DNA 




factor, and ER retention and release is also controlled by BiP (Figure 5). Upon stress, ATF6 is released 
and transported to the Golgi, where it is cleaved by Golgi-resident proteases, first S1P (site 1 protease) 
and then S2P (site 2 protease), releasing the DNA-binding and transcriptional  domains to the nucleus, 
where it binds to the ATF/cAMP response element (CRE) and to the ERSE to activate gene expression 
[46,50]. Other related bZIP-containing transcription factors localized at the ER membrane have been 
identified, such as Luman/LZIP/CREB3 and CREB4 (cyclic  AMP-responsive element binding protein 3/4); 
OASIS (or CREB3-like-1); and the liver-specific  CREBH [50]. Finally, PERK is also an ER-localized type I 
transmembrane protein with a cytoplasmic kinase domain that undergoes activating trans-
autophosphorylation upon dimerization in ER stressed cells. PERK is responsible for phosphorylation of 
the α-subunit of the eukaryote translation initiation factor-2 (eIF2α), which inhibits translation activity 
(Figure 5) [50]. A global reduction in protein translation reduces the load of newly synthesized proteins, 
many of which are destined to the ER, alleviating ER stress and contributing to a re-establishing of 
homeostasis. Paradoxically, in addition to translation attenuation, PERK-mediated eIF2α phosphorylation 
contributes to translation of the fundamental  transcription factor ATF4 (activating transcription factor 4, 
Figure 5), which in turn upregulates amino acid transporters, redox enzymes such as ERO1 (ER 
oxidoreductin 1), and UPR genes that contribute to amplification of the UPR [46,48]. The ultimate response 
to stress is cell death by apoptosis, and is triggered if UPR fails to re-establish homeostasis, to protect the 
tissue or organism from accumulation of misfolded proteins [45,46,50]. 
 Studies performed in C. elegans have given evidence for mitochondrial UPR (UPRMT) that relies 
on the communication between the organelle and the nucleus [28,29]. Mitochondrial  Hsp70 (HSP-6) and 
Figure 5: Unfolded protein response. The UPR responds directly to the accumulation of unfolded and misfolded 
proteins that recruit ER-Hsp70 (Grp78/BiP) in the ER lumen. The UPR consists of three branches, each regulated by 
distinct transmembrane sensor proteins in the ER: PERK (top), ATF6 (middle), and PERK (bottom). The UPR 
integrates all three pathways to produce a stress response that results in both translational attenuation of new 




Hsp60 are induced by conditions that perturb mitochondrial protein folding and processing, and by 
accumulation of reactive oxygen species, but not by impaired pathways involved in metabolism or ATP 
synthesis, suggesting that it is not a general response to mitochondrial dysfunction. However, it is not yet 
understood if UPR signaling in the mitochondria is activated by direct recognition of misfolded proteins by 
folding sensors. 
 Oxidative Stress Response
 The redox state of the cell is also a fundamental aspect for homeostasis. The exposure of cells to 
conditions of oxidative stress leads to accumulation of oxidized-modified molecules, such as carbonylated 
proteins, lipids and DNA; and predisposes the organism to age-related disorders. Reactive oxygen species 
(ROS) can be generated exogenously or produced within cellular compartments. Under a set threshold, 
intracellular generation of ROS has important physiological roles in defense against infection, regulation of 
cell  proliferation, and signaling mechanisms in situations of metabolic stress [51]. Multiple metabolic 
pathways and cytosolic enzymes contribute to ROS production but the primary source is the mitochondrial 
electron transport chain, in particular complex I (NADH dehydrogenase) and complex III (ubiquinone-
cytochrome c  reductase) [51]. Separately, the lumen of the ER is also an oxidizing environment for protein 
folding and disulfide bond formation, which uses molecular oxygen as the terminal electron acceptor, 
posing potential for ROS production [52,53]. ROS can also result from exposure to UV radiation, 
chemotherapeutic agents, hyperthermia and growth factors among others, that perturb the cellular redox 
state. Oxidative stress increases leakage of Ca2+ from the ER lumen, which in turn stimulates 
mitochondrial permeability, cytochrome C release, disruption of the respiratory chain at the complex III, 
and even apoptosis. It is the balance between ROS production and the anti-oxidant defenses that 
determines the degree of oxidative stress [51]. The central mediators of anti-oxidant defense response, 
include ERK (extracellular signal-regulated kinase), JNK, MAPK (p38 mitogen-activated protein kinase), 
(NF)-κB nuclear factor and p53 signaling cascades, in addition to the HSR. Altogether, these pathways 
contribute to the expression of the anti-oxidant enzymes superoxide dismutase (SOD), catalase, 
thioredoxin reductase glutathione peroxidase (GPX) and peroxiredoxins [51,52]. In C. elegans, the 
transcriptional regulator SKN-1 is important for oxidative stress resistance and regulates the expression of 
a particular group of anti-oxidant response genes: SOD, GSTs (glutathione S-transferases), cytochrome 
P450 family proteins, catalase, and also Hsp genes [51,54-57].
1.3. The Protein Homeostasis (Proteostasis) Network
 Protein homeostasis, or proteostasis, is by definition, “the state of dynamic equilibrium between 
protein synthesis, folding and degradation, that allows for the conformational flexibility necessary for 
function and stability of the proteome” [58,59]. The network of cellular processes that regulate and 
maintain normal protein folding and function is referred to as the proteostasis network (PN). As a biological 
network, the PN is defined by nodes (or proteins) and edges (or protein interactions) that broadly cover the 
processes of protein synthesis, folding, trafficking and degradation. Although largely centered on QC and 
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the core Hsp70 and Hsp90 chaperone systems in the cytosol and their homologs in the ER, additional 
network components include metabolic  enzymes that influence folding efficiency by regulating availability 
of organic/inorganic solutes and ligands that promote and stabilize specific conformations [5]. The PN 
relies on stress sensors and the stress inducible pathways to maintain homeostasis upon different stimuli 
(system perturbations), and is adjusted through the signaling pathways UPS, UPR, HSR, oxidative stress 
response, diet restriction, and inflammatory signaling. The PN functions to promote successful 
development and aging of an organism, by preventing disease amidst constant intrinsic and environmental 
challenges, by maintaining system homeostasis. Proteome stability is constantly challenged by stimuli 
(perturbations) like exposure to exogenous insults as well  as intrinsic propensity for misfolding that rises 
with aging [60]. Proteostasis regulation also has a temporal component, as the network adapts to an ever-
changing proteome during development and aging [58]. In addition to age-associated decline in PN 
function (see below), proteostasis maintenance does not seem to be equal in all  cells and tissues, as some 
cell  types such as the neurons seem be particularly sensitive to the toxicity of misfolded and aggregation-
prone proteins. This seems to be consistent with the late onset of many neurodegenerative disorders. 
Emerging strategies are focusing on restoring and increasing the network efficiency to prevent or delay the 
onset, and alter the clinical course, of conformational diseases [58,61].
2. PROTEIN MISFOLDING DISORDERS
 There is still  limited understanding of how protein misfolding and aggregation cause cellular 
toxicity. Mutations that lead to conformational changes and ultimately to disease do so by either 
destabilizing the normal protein conformation and function (loss-of-function), favoring premature 
degradation; or instead by promoting aggregation. In the later case, misfolded proteins may become toxins 
to cells as a result of their ability to perturb the proteostasis machinery (gain-of-function) [62]. An 
increasing number of diseases are now recognized to be associated with protein misfolding and 
aggregation, and the pathological  mechanisms start to converge on the inability of the PN to prevent 
toxicity. 
2.1. Protein Loss-of-Function 
 Protein loss-of-function is typically caused by inherited mutations leading to inefficient folding and 
premature degradation by the cellular clearance machinery. Mutant proteins destined to the secretory 
pathway, which fold slowly, have trafficking defects, and are degraded prematurely, are over-represented in 
loss-of-function genetic  diseases [63-65]. Two examples are described. The Cystic  Fibrosis 
transmembrane conductance regulator (CFTR) functions as a cAMP-regulated chloride (Cl-) channel  in the 
apical membrane of epithelial tissues. Cystic  Fibrosis (CF) is an inherited disease of epithelial  tissues 
dominated by chronic lung disease, caused primarily by point mutations that disrupt CFTR folding and 
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export from the ER to the cellular membrane [66,67]. Over 90% of CF patients carry at least in one allele 
the Phe508 deletion (F508del) in CFTR that leads to a severe form of the disease. F508del-CFTR folding 
is kinetically impaired as the mutant fails to acquire the proper conformation at the ER and is maintained 
bound to chaperones until it is targeted for ERAD. CFTR is a primary example in which point mutations 
disrupt the folding process, leading to retention and degradation of a still partially functional mutant form of 
the protein [68]. This is a case where the inability vs. ability of the mutant protein to achieve its functional 
conformation or destination is dependent on the cohort of chaperones involved in the process. Another 
example of loss-of-function disorders are the lysosomal storage diseases caused by the inability of mutant 
lysosomal enzymes to fold in the ER, rendering them susceptible to ERAD and leading to the accumulation 
of the enzyme substrates in the lysosomes [69]. The most prevalent lysosomal storage disease is 
Gaucher’s disease, caused by the inefficient folding of variants of β-glucocerebrosidase (β-Glu). This 
results in the accumulation of glucosylceramide, the β-Glu substrate, in the lysosomes of several cell 
types, leading to disease. As for CFTR, many Gaucher’s disease-associated mutant enzymes show 
sufficient stability and activity in the lysosome, provided they can fold in the ER and be transported to the 
lysosome [69]. Studies of these diseases reveal  that “adjustment” of the chaperone machinery and PN can 
distinguish between a deleterious mutation and a “tolerable polymorphism”, to the point of rescuing normal 
function and prevent disease phenotypes. Current therapeutic interventions focus on developing 
compounds that pharmacologically target the QC machinery to increase folding capacity, or substrate-
specific compounds that promote folding or stabilize the protein in order to prevent premature degradation 
[63,65,69]. 
2.2. Protein Toxic Gain-of-Function and Aggregation
 
 Partially folded or misfolded species that are not readily degraded often tend to self-associate. 
Hydrophobic forces lead to the formation of amorphous structures in a concentration-dependent manner, a 
process known as protein aggregation, leading to cellular dysfunction and degeneration. Alternatively, 
aggregation may consist of the formation of ordered, fibrillar assemblies called amyloid, with a 
characteristic  thermodynamically stable cross-β-structure [4,6]. Neurodegenerative diseases, also called 
amyloidoses, are some of the most debilitating disorders and include a large number of 20 diseases 
affecting thinking, movement, cognition and memory [70]. These disorders share common pathological 
mechanisms and features like inherited origin, late appearance in life and neuronal loss by programmed 
cell  death or apoptosis. These are common and prominent features in Alzheimer’s disease (AD), 
Parkinson’s disease (PD), and Amyotrophic  Lateral Sclerosis (ALS) (Figure 6). Another group of diseases, 
known as polyglutamine (polyQ) diseases, are characterized by the expansion of polyglutamine repeats in 
otherwise unrelated proteins, and include Huntington’s  disease (HD), spinocerebellar ataxias 1, 2, 3, 6, 7, 
17, spinal  and bulbar muscular atrophy, and dentatorubral and pallidoluysian atrophy. In addition, muscular 
dystrophies, metabolic  disorders (type II diabetes), and certain cancers are also associated with protein 
misfolding/aggregation [15,71,72]. Although the initiating aggregation-prone protein for each disease differs 
in sequence, function and expression patterns, the appearance of aggregates represents an early event 
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associated with cellular toxicity and symptoms’ onset (Figure 6) [62,70,73]. In AD, beta-amyloid peptide 
(Aβ) plaques are deposited extracellularly in the brain and neurofibrillar tangles composed of 
hyperphosphorylated Tau protein accumulate in the cytoplasm of degenerating neurons. In PD, aggregates 
of alpha-synuclein protein (Lewy bodies) are observed in the cytoplasm of brain neuronal cells. Alpha-
synuclein toxicity is thought to derive from ER stress, vesicle trafficking defects, impairment of the UPS 
and mitochondrial dysfunction [74]. In HD patients, the prominent feature is intra-nuclear deposits of 
polyQ-expanded huntingtin protein (Htt). The molecular pathogenic  mechanisms of HD remain poorly 
understood, but transcriptional, ER and autophagy disruption as well as dysregulation of synaptic function 
have been described [75,76]. There is an inverse exponential correlation between glutamine (CAG) repeat 
length in the Htt gene and age of disease onset and severity, with a threshold set at around 39 CAG 
repeats for disease-causing variants (Figure 7) [77]. There is also considerable individual  variation in age 
of onset within a given repeat-length range, which points to the role of other genetic and environmental 
factors (Figure 7) [78]. Amongst polyQ diseases, even for the same polyQ length, there are differences in 
severity and age of disease onset, implicating the polyQ flanking sequences and genetic and 
environmental  factors as modulators of disease [79]. In the inherited/autosomal dominant form of ALS 
(FALS, 2% of ALS cases), aggregates mainly composed of mutant superoxide dismutase (SOD1) are 
found in cell bodies and axons of motor neurons, leading to disruption of the neuronal cytoskeleton and 
muscle atrophy. There is also considerable evidence for microglial  role in pathogenesis, excitotoxicity and 
axonal transport defects, disrupted mitochondrial  function and oxidative injury in disease progression 
[80,81]. In a somewhat different subclass of neurodegenerative disorders, are the diverse forms of 
transmissible spongiform encephalopaties characterized by the accumulation of protease-resistant 
aggregates of the prion protein (PrP) [70,73].
F i g u r e 6 : P r o t e i n a g g r e g a t i o n i n 
neurodegenerative diseases. Amyloid 
deposits, neurofibrillar tangles and amorphous 
protein aggregates are forms of protein 
aggregation, a common characteristic of a group 
of human neurodegenerative diseases, 
including polyglutamine disorders, Parkinson’s 
disease, Alzheimer’s disease, Prion (PrP) 
diseases and ALS. These proteins misfold and 
accumulate in the form of fibrillar polymers, as 
depicted in the center image. Adapted from [73].
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 Aggregation and Toxicity
 The events that induce cell degeneration may be related to loss-of-function (lack of activity of the 
native protein), to gain-of-toxic-activity (neurotoxicity of the misfolded and aggregated protein), both, or due 
to inflammatory responses. In some diseases, a combination of these mechanisms may occur [73]. 
Although aggregates have been recognized as a typical feature of degenerative diseases and are usually 
present in the most damaged areas of the brain, it is not clear whether they are the direct cause of 
pathogenesis [73,82]. In fact, whether protein aggregates are a cause, a consequence or a by-product of 
toxicity is still unclear [20,83,84]. Aggregates are responsible for removing an otherwise recyclable pool  of 
amino acids, may form structures that disrupt cellular functions, and can tie up cellular chaperones and 
proteases, saturating and impairing the QC system [85]. Recent work with artificially synthesized amyloid-
like fibrils demonstrated that toxicity in human cells correlates with the propensity for interaction with other 
cytosolic proteins and to deregulate stress responses, chromatin organization, transcription, translation, 
and the QC components [86]. Extensive work with cells and animal models expressing the N-terminal 
mutant Htt fragment or polyQ alone, have also shown that essential cellular components are trapped by 
aggregates, including the transcription factor TATA binding protein (TBP) and CREB-binding protein (CBP), 
cytoskeletal proteins, molecular chaperones Hsc70, Hsp70, Hdj1 and Hdj2, as well as ubiquitin and 
proteasome components [84,87-89]. When the folding machinery is burdened with aggregation-prone 
proteins it can no longer properly assist other metastable proteins that require vigilant folding assistance 
for proper conformation [90]. These proteins, although innocuous under normal physiological  conditions, 
can enhance aggregation of disease-related proteins, and contribute to the propagation of misfolding, 
toxicity and disease progression [75,86,90-95]. It is a “fatal chain of events” that is further enhanced by 
aging-dependent decline of proteostasis maintenance and reduced stress protection capacity [86]. 
 The cytotoxicity of the oligomeric soluble states formed during aggregation has also been more 
carefully considered, as the question of the identity of the toxic species remains unanswered. Current 
evidence suggests that there are probably multiple toxic conformations (Figure 8). It was initially thought 
that large amyloid-like protein deposits were the species responsible for brain damage, but this was 
challenged by histopathological, biochemical  and cell  biological studies that show that large inclusions 
correlate poorly with onset and severity of neurodegeneration [62,73,96-98]. For example, cerebral 
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Figure 7: Inverse correlation between CAG-
repeats and age of HD onset. The length of 
polyQ expansion in the Htt-encoding gene, 
correlates inversely with the age of disease onset. 
For a given CAG-length, the variability in 
neurological onset is attributed to other genetic and 
environmental factors. Adapted from [78].
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shown that the presence of soluble Htt oligomers in cultured striatal neurons was a better predictor of cell 
death: appearance of nuclear Htt inclusions was insufficient to cause neurodegeneration, and accelerated 
cell  death was associated with a reduction in inclusions [100,101]. Likewise, in cell models of PD, 
expression of α-synuclein showed enhanced toxicity when the formation of inclusion bodies was reduced 
[98]. In human brains, soluble Aβ showed a higher correlation with the severity of AD than the accumulated 
insoluble plaques [102-104]. Taken together, these examples support a role for the soluble oligomeric 
species in toxicity [93,100,105,106]. Biophysical studies have demonstrated that diverse species with 
progressive degrees of aggregation are present simultaneously and in dynamic equilibrium with each other 
(Figure 8), making it difficult to evaluate the relative contribution of different species to disease progression 
[70,107-110]. Recently, synthesis of antibodies that recognize specific  types of oligomeric  conformations 
has shed some light on the role of these species on degeneration. The intermediate species formed by 
different proteins can be recognized by the same antibodies, suggesting a common intermediate motif that 
is independent of amino acid sequence but shared by the distinct protein oligomeric  states [111,112]. 
Others have also shown that the soluble intermediates have a toxic  ‘gain-of-function’ and that amyloid 
aggregates may recruit these toxic species, to prevent interaction with other cellular entities [62,72]. 
Therefore, the formation of protein inclusions may actually serve a cytoprotective function, as part of a 
cellular organized response when the QC has been overrun [15]. The most accepted hypothesis is that 
both soluble misfolded intermediates and amyloid-like deposits are toxic, perhaps by different 
mechanisms. 
2.3. The Aging Component
 The aging process is regulated by transcription factors and signaling pathways that include insulin-
like peptides, the insulin-like growth factor (IGF), lipophilic  signaling molecules, and sterols [113]. Among 
the best-characterized genetic regulatory pathways is the insulin-like signaling (ILS) pathway in the worm 
Figure 8: Two models of assembly of misfolded 
proteins into amyloid-like fibrils or amorphous 
aggregates. These are predictions for assembly of 
expanded polyQ proteins. (a) Monomers may co-
exist in multiple misfolded conformations, each one 
originating a specific type of ‘aggregate’. However, 
only one conformer is the precursor of fibrils (most 
stable), whereas other types of aggregates are 
metastable by comparison. (b) Oligomeric species 
are obligatory intermediate precursors of higher 
order aggregates, including fibrils. Thicker arrows 
denote, in the polyQ model, the propensity for fibril 
formation. Figure from [193].
Chapter I
26
C. elegans, the fly D. melanogaster and the mouse M. musculus [113,114]. The insulin-like growth factor 1 
(IGF-1) is a hormone similar to insulin that binds to the insulin-like growth factor 1 receptor (IGF1R, 
receptor tyrosine kinase). Binding to IGF1R initiates an intracellular signaling cascade, with activation of 
the AKT signaling pathway and inhibition of the FOXO (forkhead box O) transcription factor by 
phosphorylation. This pathway has been extensively studied in C. elegans, where the daf-2 gene encodes 
the only IGF1R and where IGF-1-mediated signaling regulates cell growth and development, DNA 
synthesis, resistance to oxidative stress, thermo tolerance, resistance to hypoxia, resistance to bacterial 
pathogens, and neuroendocrine signaling. Activation of the DAF-2 initiates a kinase cascade that includes 
AGE-1 (phosphatidylinositol 3-kinase/PI(3)K homolog), AKT-1 and AKT-2, PDK-1 and SGK-1 (homologous 
to serum and corticoid-responsive kinase); and results in phosphorylation and repression of the forkhead 
transcription factor DAF-16 (FOXO-like) activity [115]. DAF-16 positively regulates longevity determinants 
and is also a key regulator of heat and oxidative stress resistance, fat storage, fertility and metabolism. 
Mutations in daf-2 or age-1 de-repress DAF-16, and non-phosphorylated DAF-16 is translocated to the 
nucleus to promote longevity and stress resistance [113,116].
 Aging is associated with progressive decay in physiological  function and homeostasis. At the 
molecular level, aging is characterized by a gradual accumulation of deleterious modifications in nucleic 
acids, proteins, lipids and carbohydrates, together with a decline in the capacity to maintain proteostasis 
[28,58,60,92]. Alterations in the cellular environment (oxidation, glycation, nitration) also contribute to 
altered physical and functional protein properties, and accumulation of damaged and disease-associated 
proteins [28]. Eventually, the chaperone system becomes saturated, leading to the failure of multiple 
cellular processes, revealing disease symptoms. This offers a plausible explanation for symptoms of many 
conformational diseases beginning late in life [28,117,118]. Therefore, there is an urgent need to identify 
the changes that occur in proteostasis regulation during aging, and to define a right homeostatic  balance 
for maintaining or prolonging health span.
 
 QC, Stress Responses and Aging
 Aging is associated with a progressive failure in maintaining protein quality control, and reduction 
in capacity for HSR and UPR, leading to increase in the frequency of misfolding events and accumulation 
of misfolded proteins [28,60]. Both cytosolic  HSR and the UPRER and UPRMT responses depend on the 
detection of protein damage, transmission of ‘stress signal’ to the nucleus, upregulation of stress protective 
proteins and their translocation to the site of damage. Aging affects all these steps to compromise the 
overall response. Whereas the levels of HSF1 itself appear to not be affected, the HSR becomes impaired 
as an apparent result of deregulation of the signal transduction pathways involved [28,92]. Aging is also 
associated with an elevated expression of Hsp genes in the absence of other external stressors, consistent 
with the concept of aging as a form of chronic  stress. Metastable proteins are a fraction of the proteome 
that is very sensitive to the gradual  deterioration of the cellular QC, and by misfolding exacerbate 
disruption of protein homeostasis during aging [28]. Recent results obtained in the C. elegans model using 
folding sensor proteins harboring destabilizing temperature sensitive (TS) mutations [90] demonstrated 
that folding capacity decreases from early adulthood on, coincident with a sharp decline in stress 
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responses activation, which could be restored by upregulation of HSF-1 and DAF-16 [22,60,119]. Oxidative 
stress, mitochondrial  dysfunction and compromised UPRMT are also associated with aging and 
neurodegenerative disorders incidence [28,120]. In addition, saturation and inhibition of the proteolytic 
machinery and decreased autophagy are consequences of age-related increase in protein misfolding, and 
contribute to the decline in cellular homeostasis [24,28].
 
3. GENETIC MODIFIERS OF PROTEIN MISFOLDING AND TOXICITY 
 The cause for toxicity, cell  dysfunction and often cell  death in diseases of protein conformation and 
neurodegeneration has been the focus of intense research. A complementary approach focuses on the 
incapacity of the PN to deal with the misfolded proteins and maintain homeostasis, to identify pathways 
that respond more or less efficiently to the stress posed by misfolding and aggregation. It is crucial  to 
identify nodes and processes within the PN that can be modified genetically or chemically 
(pharmacologically) to enhance proteostasis function and prevent/delay disease onset. Human genetic 
studies have been able to provide limited mechanistic insight into the molecular processes that determine 
disease susceptibility, onset or progression. Studies that have identified gene alterations underlying 
disease pathology, as well as pathways that modify disease progression, have benefitted from the 
development of model systems (Figure 9).
 
3.1. C. elegans and Other Model Organisms 
 Much of our understanding of aging related events, stress responses, proteostasis function, and 
the link to disease, is offered by studies in cultured cells and the model  organisms yeast (S. cerevisiae), 
worm (C. elegans), fly (D. melanogaster) and mouse (Mus muluscus) (Figure 9). Animal  models provide 
critical testing platforms for both disease pathogenesis and for potential  therapeutics. Mouse and cell 
culture models continue to complement clinical  studies for their complexity and simplicity, respectively. In 
studying human diseases, one typically employs cell-based models to generate stably expressing lines 
that phenocopy cellular aspects of disease. However, in many cases, the response of the intact organism 
is not fully recapitulated in cultured cells because, intercellular physiological pathways and responses (e.g., 
neurotransmitter circuitry) are eliminated, and new parameters such as those used to immortalize cells are 
introduced, reducing the ability of cultured cells to mirror in vivo pathology. On the other hand, systematic 
and relatively high-throughput biological analysis approaches are poorly suited to rodent models of 
disease, and so researchers have turned to less complex model  organisms such as nematode worms, fruit 
flies and yeast. The advantages of using these organisms are multiple but arise mainly from their well 
defined genetic  characteristics, abundance, short life spans and tractability to genetic  manipulation. Flies 
and nematodes combine sufficient complexity that allows investigation of both cellular and behavioral 
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phenotypes, with simplicity that facilitates rapid, high‐throughput testing of hypotheses [121]. Fortunately, 
despite marked anatomic divergence, basic  cell biological processes are highly conserved between 
nematodes, flies and mammalians. Most importantly, genotype-phenotype correlations of misfolding 
diseases are recapitulated in the simple model organisms and, in a number of cases, disease gene 
orthologs have been identified and studied [122,123]. These systems have provided genetic  instruments to 
model aggregation and toxicity of misfolding disease-related proteins, and to identify modifiers of both 
cellular and behavioral  phenotypes, with a relative ease of technical  manipulation [119,124-131]. Since a 
major feature of all  of the protein-misfolding diseases is that they manifest late in life, an important practical 
advantage of using these models is that, while they do show a well-defined biology of aging, they have a 
short lifespan that enables the progressive stages of age-related disease pathology to be monitored 
(Figure 10) [132]. The low cost, rapid generation time, and large repertoire of genetic  tools available with 
these models allow speeding the progress of study of genes and pathways involved in complex 
physiological processes and pathology, and identifying promising therapeutic  candidates for testing in 
mammals [28,133].
 To fully understand the causes and consequences of protein misfolding, it is also relevant to find 
ways of bridging the conclusions drawn from model organisms and powerful in vitro  biophysical and 
computational techniques. The molecular elucidation of protein aggregation has received great input from 
a large number of biophysical in vitro studies. These studies are carried out in the simplified environment 
of the test tube, but have yielded a great amount of information on protein sequence, intrinsic physical-
chemical properties and perturbations that affect aggregation propensity [109]. The relevance of this data 
is then answered in the model organisms. Research has taken advantage of both classical techniques in 
biophysics and newly developed biological tools, to provide exciting new insights into the molecular 
determinants of the pathogenesis of protein-misfolding diseases [132].
 Caenorhabditis elegans
 C. elegans are approximately 1 mm transparent self-fertilizing roundworms of the phylum 
Nematoda, with a 3-day life cycle and a mean lifespan of approximately 18-20 days, when cultured at 20°C 
(Figure 10) [121,134,135]. In the laboratory, C. elegans can be readily cultured in large numbers on agar 
plates seeded with a lawn of E. coli. The adult stage is preceded by progression through embryonic 
development and four larval  stages (Figure 10). Adult C. elegans have 959 somatic cells and the complete 
cell  lineage, connectivity of the nervous system and nerve-muscle synaptic  connections have been 
MAMMALIAN CELLS YEAST NEMATODES FRUIT FLY MOUSE 
Figure 9: Model systems for the study of human diseases of protein misfolding.
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determined [134]. The body wall  consists of tough collagenous cuticle underlain by hypodermis, muscles, 
and neurons. Striated body wall muscles (BWM, 95 cells) are responsible for locomotion and non-striated 
muscles have an important role in the function of organs such as the pharynx, intestine, anus, uterus, 
gonad and vulva [135,136]. The nervous system of adult hermaphrodites is divided into pharyngeal  and 
central  nervous systems (longitudinal), and contains 302 neurons, 56 glial  and support cells. In the adult 
worm, embryogenesis occurs in the uterus (Figure 10). 
 The establishment of C. elegans as a model  system for fundamental biological research began in 
1963 with the molecular biologist Sydney Brenner. C. elegans is now the best investigated multicellular 
organism and the standard laboratory strain is Bristol N2 [137,138]. This organism has been particularly 
advantageous in the functional analysis of human ortholog genes, in the study of aggregation-prone 
proteins associated with neurodegenerative diseases, in the characterization of physiological changes 
occurring during aging, in the characterization of stress response pathways in cell and tissue-specific 
manners, and in the study of the integration of signaling and stress pathways at the organismal level 
[60,90,119,131,134,135,139-148]. C. elegans is a highly tractable genetic model system that offers ease 
for genome‐wide RNA interference (RNAi) analysis to identify comprehensive set of genes and processes 











Figure 10: C. elegans anatomy (top right corner) and life cycle. C. elegans reproductive life cycle, from egg to egg-
laying adult hermaphrodite animal. The complete life cycle takes approximately 3 days at 20°C. The insert is a 
schematic representation of some of the anatomical features of the adult C. elegans. Image from the WormAtlas.
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3.2. Genetic Screens for Modifiers of Proteostasis Regulation
 Model transgenic organisms, expressing human disease-related proteins, together with large-scale 
genetic screens, ranging from deletion libraries to genome-wide RNAi screens, have been exploited to 
elucidate the mechanisms of protein-misfolding diseases. The ease of culturing and screening in yeast, 
worm and fly models renders these organisms uniquely suited for unbiased high-throughput screens to 
identify novel  modifier genes of disease phenotypes and uncovered the basal cellular processes that play 
a role in pathology [124-128,130,131,144,149-153]. Screens in C. elegans have used genome-wide RNAi 
libraries composed of about 17,000 bacterial  strains expressing double-stranded RNA against almost 
every gene (reverse genetic screens) [154,155]. Screens for modifiers of aggregation initially took 
advantage of the transparency of C. elegans and the amenability of the body wall  muscle cells for RNAi. 
Unfortunately, C. elegans neuronal cells are particularly refractory to the effect of gene knockdown by 
RNAi, and this poses a serious concern about the results from genetic  screens, which may have missed 
genes with a specific  role in neurons, the actual site where many misfolded proteins cause disease. In an 
attempt to identify these factors, mutant C. elegans strains hypersensitive to RNAi have also been used 
[156]. Alternatively, forward genetic screens in C. elegans are also a powerful  tool to identify mutant gene 
alleles that modify disease phenotypes. EMS (ethane methyl  sulfonate) is a chemical  mutagen used to 
generate random genomic mutations that produce the phenotype of interest, followed by mapping and 
identification of the mutated gene [157].
 An integrative comparison between genetic  screens highlights alterations of a wide variety of basic 
cellular processes associated with protein aggregation-toxicity. The modifiers primarily cover QC proteins 
that maintain homeostasis and components of the stress response pathways, including the HSF-1 and 
DAF-16 transcriptomes. The largest common class of genes that act on the pathology of all  disease 
proteins is that involved in protein degradation, followed by molecular chaperones. This is consistent with 
components of the ubiquitin proteasome system found to co-localize with aggregated proteins in the brain 
of patients, together with molecular chaperones [158,159]. Furthermore, a link between the molecular 
mechanisms of aging and protein misfolding is highlighted by screens that point to molecular pathways 
that regulate lifespan as modifiers of progression of misfolding phenotypes [22,119,130]. Moreover, 
processes involved in RNA processing, protein synthesis and cellular metabolism have been identified as 
modifiers of polyQ and SOD1 aggregation (Chapter II) [144], osmotic stress-induced protein damage [160], 
and heat-induced stress (unpublished), suggesting a core set of processes respond to general protein 
damage [161]. Notably, results from genetic  screens have been successfully extrapolated to human 
neuronal  cells as disease modifier genes. One example is offered by the C. elegans genome-wide RNAi 
screen for modifiers of polyQ aggregation, where TCP-1 chaperonin orthologs were identified [144]. 
Several  studies later confirmed the role of this chaperonin in aggregation of mutant Htt in mammalian cells 
[93-95]. In a similar way, the ER-Golgi  transport regulator, Rab1, identified in a yeast screen as a 
suppressor of α-synuclein toxicity, rescued different α-synuclein toxicity phenotypes in mammalian neurons 
[153]. These examples highlight the potential  of genome-wide screens in simple organisms to provide 
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insight into the molecular mechanisms of neurodegeneration in humans. Despite the unifying theme of 
protein aggregation, the pathology of each disorder seems to be influenced by a disease-protein-specific 
subset of genes, in addition to an overall  overlap in molecular pathways and functional  classes to which 
individual modifiers belong [161]. The processes and genes identified represent potential targets for 
therapeutics of proteostasis enhancement. 
 mRNA profiling experiments have also identified genes that are differentially expressed following 
expression of disease proteins, but produce large sets of data that are not straightforward for extraction of 
relevant biological information. To bridge the gap between these two forms of high-throughput studies, an 
algorithm that integrates complementary genetic, physical  and transcriptional data has been developed, 
connecting screen hits to differentially expressed genes and molecular interactions data, to reveal  the 
functional  context of genetic  hits and additional  proteins that participate in the response to misfolding and 
toxicity [162]. This algorithm (ResponseNet) has successfully provided functional context to many of the 
genetic hits identified in a screen for α-synuclein toxicity modifiers in yeast and complementary 
transcriptional data, and pointed to the involvement of several new cellular pathways in disease 
progression [162].
 Cell Autonomous Regulation of Proteostasis
 Molecular chaperones and the components of the degradation machinery are among the strongest 
and most consistent modifiers of protein aggregation and disease-related phenotypes, demonstrating that 
assistance in folding and the disposal of the misfolded species are crucial. Some features of the response 
to protein misfolding and aggregation are certainly cell  autonomous, and this is the case for the activation 
of stress pathways that up-regulate folding and QC components [58,92,143]. Accordingly, biochemical data 
demonstrated that tissue- or cell-specific increase in the levels of chaperones, in particular members of the 
Hsp70 and TRiC/CCT families, enhances the solubility of polyQ proteins, inhibits the formation of toxic 
species and protect against cytotoxicity [15,89,94,163]. Overexpression of chaperones may also suppress 
toxicity by maintaining proper folding of silent mutations within the genome encoding metastable proteins, 
preventing propagation of proteome instability in the presence of aggregating proteins.
 Cell Non-Autonomous Regulation of Proteostasis
 The stress response was initially thought to be only a cell-autonomous response, initiated by the 
presence of misfolded proteins. However, multicellular organisms seem to sense stress differently than 
isolated cells, as exposure of an organism to stress conditions can result in a selective and asynchronous 
activation of the stress response in different tissues [143]. A growing body of work shows additional levels 
of regulation of stress responses at the organismal level, in a cell-non-autonomous manner. Results 
showing that perturbations of the insulin/IGF-1 pathway in one tissue cause alterations in other tissues to 
establish homeostasis, argue in favor of an organism-wide regulatory network. Studies in the model 
organism C. elegans have revealed that increase in the levels of the transcription factor DAF-16 in one 
tissue can increase DAF-16 activity in other tissues and extent organism life span [114]. Similar results 
have been obtained for HSF-1 and SKN-1. Furthermore, it is now known that cell-autonomous stress 
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responses are regulated by neuronal  and endocrine signaling, yielding an integrated systemic  response. 
The neuroendocrine signaling pathways include the ILS, the transforming growth factor-β (TGF-β) pathway 
and the nuclear hormone receptor (NR) [164]. Both neuronal and endocrine signaling are transduced to 
muscle and intestinal cells to improve stress resistance, folding and even lifespan [143,164,165]. Protein 
misfolding and aggregation within C. elegans muscle cells is also influenced cell  non-autonomously by 
neuronal  signaling pathways [166,167]. Recently, it has been put forward that perturbation of mitochondrial 
function in one tissue, specifically at the respiratory chain level, can be detected and have consequences 
in another tissue and organism life span through activation of the UPRMT, revealing a cell-non-autonomous 
mitochondrial-mediated effect on longevity [120]. 
 Genetic studies in multicellular model organisms have provided crucial information on the 
composition, function and hierarchical control of the proteostasis network, starting to unravel  the 
organization of stress regulation at the organismal level, and new target genes and pathways to increase 
proteostasis maintenance. This aspect is of extreme relevance for the understanding of conformational 
disorders with tissue-specific pathogenesis and for the development of custom therapeutics.
4. AIMS AND PERSPECTIVES: FROM MODEL ORGANISMS TO THERAPEUTICS
 The cellular processes that ensure proteome quality and function, in normal and stress conditions, 
as well as during aging, are of great medical  relevance since a growing number of conformational  and late-
age-onset diseases are linked to proteins that misfold and aggregate. Genetic screens and expression 
data from model organisms for human diseases have provided a wealth of information regarding genes 
and pathways associated with disease, as well as a cohort of PN protective components that function to 
prevent toxicity. Compilation and integration of this information still  poses a challenge for understanding 
the processes compromised in disease and aging. One clear conclusion that can be drawn so far, 
however, is that overexpression of proteostasis core or accessory chaperone components increases 
folding capacity, and that the “new PN” is likely to have an enhanced protective capability [5]. Meanwhile, 
increasing information from the genetic screens offers new target genes that can reshape the PN to 
increase homeostasis maintenance capacity. A positive aspect of a highly integrative network such as the 
PN is that small  readjustments of a single process seem to have global beneficial effects. Thus, 
pharmacologic up- or down-regulation of the capacity of the PN, by targeting key components such as 
molecular chaperones and/or protein clearance, provides an avenue for intervention in disease [168]. 
 The complementarity between genetic  and chemical modulation of proteostasis reveals great 
value for models organisms  in the search for therapeutic options. Loss-of-function diseases are currently 
treated by intravenous administration of a wild-type (WT) version of the deficient protein to restore function. 
Protein replacement therapy is very limited because the injected protein must find its way to the 
appropriate cell type and to the relevant subcellular compartment through an endocytic  trafficking pathway. 
For instance, in Gaucher’s disease, less than 5% of the injected β-Glu enzyme makes it to the lysosomes. 
Alternative strategies are clearly necessary when it comes to brain disorders, because recombinant 
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proteins do not cross the blood-brain-barrier [58]. Another challenge with loss-of-function misfolding 
diseases is to identify small-molecule pharmacologic agents that selectively or specifically enhance protein 
stability and function. Currently, pharmacological correctors cover chemical chaperones that mimic  the 
effect of molecular chaperones and stabilize the folded state but in a rather unspecific  manner (such as 
DMSO and glycerol); pharmacological chaperones that are substrate-specific  and stabilize the protein of 
interest in a conformation that prevents premature degradation; and proteostasis regulator compounds 
(PRs) that modulate the levels and activity of specific  chaperones to enhance folding efficiency 
[5,63,65,69]. PRs offer the advantage of expanding proteostasis capacity for numerous misfolding-prone 
proteins simultaneously. As an example, small  molecule proteostasis regulators that increase the ER Ca2+ 
concentration were shown to enhance the capacity of calnexin to fold mutant β-Glu, increasing the 
probability of mutant β-Glu to engage the trafficking machinery and escape ERAD in Gaucher’s disease. 
Similarly, proteostasis ‘correctors’ for CFTR that promote folding and export, and/or enhance activity of the 
partially destabilized channel are also under clinical trial [5]. 
 Other emerging therapeutic strategies focus on developing pharmacologic  chaperones that bind to 
and increase kinetic  stability of proteins, to shift the equilibrium from aggregation to folding in diseases of 
toxic-gain-of-function  [58,168]. Chemical  inducers of the HSR and Hsp levels can have a significant effect 
in cellular and animal  models of neurodegeneration [169] (Appendix III). PRs that activate the HSR through 
HSF1 include triptolide, quercetin, and celastrol  [170,171]. Another emerging category of PRs are HDAC 
inhibitors (HDACi) that presumably function through regulation of gene transcription, by preventing histone 
deacetylation. Pharmacological  activation of SIRT1 by resveratrol prolongs HSF1 binding to target 
promoters and enhances the HSR [172]. Nonetheless, caution is imposed by observations that HSR 
induction can have adverse effects in cells and tissues, as seen in rapid proliferating tumor cells. HSF1 is a 
potent modifier of tumorigenesis and, therefore, a potential target for cancer therapeutics. In fact, 
chaperone inhibitors, especially Hsp90 inhibitors, decrease cell proliferation in animal  models, possibly by 
counteracting the high demand for folding in tumor cells, preventing growth of specific  classes of cancer 
[5,58]. 
 
 Here, we describe the work performed with C. elegans models of protein misfolding and 
aggregation to identify and characterize new genetic and small molecule modifiers of the PN function. The 
aim was to identify novel components of the PN that, when genetically down-regulated or targeted by small 
molecules, activate protective cell  autonomous and non-autonomous pathways that enhance folding 
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 A hallmark of diseases of protein conformation and aging is the appearance of protein aggregates 
associated with cellular toxicity. We posit that the functional  properties of the proteostasis network (PN) 
protect the proteome from misfolding and combat the proteotoxic events leading to cellular pathology. In 
this study, we have identified new components of the proteostasis network that can suppress aggregation 
and proteotoxicity, by performing RNA interference (RNAi) genetic screens for multiple unrelated 
conformationally challenged cytoplasmic proteins expressed in Caenorhabditis elegans. We identified 88 
suppressors of polyglutamine (polyQ) aggregation, of which 63 modifiers also suppressed aggregation of 
mutant SOD1G93A. Of these, only 23 gene-modifiers suppressed aggregation and restored animal  motility, 
revealing that aggregation and toxicity can be genetically uncoupled. Nine of these modifiers were shown 
to be effective in restoring the folding and function of multiple endogenous temperature-sensitive (TS) 
mutant proteins, of which five improved folding in a HSF-1-dependent manner, by inducing cytoplasmic 
chaperones. This triage screening strategy also identified a novel set of PN regulatory components that, by 
altering metabolic  and RNA processing functions, establish alternate cellular environments not generally 




 A common characteristic of protein conformational  diseases is the appearance of protein 
aggregates associated with late onset symptoms. Here, we have taken an unbiased genetic approach to 
test the hypothesis of whether protein aggregation and toxicity are co-linked genetic traits that are 
regulated by a common proteostasis network. To address this, we took advantage of the tractable genetic 
model Caenorhabditis elegans expressing expanded polyglutamines (polyQ), and performed a genome-
wide RNA interference (RNAi) screen to identify genes that altered the proteostasis environment and 
suppressed aggregation and toxicity. These modifiers were subsequently tested on animals expressing 
mutant SOD1, and on animals expressing endogenous proteins with temperature-sensitive mutations. This 
screening triage resulted in the identification of nine genes with effects on protein folding, corresponding to 
new proteostasis pathways involved in metabolism and RNA processing functions. 
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INTRODUCTION
 Protein misfolding is an intrinsic aspect of protein biogenesis that, under optimal  conditions, is kept 
in check by the properties of the proteostasis network (PN), and upon stress, aging, and expression of 
aggregation-prone proteins causes cellular dysfunction that places the organism at risk for diseases of 
protein conformation. These are common and prominent features in Alzheimer’s disease (AD), Parkinson’s 
disease (PD), Amyotrophic Lateral Sclerosis (ALS), polyglutamine disorders such as Huntington’s disease 
(HD), muscular dystrophies, metabolic disorders, and certain cancers [62,70-73]. Each disease is 
associated with its own characteristic set of aggregation-prone proteins that differ in sequence, function 
and expression patterns. Nevertheless, protein misfolding and aggregation have similar consequences to 
the cell  with deleterious consequences on gene expression, protein synthesis, folding, trafficking, 
clearance, and cell signaling. 
 The PN of molecular pathways coordinates protein synthesis, folding, trafficking and clearance 
[58,61,92] and determines the fate of proteins that do not acquire a native conformation. The chronic 
expression of aggregation-prone proteins, as occurs in conformational  disorders, not only affects the 
function of proteins harboring mutations, but also challenges the stability of the PN, leading to the 
amplification of protein damage and persistent proteotoxicity [59,70,86,90,91]. While protein aggregates 
and inclusions represent a prominent feature of many human diseases, it remains unanswered whether a 
cell  responds identically to different protein aggregates.  Elucidating the mechanism(s) by which misfolded 
proteins, oligomeric  species, and/or aggregates interfere with cellular function represents a prominent 
challenge, given the complexity of the aggregation process, and the large number of cellular processes 
affected as proteostasis decline is propagated across tissues [58,86,98,173]. Many studies have indicated 
that large inclusions correlate poorly with onset and severity of neurodegeneration and support a role for 
the soluble oligomeric species in toxicity [96-100,103,173]. Although intermediate species formed by 
distinct proteins have been suggested to display common structural motifs, it has been difficult to evaluate 
the contribution of different types of oligomers to toxicity [112]. Furthermore, despite the common theme of 
protein aggregation, growing evidence suggests that the cause of toxicity for each disease may, in part, be 
specific to the subset of molecular processes affected by the aggregated protein [174]. 
 An alternative approach to understanding the origin of toxicity in each disease is to identify genetic 
modifiers that suppress aggregation and prevent the accumulation of metastable and misfolded proteins by 
enhancing global folding capacity [5]. Multiple in vitro, cell-based, and animal model systems have been 
developed to investigate the molecular events underlying aggregation-driven toxicity and identify modifiers 
of disease phenotypes [119,140,141,175-180]. While mammalian model systems are notoriously 
challenging to perform genome-wide screens due to the differences in genetic background and 
environment, screens performed in S. cerevisiae, C. elegans and D. melanogaster have identified 
processes that maintain proteome stability, promote folding and clearance. These include among others, 
molecular chaperones, proteasome subunits, components of the autophagy machinery, and the stress-
induced transcriptional regulators DAF-16/FOXO and HSF-1 [127,128,130,144,149,151,181,182]. 
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 Here, we established a screening strategy in C. elegans to identify novel genetic modifiers of 
proteostasis that reshape the network to increase the cellular capacity for folding, prevent protein 
aggregation and suppress toxicity. Our approach was to identify components of the PN, that when down-
regulated, enhance the functional  properties of the PN to restore folding stability of the various folding 
sensors employed in the screen. This approach was designed to complement our previous efforts to 
identify enhancers of misfolding by screening for genes that when down-regulated caused the premature 
appearance of protein aggregates [144]. We identified 63 genetic  modifiers that suppressed both polyQ 
and mutant SOD1 aggregation in muscle cells, of which 23 also suppressed associated toxicity. Of these, 
9 modifiers systematically reduced the misfolding phenotypes of endogenous temperature-sensitive 
proteins. These modifiers were then characterized for dependence on HSF-1 activation and expression of 
cytosolic chaperones to enhance folding. This study introduces new proteostasis modifiers with a global 
effect on the stability of the muscle cell  proteome, with likely broader relevance for conformational 
disorders.
RESULTS
Screening Strategy for Genetic Modifiers of Protein Aggregation
 We sought to determine whether modifier genes identified in a genome-wide RNAi screen for 
suppression of polyQ aggregation and toxicity in C. elegans would be efficacious on other disease-
associated aggregation-prone proteins and endogenous metastable proteins. With this strategy, we tested 
the hypothesis of conserved modifier genes and pathways within the PN for protein misfolding and 
aggregation.
 We initiated the screening strategy with a genome-wide RNAi screen to identify genes in C. 
elegans that when knocked down suppress aggregation of expanded polyQ::YFP fusion proteins 
expressed in body wall muscle (BWM) cells [119]. For this screen, animals expressing Q35 were used, as 
this is a threshold length for polyQ that exhibits adult onset protein aggregation and toxicity [119]. This 
screen was accomplished using a semi-robotic  assay developed for feeding RNAi bacteria [155] to larval  1 
(L1, day 1) stage Q35 animals [144]. During early development, Q35 protein is soluble in muscle cells until 
animals reach day 3 of age, when aggregation is first detected, and thereafter aggregation and toxicity 
increase with aging (Figure S1B, D) [119]. Therefore, we selected day 6, corresponding to three days after 
the onset of Q35 aggregation (Figure S1B), to perform the RNAi screen to identify gene knockdowns that 
led to suppression of polyQ foci, relative to the empty vector (EV) control. RNAi against yfp was used as a 
control  for the efficiency of RNAi gene-knockdown (Figure 1A: VIII, XVI, XXIV; Figure 1C). The screen was 
highly robust and identified 151 genetic modifiers that suppressed Q35 aggregation (Figure 1A, Table S1). 
Of these modifier genes, 91 exhibited a strong suppressor effect on aggregation by reducing the number of 
Q35 foci  by 60 to 80% in ≥75% of the RNAi-treated animals (Table S1, Figure 1C). The remaining 60 
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modifiers gave more variable results and were less effective as suppressors (i.e. observed in ~50% of the 
RNAi-treated animals with ~50% reduction in foci; Table S1). 
 We next used a counter-screen with animals expressing soluble Q24, as these animals do not 
exhibit aggregation or toxicity [119], to control for phenotypic changes caused by RNAi that are not related 
to aggregation, such as changes in YFP fluorescence, body morphology and size, egg-laying and sterility 
(Table S1). We observed that none of the Q35 aggregation modifiers had any effect on Q24 protein (Figure 
1B), suggesting that the RNAi suppressor effect was not due to transgene silencing. The modifiers that did 
not meet these criteria or had deleterious consequences on animal  development and viability were not 
studied further. Moreover, to assess whether suppression of aggregation was due to changes in polyQ 
expression, we examined mRNA and steady-state protein levels for a representative group of modifiers. 
We quantified the levels of q35::yfp mRNA by rt-PCR (Figure S2) and the levels of Q35::YFP protein by 
Figure 1. Genome-wide RNAi screen for suppression of Q35 aggregation. (A) Q35 animals (6 days old) show 
suppression of aggregation relative to EV control. Representative modifier genes: cdk-1 (cyclin-dependent kinase); let-607 
(CREB/ATF transcription factor); cyn-11 (cyclophilin); klp-15 (kinesin-like protein); sri-57 (serpentine receptor) and F59C6.5 
(NADH-ubiquinone oxidoreductase). yfp-RNAi is the control for RNAi efficiency. Panels IX-XXIV are higher magnification 
images of the boxed areas in I-VIII. Scale bars: 0.1 mm (I-XVI), 0.05 mm (XVII-XXIV)]. (B) Animals expressing soluble Q24 
were used as a control for RNAi phenotypes dissociated from aggregation (scale bar 0.1 mm). (C) Q35 aggregate count (% 
foci relative to EV control) for a representative group of modifiers (±SD, n>3). Student t-test ***p<0.001 relative to control. 
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SDS-PAGE and western blot analysis (Figure 2A). The results show that, for the RNAi modifiers tested, 
suppression of aggregation occurred without affecting the polyQ mRNA or protein levels. 
 To obtain evidence that the suppression of visible Q35 aggregates corresponds to the appearance 
of soluble Q35 protein (Figure 1A), we used the dynamic  imaging method of Fluorescence Recovery After 
Photobleaching (FRAP). Inclusion-localized Q35 corresponds to an immobile state with very limited 
fluorescence recovery following photobleaching (Figure 2B and C: Q35 control) [122,144], whereas the 
fluorescence of diffuse-looking Q35 in animals fed with modifier RNAi recovered immediately, consistent 
with a diffuse and soluble state analogous to soluble Q24 (Figure 2B hmg-3  and C). These results provide 
biophysical evidence for Q35 solubility identified by the visual  screening. We further examined the 
biochemical  properties of Q35, for a representative group of modifiers, in total protein extracts. We found 
that the amount of aggregated polyQ protein detected using native PAGE analysis was reduced, and that 
the levels of soluble and diffuse species were increased(Figure 2D). Taken together, these results reveal 
that RNAi knockdown of specific modifier genes suppressed polyQ aggregation by maintaining the protein 
in a mobile soluble state.
 The identity of the RNAi-targeted genes was verified by sequencing of the dsRNA plasmids, 
followed by Blast analysis in NCBI and Wormbase databases. The Q35 aggregation modifier genes are 
88% conserved with predicted human orthologs, and can be grouped into seven functional categories of 
cell  cycle, DNA synthesis and repair; RNA synthesis and processing; protein synthesis; protein folding and 
turnover; cell  structure and protein trafficking; signaling; and energy and metabolism (Table S1, Figure 
S3A, B). The fraction of modifiers represented in each functional class is significantly distinct from their 
representation in the C. elegans RNAi library (Figure S3A, B) [155], indicating enrichment for cellular 
processes important for proteostasis. 
 We next asked whether the Q35 modifiers were effective on another polyQ model as a way to 
distinguish the most robust polyQ aggregation suppressors. This was done by screening a transgenic  line 
expressing Q37::YFP. These animals exhibit a more rapid onset of aggregation relative to Q35 animals, 
between day 2 and 3 of age, together with a more rapid decline in motility (Figure S1A, B, D). These 
phenotypes are dependent solely upon the CAG-repeat length as the levels of Q35 and Q37 are identical 
(Figure S1C). Q37 animals were fed RNAi from L1 stage (day 1) and aggregation was examined on day 5, 
corresponding to two days post-aggregation onset (Figure 3A, B). Of the initial 151 modifiers of Q35 
aggregation, only 88 of these also suppressed Q37 aggregation, of which 81 corresponded to the 
strongest Q35 suppressors (Table S1). We designated the set of common modifiers of Q35 and Q37 
aggregation as Class A strong modifiers (Table 1); and the remaining 63 genes as Class B weak modifiers 
(Figure 3C). 
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Figure 2. Suppressors of aggregation maintain polyQ in a diffuse state without affecting expression levels. (A) SDS-PAGE 
and western blotting analysis of protein samples from Q35 RNAi-treated animals (6 days old), immunoblotted with anti-YFP (32 
KDa) and anti-α-tubulin (55 KDa) antibodies. Control refers to EV RNAi (I-IV). YFP/tubulin ratios were calculated from protein band 
intensities and are shown as an average % of the control (±SD, from ≥3 biological replicates, Student t-test p>0.05). yfp-RNAi in 
panel II is the positive control for reduced protein levels. (B, C) FRAP analysis confirms suppression of polyQ aggregation to a 
diffuse state. (B) Q35 protein was subjected to photobleaching in animals treated with control RNAi (left) or hmg-3 RNAi (right) 
and fluorescence recovery was measured at the indicated time points. (C) Quantitative FRAP analysis indicates the relative 
fluorescence intensity (RFI) at each time point, and it represents an average of ≥12 independent measurements for each RNAi 
(5 for the controls). The soluble Q24 control is shown in black solid line, and the Q35 foci control in black dashed line. (D) Native 
PAGE analysis of whole protein extracts from 6 day old Q35 animals treated with RNAi. Q35 aggregated protein retained at the 
top of the gel was reduced by each of the modifiers tested.
Chapter II
44
Identification of Common Modifiers of PolyQ and Mutant SOD1 Aggregation
 We next tested whether the genetic  modifiers of polyQ aggregation would be effective on yet 
another model  that expresses the mutant human SOD1G93A. This model shows aggregation onset during 
embryonic development and a distinctive pattern of foci that persists throughout adulthood (Figure S1E, F) 
[91]. Of the 88 polyQ aggregation modifiers, 63 also suppressed mutant SOD1G93A aggregation in 5 day 
old animals (Figure 4A, Table S1), without causing phenotypic  changes in SOD1wt animals (not shown). A 
subset of these common aggregation suppressors were also examined by SDS-PAGE and western blot 
analysis, and shown not to reduce steady-state protein levels of SOD1G93A (Figure 4B). 95% of the mutant 
SODG93A suppressors belong to the polyQ Class A modifiers (Table S1). Unlike Q35 aggregation that is 
only detected in young adult animals, mutant SODG93A aggregation occurs in embryos [91], and yet many 
Class A modifiers were effective suppressors of SOD1 aggregation providing additional  support that Class 
A modifiers are robust modifiers of protein folding. Moreover, these modifiers, that are common to polyQ 
and SOD1, exhibit a similar overall distribution into functional  classes (Figure S3C) as was described for 
modifiers of polyQ aggregation (Figure S3B), thus identifying new modifier pathways that are common to 
protein aggregation. 
Figure 3. Common RNAi suppressors of Q35 and Q37 aggregation. (A) Counter-screen in 5 day old Q37 animals to 
identify the strongest suppressors of polyQ aggregation. Panels IX-XVI show a higher magnification image of the boxed areas 
on I-VIII. Scale bar is 0.1 mm. (B) Q37 aggregate count (% foci relative to EV control) for a representative group of modifiers 
(±SD, n>3). Student t-test ***p<0.001 relative to control. (C) Screen strategy: genome-wide screen with the threshold Q-length 
for aggregation Q35, and counter-screens with the soluble Q24 and the higher Q-length Q37 strains. Class A refers to Q35 
and Q37 common strong modifiers, and Class B to modifiers only affecting Q35. 
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 We propose that these new modifiers can either suppress aggregation directly by affecting cellular 
processes that mediate aggregate formation, or indirectly by altering some aspect of the PN that confers a 
protective action that increases folding. To distinguish between these two possibilities, we employed 
genetic tests to determine which modifiers reflect an improvement of the folding environment, by reducing 
misfolding and associated toxicity.
Suppression of Aggregation Can Be Uncoupled From Toxicity
 Protein aggregation is a common feature of many diseases; however, the relationship between 
aggregation and cellular toxicity remains controversial. The appearance of aggregates and inclusions has 
been linked both to cellular dysgenesis and toxicity, as well  as protection from toxicity [96-100,103,173]. 
Therefore, we took advantage of an unbiased genetic approach to test the relationship between 
suppression of aggregation and toxicity. Because the initial  genetic screens were based solely on 
aggregation phenotypes, we were able to subsequently perform cellular toxicity assays to assess this 
relationship. 
 Relative to wt animals or animals expressing soluble polyQ (Q24), Q35 animals exhibit muscle 
dysfunction resulting in a 40% loss of motility at 6 days of age (Figure S1D) [119]. Therefore, we quantified 
Table 1: Overview of the modifiers that suppress Q35 and Q37 (Class A) aggregation in C. elegans BWM cells.
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the motility of RNAi-treated Q35 animals as a measure of polyQ-associated cellular toxicity, using an 
automated worm tracker system analysis, validated by manual methods. As a reference positive control  for 
toxicity suppression, we showed that motility was restored to near wt levels by knockdown of the Q35 
transgene expression with yfp-RNAi (Figure 5A). All 88 Class A modifiers were tested for effects on the 
motility of Q35 animals and wt control animals (Table S2). Because we sought to identify improvement of 
motility directly associated to suppression of Q35 aggregation, we excluded any modifier that, alone, had 
effects on the motility of wt animals. Of the 88 modifiers tested in wt animals, 33 gene knockdowns (37%) 
affected the motility of wt animals (Figure 5B), and were excluded from further analysis. For the remaining 
55 modifiers, 42% improved the motility of Q35 animals to wt levels, 36% had no effect, and 22% 
enhanced the toxicity of Q35 (Figure 5A). These results revealed that suppression of aggregation, as 
detected by visual, biophysical, and biochemical measures, does not necessarily predict that the 
physiological health of the cell will  be restored. The genetic uncoupling between aggregation and toxicity 
further reinforces previous similar observations [96,98,173]. Taken together, the toxicity in diseases of 
protein conformation is the outcome of a complex series of misfolding events, involving multiple species 
and aberrant interactions within the cell. 
Figure 4. PolyQ aggregation modifiers tested in the mutant SOD1G93A model. (A) Representative RNAi suppressors of 
SOD1G93A aggregation: ucr-2.3 (ubiquinol cytochrome c reductase); F43G9.1 (isocitrate dehydrogenase); ZK430.7 (sof1-like rRNA 
processing protein); gei-11 (GEX-3-interacting protein, Myb transcription factor); let-607 (CREB/ATF transcription factor); R05D7.2 
(unknown) and yfp RNAi control. Higher magnification images (IX-XVI) of the boxed areas (I-VIII) show reduced number of 
SOD1G93A foci in animals treated with RNAi, relative to the EV control. Scale bar is 0.1 mm. (B) SDS-PAGE and western blotting 
analysis of protein samples from SOD1G93A RNAi-treated animals (5 days old), immunoblotted with anti-YFP (32 KDa) and anti-α-
tubulin (55 KDa) antibodies. Control refers to EV RNAi. YFP/tubulin ratios (bottom) were calculated from protein band intensities 
and are shown as an average % of the control (I, II) ±SD, from ≥3 biological replicates (Student t-test p>0.05). yfp-RNAi (II) is the 
positive control for reduced protein levels.
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Identification of a Core PN by Screening With Endogenous Metastable Proteins 
 Among the challenges with studies of protein misfolding and aggregation have been the concerns 
with the physiological  imbalance associated with overexpression of heterologous proteins in the respective 
model systems. To circumvent this concern, we asked whether the PN modifiers that suppressed polyQ 
and mutant SOD1 aggregation (Figure 5C) would also restore the folding of endogenous metastable 
proteins harboring temperature sensitive (TS) mutations. TS-mutations represent an important class of 
highly sensitive folding sensors that are expressed at normal endogenous levels and have quantifiable 
phenotypes when properly folded at the permissive condition or misfolded at the restrictive temperature 
Figure 5. Suppression of polyQ aggregation and toxicity are genetically uncoupled. (A) Motility measurements of Q35 
(black) and wt (grey) animals treated with aggregation suppressor RNAi. Motility is measured in body-length per second relative to 
wt motility in EV control (% BLPS±SEM). Shown here are the modifiers that did not affect wt motility, grouped in three classes that: 
enhance Q35 motility defect (Student t-test **p<0.001); cause no change (Student t-test p≥0.05); or suppress Q35 motility defect 
(Student t-test **p<0.01) relative to Q35;EV (red line). T-test ***p<0.001 for Q35 relative to wt in control RNAi. Statistical 
significance between classes calculated by 1-way ANOVA ***p<0.0001. (B) Aggregation modifiers that alone caused a deleterious 
effect on wt motility (% BLPS±SEM, relative to EV control). Student t-test ***p<0.0001 relative to control. (C) Screening triage for 
modifier suppressors of protein aggregation and toxicity.
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[90,131,167]. This strategy was also used to distinguish between modifiers that directly perturb and 
suppress the formation of protein aggregates, from the modifiers that reshape the PN to improve the 
protein-folding environment. 
 We examined the properties of four TS mutant proteins corresponding to the paramyosin ortholog 
UNC-15, the basement-membrane protein perlecan UNC-52, the myosin-assembly protein UNC-45, and 
the myosin heavy chain UNC-54 [90]. At the permissive temperature (15°C), each of these TS-proteins is 
known to be fully functional  and animals harboring these mutants exhibit a wt phenotype, whereas at the 
restrictive temperature (23° or 25°C) these TS-proteins misfold and cause muscle dysfunction that can be 
measured as slow movement and paralysis (UNC-15, UNC-54, Figure 6A, C), egg-laying defects leading 
to swelling and paralysis (UNC-45, Figure 6B), and stiff-paralysis (UNC-52, Figure 6D) (see Materials and 
Methods) [90,167,183]. These phenotypes are specific  to animals expressing the TS mutations, and are 
not observed in wt animals. We tested all  23 RNAi  modifiers that suppressed both Q35 aggregation and 
toxicity (Figure 5C), on each of the TS strains, and found that a total  of nine modifiers reduced the number 
of animals displaying TS phenotypes by 40% to 90% at 23°C, a slightly lower restrictive temperature at 
Figure 6: Aggregation modifiers that rescue the folding of endogenous TS mutant proteins. Modifiers of aggregation 
and toxicity were tested on endogenous muscle TS mutant proteins. 15°C is the permissive temperature, 25°C is the restrictive 
temperature and 23°C is the temperature used for RNAi. Misfolding of TS mutant proteins was assessed by measuring the % 
of animals displaying the associated muscle dysfunction phenotype. (A) unc-15(e1402) (paramyosin), uncoordinated/slow 
movement; (B) unc-45(e286) (myosin assembly protein), egg laying and paralysis defect; (C) unc-54(e1157) (myosin), slow 
movement/paralysis; (D) unc-52(e669su250) (perlecan), stiff paralysis (±SD, n>3, Student t-test relative to 23°C control 
**p<0.01, ***p<0.001). Statistical comparison using 1-way ANOVA ***p<0.001.
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which  the efficiency of the RNAi protocol was maintained (Figure 6A-D, Table 2). These results suggest 
that while protein misfolding is common to all  three classes of folding sensors (polyQ, mutant SOD1, and 
TS-mutant proteins), the cellular environment and the PN are influenced differentially by the modifiers, as 
reflected by the effects on these sensors. We propose that these final nine modifiers (Figure 7A) are core 
PN modulators that confer improvement of cellular folding capacity in C. elegans muscle cells. 
Folding Enhancement by Activation of the Heat Shock Response
 Upstream of the core components of the PN is the master cytosolic stress-responsive pathway 
that leads to HSF-1 activation and expression of molecular chaperones for stability of the proteome. To 
examine whether the nine PN modifiers (Figure 7A) lead to HSF-1 activation as a general  mechanism for 
proteostasis improvement, we introduced a hypomorphic  mutation of hsf-1(sy441) into the background of 
the polyQ strain Q37 and knocked-down each modifier gene (Figure 7B).
 Our results show that: suppression of aggregation by ucr-2.3, gei-11 and C45G3.4 was completely 
dependent on HSF-1; whereas T22D11.5, ZK430.7, Y110A7A.8  and R05D11.4 exhibited a weaker 
dependence on HSF-1; and F43G9.1 and let-607 were independent of HSF-1. We next examined whether 
chaperone gene expression was affected downstream of the nine PN modifiers, by monitoring the 
expression of Hsp70 (C12C8.1, F44E5.4) and small  Hsp (hsp-16.1), upon knockdown of each genetic 
modifier (Figure 7C). We show that five of nine PN modifiers induced expression of cytoplasmic 
chaperones. Knockdown of let-607  (ER-UPR, Table 2) had the strongest effect, suggesting an important 
regulatory crosstalk between cytoplasmic and ER stress response pathways. Knockdown of the TCA cycle 
component T22B11.5 led to upregulation of chaperones and establishes a link between folding and 
metabolic  state, whereas knockdown of gei-11 (putative negative regulator of cholinergic  signal, Table 2) 
induction of hsp suggests an effect of cholinergic signaling on muscle homeostasis (Figure 7C). Reduction 
of R05D11.4 (translation) leading to induction of hsp-70 was consistent with an effect of protein synthesis 
on folding machinery. For the remaining four PN modifiers, knockdown of ZK430.7 (RNA processing) had a 
modest effect on hsp expression, while knockdown of Y110A7A.8 (splicing), ucr-2.3 (component of the 
ETC) and F43G9.1 (TCA cycle) had no effects on hsp levels (Figure 7C). This suggests that proteostasis 
was restored through other pathways involving reduced metabolism and energy production. Taken 
together, these results demonstrate that improvement of the cellular folding environment by these novel 
proteostasis modulators is not simply a consequence of a generalized induction of the heat shock 





 Genetic screens have provided invaluable insights into biological processes, and have the 
advantage of being unbiased and entirely based on endpoint phenotypes. We have employed a genetic 
strategy to explore how the proteostasis network can be genetically modulated to increase cellular 
protection against the toxicity of protein aggregation (Figure 7A). This strategy benefitted from certain 
advantages of C. elegans as a metazoan model  for the expression of conformationally challenged proteins 
and the ability to screen the genome for modifiers that suppress both aggregation and toxicity by gene 
knockdown. This complements the candidate gene approaches that led to the identification of molecular 
chaperones, ubiquitin proteasome, autophagy, and the upstream stress response signaling pathways. The 
use of a screening triage approach (Figure 7A) revealed that genetic modifiers that suppress aggregation 
of polyQ are also effective with mutant SOD1, and revealed the identity of candidates of a core PN. 
However, only a subset of these suppressors of aggregation also suppressed cellular toxicity, a result that 
is consistent with the genetic  uncoupling between aggregation and toxicity observed in various disease 
models [96-100,103,173]. This screen ultimately provided a filter that led to identification of a final set of 
Figure 7: Core PN modifiers and activation of the heat shock response. (A) Screening strategy to identify genetic 
modifiers that enhance the folding environment and are effective in multiple misfolding models. (B) Suppression of polyQ 
aggregation by the final nine modifiers dependence on HSF-1. Aggregate quantification on RNAi-treated Q37;hsf-1(sy441) 
hypomorphic mutant animals relative to control (±SD). Student t-test *p<0.05; **p<0.01; ***p<0.001 (ns, non-significant). (C) 
Real-time qPCR analysis of the levels of hsp (C12C8.1, F44E5.4, hsp-16.1) genes in RNAi-treated wt animals. Data are 
relative to the levels of each gene in wt;EV control (±SD), from 3 biological replicates. 
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nine core muscle PN modifier genes (Table 2), not previously shown to be directly involved in protein 
homeostasis and the restoration of folding in both animal  models of protein aggregation and of 
endogenous metastable proteins.
New Genetic Modulators of Protein Aggregation
 The genome-wide screen for suppression of polyQ aggregation identified a collection of modifier 
genes from distinct cellular functional classes (Table S1, Figure S3B). Modifiers in the category cell 
structure and protein transport, include cytoskeleton components (filamin) and matrix proteins (ppn-1, 
mua-3, gon-1), supporting observations that aggregation can be affected by disturbing the integrity of cell 
structure [90]. Other genes in this group encode motor proteins involved in vesicular trafficking (klp-15, 
nex-1), consistent with a role for protein movement and transport in aggregation. Cell  growth and 
replication modifiers are involved in progression through the cell  cycle (cyclin-dependent kinases), and 
DNA replication and recombination (transposases), with a likely general effect on growth and development. 
Energy and metabolism modifier genes are involved in energy production and mitochondrial  electron 
transport chain (ETC) function. Restriction in energy levels not only affects overall protein biogenesis, as it 
Table 2: Core modulators of protein homeostasis in C. elegans BWM cells.
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is a highly ATP-dependent process, but also, metabolic enzymes can influence protein folding in the cell  by 
altering the levels of organic/inorganic solutes with effects in polypeptide chain solvation [58]. Notably, 
reduced ATP synthesis, ETC activity or mitochondrial function have been shown to enhance lifespan, 
possibly by delaying age-dependent decline in protein folding capacity and by upregulation of stress-
response pathways that promote proteostasis and survival [143,147,184,185]. Gene expression and 
protein synthesis related modifiers function in RNA metabolism, ribosome biogenesis, and protein 
synthesis. This is consistent with reduced translation increasing C. elegans lifespan, perhaps by activating 
a physiological state with increased stress resistance and folding capacities [186-188]. Post-translational 
control  modifier genes are involved in chaperone-assisted folding, such as HSP70 superfamily members, 
DNAJ co-chaperones and cyclophilins, and post-translation modifying enzymes such as SUMO and E3-
ubiquitin ligases. The role of chaperones on protein solubility, misfolding and aggregation has been well 
established [163,189], and an imbalance in certain co-chaperones has been suggested to alter chaperone 
activity in the cell and folding [67]. Signaling RNAi-targeted genes included nuclear hormone receptors, G-
protein-coupled receptors, C-type lectins (endocytic  receptors), or calcium export and channel-transport 
activity. These regulators affect reproduction, growth, morphogenesis (development), and locomotion by 
altering signaling pathways involved in neuronal and muscle function.
 
Genetic Screens for Enhancer and Suppressor Modifiers of PolyQ Aggregation
 Information retrieved from comparative analysis of genetic screens of different misfolded proteins 
can provide important insights to identify both common and protein-specific pathways for conformational 
disorders (Table S3). Highly relevant to this point is our ability to compare the modifier genes identified in 
this study with a previous complementary screen using the same threshold Q-length properties of the Q35 
model to identify genes that when knocked-down by RNAi led to enhanced onset of polyQ aggregation 
[144]. Together, these genome-wide screens identified 341 genetic modifiers that cluster into the same 
functional  classes and pathways, but correspond to distinct genes within these pathways. Specific  modifier 
genes may interfere with the misfolded species at different stages of the aggregation process with opposite 
outcomes, consistent with the functional properties of a network, where different components within a 
process can shift the equilibrium in opposing directions to alter the stability of the proteome, to intensify or 
suppress the polyQ phenotype. 
 While it might seem counter-intuitive that molecular chaperones could suppress polyQ aggregation 
when knocked-down, this is consistent with observations that proteome stability can be enhanced or 
suppressed by changing the composition of the cellular chaperome [67,163,189,190]. For example, 
reducing the expression of cyn-11 and cyn-12  (cyclophilin D isoforms) and dnj-5, that function primarily as 
co-chaperones to regulate Hsp70 and Hsp90 activities [191], promotes a polyQ soluble state. These co-
chaperones could function as negative regulators of chaperone function, and their down-regulation results 
in enhanced chaperone activities leading to suppression of misfolding [163,192,193]. This would be 
consistent with evidence that Hsp70 folding activity is negatively regulated by co-chaperones and co-
factors such as CHIP [194] and BAG-1 [195]. Therefore, enhancement of folding can be achieved by both 
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positive and negative regulation of chaperones or by a compensatory response that up-regulates other 
chaperones. 
 Another functional class common to both Q35 screens is the protein trafficking and cell  matrix. 
Suppression of aggregation by knockdown of cell cytoskeleton proteins, such as intermediate filaments 
(MUA-3 and MUA-6) and filamin, is supported by experimental evidence that the dynamics of aggregation 
rely in part on translocation of proteins into inclusions. For example, the active transport of Htt-exon1 along 
microtubules has been shown to be required for inclusion body formation [196]. In contrast, premature 
aggregation was observed when the expression of vesicle proteins involved in protein trafficking was 
knocked-down [144], including TFG-1 COP-II complex, APT-3 and APT-1, and cell membrane assembly 
proteins (SNAP-25). Interference with these processes can disturb essential steps of the folding and 
secretory pathways, increase the load of misfolded proteins in the cell and lead to premature polyQ 
aggregation. 
Suppression of PolyQ Aggregation and Toxicity Can Be Uncoupled
 An important observation from these studies is that the Class A PN modifiers (Figure 3C, Table 1) 
were highly effective to suppress polyQ aggregation, and yet only 42% of these modifiers also reduced 
toxicity, with approximately equal numbers of modifier genes with either no effect on toxicity or even 
enhancing toxicity (Figure 5A). These results provide independent evidence that suppression of 
aggregation alone does not predict that the physiological health of the cell  will  be restored. From a 
mechanistic  perspective, it is increasingly clear that a series of events are associated with the conversion 
of the nascent polyQ protein into different oligomeric states, immobile aggregate species and inclusion 
bodies [110,197-199]. We conclude that the genetic  suppression of aggregation can occur via a wide 
range of mechanisms that are dissociated from the effect on toxicity, consistent with previous observations 
that interference with the aggregation process could in some cases enhance the formation of “toxic 
oligomeric  species” [22,96-101,103,173]. Moreover, each modifier gene is certain to function within its own 
network of interacting partners, revealing an expanding network through which each modifier can suppress 
aggregation, but with differential effects on toxicity depending on the affected cellular function. The 
demonstration that protein aggregates are uncoupled from cellular toxicity has implications for the 
understanding of the PN and for development of therapeutics. 
A Triage Screening Method for Identification of Core Modulators of BWM Proteostasis
 We took advantage of C. elegans models of protein aggregation-toxicity in addition to folding 
sensor strains harboring TS mutations in endogenous proteins to identify a core group of modulators that 
improve folding in muscle cells (Figure 7A). Our results highlight important aspects of the PN, relevant for 
both ‘gain-of-toxic  function’ by aggregation-prone proteins, and ‘loss-of-function’ derived toxicity due to 
misfolding. The nine PN modifiers that remained at the end of the screening tree function in the 
mitochondrial respiratory chain and TCA cycle, that regulate metabolism, energy balance and prevention of 
oxidative stress, in addition to rRNA processing and transcription, that determine gene expression and 
proteome load (Table 2). While these modifier genes, upon initial inspection, seem not to be directly 
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involved in folding, perturbation of their specific functions and networks of interactions re-adjusts the PN to 
enhance its capacity, as suggested by activation of the heat shock response and chaperone expression 
(Figure 7B, C). Moreover, comparison to other genetic  screens performed in Drosophila [127,149,182], C. 
elegans [115,128,130,144,148,160,200] and yeast [150,151] (Table S3) provides additional  insights into 
the regulation of the PN by these modifiers. ucr-2.3 encodes an ubiquinol-cytochrome c reductase subunit 
of the mitochondrial respiratory chain, and F43G9.1  and T22B11.5 encode TCA-cycle enzymes (isocitrate 
dehydrogenase and 2-oxoglutarate dehydrogenase, respectively) (Table 2). Disruption of the respiratory 
chain and energy production has been suggested to have consequences on cellular homeostasis 
[143,185]. Intriguingly, knockdown of ucr-2.3 was shown to enhance the toxicity of human Tau expressed 
in C. elegans neuronal cells (Table S3) [128]. This discrepancy may be related to Tau-specific 
proteotoxicity, not derived from aggregation or misfolding, but associated with microtubule binding and 
disruption. F43G9.1 was also identified as a enhancer of lifespan [148], which is consistent with a role in 
proteostasis. ZK430.7 encodes an rRNA processing factor, Y110A7A.8 is a putative mRNA splicing factor, 
and R05D11.4 encodes an RNA helicase required for translation (Table 2). Thus, perturbing components of 
the gene expression machinery can enhance proteostasis, likely by altering the expression load of 
unstable proteins and activating stress responses to restore proteostasis. In particular, knockdown of 
Y110A7A.8 activates the osmotic  stress response [160] and causes premature onset of polyQ aggregation 
on 3 day old animals [144], consistent with an increase in misfolding (Table S3). However, on 6 day old 
animals we show that the number of aggregates is suppressed, which suggests a time-dependent 
response by the PN to enhance the folding machinery and restore folding. gei-11 encodes a Myb-family 
transcription factor proposed to regulate cholinergic receptor function at the BWM cells [201], which affects 
muscle function and homeostasis [166,167]; and let-607 encodes a CREBH ortholog transcription factor 
predicted to be a component of the C. elegans ER stress response. The role of let-607 is particularly 
intriguing as it reveals a genetic crosstalk between the cytoplasmic  and ER lumen stress pathways. 
Knockdown of let-607 induces chaperone expression that is not dependent upon HSF-1 (Figure 7B, C), 
suggesting that other stress responses such as the ER unfolded protein response may be involved in the 
suppression of cytosolic  protein aggregation. Taken together, these results emphasize that diverse genetic 
and cellular mechanisms can restore cellular proteostasis beyond the traditional heat shock response. 
These nine gene modifiers of BWM protein homeostasis represent core components of the PN that evoke 
a robust and effective improvement of disease-related and endogenous metastable protein folding. 
Identification of these processes is a fundamental step towards identifying new components that constitute 
the network, and the cellular and organismal  mechanisms by which they contribute to protein homeostasis 
and protect against chronic expression of misfolded toxic proteins.
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MATERIALS AND METHODS
C. elegans Strains and Maintenance
 Animals  were maintained according to standard methods, at 20°C on nematode growth media (NGM) with 
OP50 E. coli [138].  The strains utilized in this work, and previously  described, are the following: wild-type (wt) Bristol 
strain N2; polyQ strains Q0 AM134 (rmIs126[Punc-54::yfp]), Q24 AM138 (rmIs130[Punc-54::q24::yfp]II),  Q35 AM140 
(rmIs132[Punc-54::q35::yfp]I), Q37 AM470 (rmIs225[Punc-54::q37::yfp]II) (Supporting Information) [119]; human SOD1 
strains SOD1G93A AM265 (rmIs177[Punc-54::sod1G93A::yfp]) and SOD1WT AM263 (rmIs175[Punc-54::sod1wt::yfp]) [91]; 
temperature sensitive (TS) mutant strains CB1402 [unc-15(e1402)],  CB1157 [unc-54(e1157)],  HE250 [unc-52
(e669su250)]  and CB286 [unc-45(e286)]  [90]. The transgenic polyQ and SOD1 strains had been integrated by 
gamma-irradiation,  5 times backcrossed, and were previously  described [91,119].  The strain Q37;hsf-1(sy441) was 
generated by genetic cross of the original strains AM470 and PS3551[hsf-1(sy441)]I.
RNA Interference Screen
 The genome-wide RNAi screen for suppression of  aggregation in C. elegans muscle cells was performed 
using the commercial RNAi library,  with bacteria expressing dsRNA for 87% of  the predicted C. elegans genes 
(GeneServiceTM, USA) [144,155]. A semi-automated high throughput setup system was used, consisting of  a robotic 
device (Biomek FX Liquid Handler,  Beckman Coulter, Inc., USA) programmed to add bacteria and age-synchronized 
animals  in liquid culture to 96-well plates. RNAi bacterial cultures were grown for approximately  8 h in LB-ampicillin 50 
µg/ml (65 µl), at 37°C with continuous shaking at 315 rpm (Orbital shaker, GeneMachines HiGro®, Genomic Solutions, 
USA),  and induced with 0.5 mM isopropyl β-D-thiogalatoside (IPTG, Sigma) for 3 h at 37°C. To obtain an age 
synchronized population of  L1 larvae (first larval state post egg hatching), Q35 gravid adults were bleached with a 
NaOCl solution [250mM NaOH and 1:4 (v/v) dilution of  commercial bleach] and the eggs hatched in M9 buffer 
overnight  at 20°C. Day  1 is defined as 18h following NaOCl age-synchronization and animals are said to be 1 day  old 
(L1 stage). 10 to 15 animals were added to each well in the 96-well plate in a volume of  50 µl of  M9 plus [M9, 1 µg/ml 
cholesterol,  50 µg/ml ampicillin, 10 µg/ml tetracycline, 0.1 µg/ml fungizone and 170 µg/ml IPTG] and incubated at 20°C 
with continuous shaking at 200 rpm (Innova™ 4430 Incubator Shaker, New Brunswick, USA). Animals were scored 5 
days later (6 days old) for reduction in the number of  fluorescent foci using the stereomicroscope Leica MZ16FA 
equipped for epifluorescence (Leica Microsystems, Switzerland). As a negative control, animals were fed bacteria 
carrying the L4440 empty  vector (EV). Suppression of  aggregation was scored positive when more than 50% of  the 
animals  had a 50% or higher reduction in foci number relative to the EV control, without loss of  YFP fluorescence, 
changes in growth rate or development  of  the animals. The candidate positive hits were re-screened (n≥3), then tested 
in the Q24 soluble control strain, and counter screened in Q37 animals (5 day  old) and SOD1G93A animals (5 day  old). 
In Q37 and SOD1G93A animals, suppression of  aggregation was scored positive when more than 50% of  the animals 
showed a reduction in foci number (>25%). RNAi was always added on day  1. The identity  of  the RNAi-targeted genes 
was verified by  sequencing of  the dsRNA plasmids, followed by  Blast analysis in the NCBI and Wormbase databases 
revealing high specificity  of  genomic sequence targeting. Gene-knockdown by  the respective RNAi was also confirmed 
for a representative group of  hits by  rtPCR (data not shown). For RNAi assays on plates (for foci scoring, FRAP and 
motility  analysis, to collect animals for western blot and real-time qPCR; and for TS assays), NGM media was 
supplemented with 100 µg/ml ampicillin, 1 mM isopropyl β-D-thiogalatoside (IPTG, Sigma) and 12 µg/ml tetracycline 
(Sigma),  and seeded with overnight (16h) RNAi bacteria cultures, pre-induced with IPTG (1 mM, 3 h). One day  old (L1) 
animals  (15 to 20 animals) were transferred onto NGM-RNAi bacteria seeded plates and grown at 20°C, and at the 
time indicated aggregation was scored in at least 50 animals, for each condition (n=3). Aggregates were defined as 
discrete,  bright foci that can be distinguished from their surrounding fluorescence by  increased brightness intensity. 
The detection limit for these foci, measured with the higher resolution Zeiss Axiovert 200 microscope, is in the order of 
3 µm in length (for elongated foci in Q35) and ~7 µm2 in area (for round foci), with the microscopy  tools and 
fluorescence exposure utilized in the genetic screen (Leica MZ16FA). Data collected from different experiments was 
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compiled to calculate aggregate number averages relative to the control in EV RNAi. Fluorescent microscopy  images 
were taken using an Axiovert  200 microscope with a Hamamatsu digital camera C4742-98 (Carl Zeiss, Germany). All 
assays were performed blind as to the identity  of  the RNAi by  attributing to each modifier a number corresponding to a 
well with the dsRNA bacterial stock, in a 96-well plate.
Fluorescence Recovery After Photobleaching Analysis
 To examine the biophysical properties of  polyQ protein, animals were subjected to FRAP analysis. Animals 
were mounted on a 3% (w/v) agar pad on a glass slide and immobilized in 2mM levamisole. FRAP was measured 
using the Zeiss LSM510 confocal microscope (Carl Zeiss, Germany), and the 63X objective lens at 5X zoom power, 
with the 514nm line for excitation. An area of  0.623µm2 was bleached for 35 iterations at 100% transmission, after 
which time an image was collected every  123.35ms. Relative fluorescence intensity  (RFI) was determined as 
previously described [167,202].
SDS-PAGE, Native-PAGE and Western Blotting Analysis
 For SDS-PAGE analysis, 6 day  old animals grown on RNAi-seeded NGM plates were collected and 
resuspended in PELE buffer [20 mM Tris pH7.4, 10% glycerol, 2% Triton X-100,  0.5 mM PMSF, 1 µg/ml leupeptin, 1 
µg/ml pepstatin, 1 mM EDTA, 1 mM DTT, protease inhibitor cocktail tablet (Roche Diagnostics #11836170001)]. Lysis 
of  ~100 animals was accomplished by  a combination of  4 cycles of  freeze-thaw, grinding with a motorized pestle 
(Kontes #749541-000 and #749520-0000), followed by  8 min sonication (Sonicator Bath Branson 1510, Branson).  To 
dissolve the polyQ aggregates, SDS was added to a final concentration of  5.5% (v/v) and samples were boiled for a 
total of  10min. Total protein concentration was determined using the Bradford assay  (Bio-Rad #500-0006). 15µg (for 
Q35) or 20µg (for SOD1) of  total protein, in the linear range for YFP detection [203], were analyzed on a 10% SDS-
PAGE followed by  Western blotting. For YFP (polyQ and SOD1) detection, blots were probed with the anti-GFP IR800 
conjugated antibody  (1:5,000 dilution; Rockland Immunochemicals #600-132-215). For α-tubulin detection, blots were 
probed with the anti-α-tubulin primary  antibody  (1;4,000 dilution; Sigma #T-5168) followed by  the secondary  antibody 
Alexa Fluor®680 goat anti-mouse IgG (1:10,000 dilution; Molecular probes #A-21057).  Antibody  binding was detected 
with the Odyssey  Infrared Imaging System (LI-COR Biosciences,  USA). The ratio between band intensities YFP/α-
tubulin was calculated for each sample (Adobe Photoshop 7.0, arbitrary  units) and compared to the EV control 
(relative %). A representative group of  modifiers was tested (3 biological replicates). Statistically  significant changes in 
protein amounts were considered if p<0.05 (Student’s T-test).
 For native PAGE analysis, animals (~100) were collected with M9 buffer and resuspended in native-lysis 
buffer [50 mM Tris pH7.4, 5 mM MgCl2, 0.5% Triton X-100, 0.2 mM PMSF, 1 µg/ml leupeptin, protease inhibitor cocktail 
tablet  (Roche Diagnostics #11836170001)]. Lysis was achieved with 4 cycles of  freeze-thaw, and homogenization by 
grinding with the motorized pestle, always maintaining the tubes on ice. Total protein concentration was determined as 
before and 40 µg were analyzed on a 5% native PAGE (at 4°C), followed by  gel scan (STORM 860, #91393, GE 
Healthcare, UK). This experiment was done in triplicate. 
Motility Assays
 Animals  (6 days old) grown on RNAi NGM plates at 20°C were picked (20-25 animals) onto the center of  a 
NGM OP50-seeded plate (full surface area covered with OP50),  equilibrated at 20°C.  Animals’ movements were 
digitally  recorded using a Leica M205 FA microscope with a Hamamatsu digital camera C10600-10B (Orca-R2, Leica 
Microsystems, Switzerland), and the Hamamatsu Simple PCI Imaging software. Videos of  45 s were recorded at 2x2 
binning and 5 frames per second, and captured frames were merged into *.avi format and imported directly  into 
ImageJ.  Using the LOCI bio-formats plugin and a custom stack de-flicker plugin (http://www.loci.wisc.edu/bio-formats/
imagej),  light average intensity  was normalized for each frame. To enhance the definition of  the animals in the movies, 
the difference between each frame and the constant background was calculated, using the Maximum Z-stack 
projection. The resulting movie was converted to binary  format using Otsu Thresholding 2. Binary  objects representing 
the animals were tracked using custom ImageJ plugin, wrMTrck (based on “MTrack2” by  Nico Stuurman [174]. The 
average speed of  each animal was calculated by  dividing the length of  each track (corrected for animal body  length) by 
the duration of  the track (body  length per second, or BLPS). The wrMTrck plugin and scripts for automated analysis 
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are open-source and publicly  available at http://www.phage.dk/plugins. Videos were recorded for a minimum of  75 
animals  per experiment (n≥3) and motility  measurements are given as a percentage of  wt motility  (% wt in EV RNAi). 
RNAi modifiers that affected the motility  of  wt animals were removed from further analysis.  All motility  assays were 
also performed blind as to the identity  of  the RNAi gene target. Measurements of  motility  were validated by  other read-
outs  that included manual-based motility  assays [90,204]. The first manual assay  measured how fast it took animals 
placed in the center of  a ring (circumference only) of  OP50 bacteria to reach the food, and the second manual assay 
monitored the number of  worms that traveled 1 cm in 1 minute on OP50 bacteria-seeded NGM plates. All results 
shown were obtained with the automated worm tracker, which provides reproducible and unbiased results.
Assay for TS Phenotypes
 Temperature sensitive (TS) mutant animals were age-synchronized to L1 stage by  NaOCl bleaching, grown 
on RNAi-seeded NGM plates (15-20 animals per plate) from day  1 at  a sensitized temperature of  23°C (to maintain the 
RNAi suppressor effect on aggregation,  which was used as a control) and scored for phenotypes on day  5. For the 
25°C restrictive temperature control experiment, L1 nematodes were grown on EV RNAi at 15°C until L4 stage to 
avoid embryonic and developmental phenotypes,  then transferred to 25°C and scored 2 days later for the same 
phenotypes.  For the 15°C permissive temperature control experiment,  animals were synchronized to L1, added to EV 
RNAi plates, grown at 15°C and scored for phenotypes on day  6 (to account for slower but normal development at this 
temperature).  At least 50 animals were scored for each specific phenotype, per experiment (n=3), as described 
previously  [90,167], and all assays were performed blind. For the slow movement/paralysis assay  [unc-15(e1402) and 
unc-54(e1157)], 15-20 animals were placed on a OP50-NGM plate at room temperature in the center of  a 1 cm circle 
(drawn on the bottom of  the plate).  Animals remaining in the 1 cm circle after 5 min were considered to possess a slow 
movement  or paralyzed phenotype. To score for stiff  paralysis [unc-52(e669su250)], partially  paralyzed animals with 
moving heads and stick-like bodies were scored. For the egg-laying phenotype [unc-45(e286)] partially  paralyzed 
animals with a large belly of accumulated eggs were scored.
Real-Time qPCR
 Wt animals (5 days old, and ~50) were collected from RNAi-NGM plates and RNA was extracted with the 
Trizol reagent (Invitrogen), followed by  DNase treatment (Applied Biosystems #AM1906).  mRNA was then reverse 
transcribed using the iScriptTM cDNA Synthesis Kit  (Bio-Rad #170-8891). 10 ng of  cDNA were used for real-time PCR 
amplification using the iQ™ SYBR® Green Supermix (Bio-Rad #170-8880) and the iCycler system (Bio-Rad) (see 
Supporting Information). The relative expression levels of  each gene were determined using the Comparative CT 
Method (Real-Time PCR Applications Guide, Bio-Rad).  Gene expression levels were normalized relative to those of 
actin (act-1) in the same sample (internal control), and then relative to the levels of  the same gene in EV control 
sample. Measurements were performed for ≥3 biological samples for each condition.
Acknowledgements: We thank members of  the Morimoto lab for discussions and comments, the High Throughput 
Laboratory  and the Biological Imaging Facility  at Northwestern University. We thank Dr Anat Ben-Zvi for generating the 
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SUPPORTING MATERIALS AND METHODS
Q37::YFP Expression in C. elegans Muscle Cells
 The unc-54p::q37::yfp C. elegans strain, was generated as described before [119]. The 37 CAG-repeats 
fused to YFP show a fluorescent diffuse pattern from hatching until day  21/2 of  age, after which small round foci start to 
appear (onset of  aggregation) (Figure S1A, B). The foci correspond to aggregated SDS-insoluble protein retained at 
the top of  the gel as shown by  SDS-PAGE western blot analysis, when protein is extracted in native-like conditions 
(Figure S1C). Expression of  Q37 in muscle cells disrupts animal motility  by  more than 40% relative to the wt or soluble 
control Q0 and Q24, indicating cellular dysfunction and toxicity (Figure S1D). 
Semi-Quantitative RT-PCR
 Six day  old animals were collected for RNA extraction with the Trizol reagent (Invitrogen #15596-026). Lysis 
was accomplished by  vortexing. Chloroform was added to each sample followed by  vortexing and centrifugation (4°C). 
2-Propanol was added to each aqueous layer and total RNA was spun down, washed with 75% (v/v) ethanol, air-dried 
and resuspended in nuclease free water. RNA aliquots of  10 µg were used for DNase treatment (Applied Biosystems 
#AM1906),  and 1 µg purified RNA was used for cDNA synthesis (Bio-Rad #170-8891). cDNA samples were diluted to 
a final volume of  500µl in water and 1µl was used for PCR amplification with specific primers for the q35-yfp sequence 
(forward primer: CCTGGAGCATTTCCCCAC; reverse primer: GAACTTCAGGGTCAGCTTGCC) and actin (act-1 
forward primer: ATCACCGCTCTTGCCCCATC; reverse primer: GGCCGGACTCGTCGTATTCTTG). A representative 
group of  22 modifiers were tested. Band intensity  ratios q35-yfp/actin were calculated with Adobe Photoshop 7.0 
(arbitrary units) and are shown as relative % to the EV control. 
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SUPPORTING FIGURES AND TABLES
Figure S1. C. elegans models of polyQ and human SOD1 aggregation. (A) Q35 and Q37 body sections show distinct morphology 
of aggregates (white arrows) in 6- and 5 day old animals, respectively. Scale bar is 0.1 mm. (B) Time dependent aggregate count for 
Q35 and Q37 animals (±SD, n>3). (C) SDS-PAGE and western blotting analysis of protein samples from animals (6 days old) 
expressing polyQ-YFP protein, immunoblotted with anti-YFP (top) and anti-α-tubulin (bottom) antibodies. By standard protein 
extraction, Q35 and Q37 aggregates are SDS-insoluble and are trapped in the loading well. YFP/tubulin ratios were calculated from 
protein band intensities (total YFP) and are shown relative to Q0 ±SD. (D) Motility measurements (in body length per second/BLPS) 
of 6 day old wt and polyQ animals show that Q35 and Q37 aggregation in BWM cells causes a motility defect (±SEM, n=3, Student t-
test ***p<0.001). (E,F) Expression of human SOD1-YFP in muscle cells: while SOD1wt adopts a diffuse soluble fluorescent pattern (E: 
II and III are zoom in of the boxed areas on I), mutant SOD1G93A displays a pattern of small foci (F: II and III are zoom in of the boxed 
areas on I). Scale bar is 0.1 mm. 
Figure S2. PolyQ mRNA levels in RNAi treated animals. q35-yfp mRNA levels from RNAi-treated animals (6 days old) analyzed by 
reverse transcriptase PCR amplification (top). Control corresponds to EV and yfp-RNAi is the positive control for reduced q35-yfp 
mRNA levels. Actin mRNA (bottom) is the control for total mRNA levels. Ratio q35-yfp/actin are calculated from band intensities, and 
averaged from 3 biological replicates. Student t-test p>0.05 for all but yfp (***p<0.001). 
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Figure S3. Gene modifiers of aggregation distribution into functional classes. (A) C. elegans genes represented in the RNAi 
library (16,757). (B) RNAi suppressors of Q35 aggregation (151). (C) Common aggregation suppressors for polyQ and SOD1G93A 
(63). Statistical significance calculated by the Chi-square test ***p<0.001.
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Table S2: Motility assays results for each modifier tested, per assay executed, for wt and Q35 animals.Table S2: Motility assays results for each modifier tested, per assay executed, with wt and Q35 animals.
RNAi Trial 1 Trial 2 Trial 3 Trial 4 Trial 5 n Mean SD SEM Trail 1 Trial 2 Trial 3 Trial 4 Trial 5 n Mean SD SEM
L4440 (EV) 1.00 1.00 1.00 1.00 1.00 107 !"## #"## #"## 0.69 0.71 0.64 0.72 0.72 210 #"$# #"#% #"#&
yfp 0.98 1.12 0.76 112 #"'( #"!) #"!# 1.34 0.89 0.68 0.60 200 #")$ #"** #"!$
B0281.5 0.71 0.72 0.40 86 #"(! #"!' #"!! 1.15 0.78 1.62 1.03 90 !"!+ #"*( #"!)
B0432.3 0.62 0.59 0.53 80 #"+) #"#% #"#* 0.98 0.41 0.71 96 #"$# #"&) #"!(
C01G12.8 0.91 0.95 75 #"'* #"#* #"#& 0.58 0.85 0.66 85 #"$# #"!% #"#)
C15H11.9 0.59 0.28 82 #"%% #"&& #"!( 0.93 1.23 0.99 135 !"#+ #"!( #"#'
let-716 0.38 0.66 82 #"+& #"&# #"!% 0.89 0.79 0.91 68 #")$ #"#( #"#%
C23G10.10 0.89 1.10 82 #"'' #"!+ #"!# 0.41 0.65 0.53 75 #"+* #"!& #"#$
C26E6.6 0.11 0.59 89 #"*+ #"*% #"&% 1.03 1.49 1.10 168 !"&! #"&+ #"!%
C30C11.4 0.49 0.68 78 #"+) #"!% #"!# 0.33 0.87 0.59 58 #"(# #"&$ #"!(
C34B2.8 0.84 1.17 78 !"## #"&* #"!$ 0.63 0.86 0.83 0.93 100 #")! #"!* #"#(
C45G3.4 0.74 0.90 70 #")& #"!& #"#) 0.84 1.12 0.98 104 #"') #"!% #"#)
C50D2.2 0.47 0.26 0.38 93 #"*$ #"!! #"#( 0.87 0.64 0.78 92 #"$( #"!! #"#$
C54C8.5 0.91 1.17 80 !"#% #"!' #"!* 0.94 0.94 0.37 0.45 0.53 114 #"(+ #"&$ #"!&
C55A6.9 1.07 0.92 0.64 86 #")) #"&& #"!* 0.67 1.02 0.72 109 #")# #"!' #"!!
cdk-1 0.44 0.59 0.47 72 #"+# #"#) #"#+ 1.34 1.12 0.54 66 !"## #"%& #"&%
clec-19 0.91 1.42 0.69 60 !"## #"*) #"&& 0.69 0.60 0.65 98 #"(+ #"#% #"#*
col-61 1.19 0.89 0.66 79 #"'& #"&$ #"!+ 0.62 0.70 0.79 75 #"$# #"#' #"#+
cyn-11 0.84 1.32 0.66 80 #"'% #"*% #"&# 0.76 0.37 0.75 0.61 102 #"(& #"!) #"#'
cyp-13B2 0.82 0.95 0.76 69 #")+ #"!# #"#( 1.29 1.19 1.15 0.88 140 !"!* #"!$ #"#'
cyp-33D1 0.87 0.84 0.98 91 #"'# #"#$ #"#% 0.61 0.60 0.59 101 #"(# #"#! #"#!
D2030.1 0.66 1.44 67 !"#+ #"++ #"*' 0.66 1.20 0.99 102 #"'+ #"&$ #"!(
dao-5 0.72 1.18 76 #"'+ #"** #"&* 0.67 1.29 1.00 79 #"'' #"*! #"!)
daz-1 0.36 0.71 0.42 92 #"+# #"!' #"!! 0.66 0.66 0.90 98 #"$% #"!% #"#)
dnj-22 0.91 1.17 82 !"#% #"!) #"!* 0.49 0.22 0.79 95 #"+# #"&) #"!(
eif-3.B 0.49 0.61 77 #"++ #"#' #"#( 0.94 0.96 0.90 90 #"'* #"#* #"#&
elo-2 0.60 1.03 1.00 109 #")) #"&% #"!% 0.52 0.73 0.63 196 #"(& #"!# #"#(
F08H9.3 0.14 0.51 0.26 62 #"*# #"!' #"!! 1.40 0.72 1.00 150 !"#% #"*% #"&#
F13H8.2 0.36 0.53 0.37 65 #"%& #"!# #"#( 1.16 0.83 0.99 100 #"'' #"!( #"#'
F14B8.2 0.87 0.87 0.89 68 #")) #"#! #"#! 0.55 1.16 0.85 0.79 104 #")% #"&+ #"!*
F17C11.9 0.41 0.69 0.29 70 #"%( #"&! #"!& 0.95 1.12 0.99 163 !"#& #"#' #"#+
F23B12.5 0.34 0.58 0.40 60 #"%% #"!& #"#$ 1.11 1.54 1.21 135 !"&' #"&& #"!*
F26E4.2 0.79 0.84 0.95 86 #")( #"#) #"#+ 0.49 1.22 0.98 76 #"'# #"*$ #"&!
F31A9.1 0.52 1.15 1.19 58 #"'+ #"*) #"&& 0.50 1.64 1.11 0.90 79 !"#% #"%) #"&%
F33D4.5 0.76 1.35 75 !"#( #"%& #"*# 0.67 0.91 0.40 0.63 80 #"(+ #"&! #"!#
F43E2.7 0.50 0.59 70 #"+% #"#( #"#+ 1.29 1.25 1.30 1.03 228 !"&& #"!* #"#(
F43G9.1 0.73 1.11 0.97 60 #"'% #"!' #"!! 1.86 0.81 0.70 1.09 156 !"!! #"+& #"&(
F46F11.9 0.98 1.32 0.63 67 #"') #"*% #"&# 0.59 0.97 0.89 1.30 74 #"'% #"&' #"!+
F47F2.3 0.27 0.83 0.35 63 #"%) #"*# #"!$ 0.67 0.67 0.70 76 #"() #"#& #"#!
F53F10.1 0.47 1.52 81 #"'' #"$% #"+* 0.50 1.42 0.89 0.97 85 #"'% #"*) #"!'
F54C4.3 0.96 0.87 0.90 80 #"'! #"#+ #"#* 0.38 0.62 0.60 109 #"+* #"!% #"#)
F57B10.1 0.73 1.19 58 #"'( #"** #"&* 0.69 1.21 0.92 80 #"'% #"&( #"!+
F59C6.5 0.95 1.17 0.84 60 #"'' #"!$ #"!# 0.80 0.37 0.65 90 #"(! #"&& #"!&
fbxa-76 1.07 0.90 117 #"'' #"!& #"#' 0.28 0.49 0.33 59 #"*$ #"!! #"#(
fbxb-11 0.37 0.42 0.54 70 #"%% #"#' #"#+ 1.34 1.31 1.20 96 !"&) #"#$ #"#%
fbxb-17 1.07 1.17 0.89 78 !"#% #"!% #"#) 0.85 0.49 0.97 82 #"$$ #"&+ #"!+
fib-1 0.87 0.79 0.89 1.20 89 #"'% #"!) #"#' 0.67 0.67 0.60 134 #"(+ #"#% #"#&
fkh-6 0.22 0.71 0.43 79 #"%+ #"&% #"!% 0.73 0.88 0.58 92 #"$* #"!+ #"#'
gei-11 0.80 1.07 80 #"'* #"!' #"!* 0.87 1.15 1.14 0.94 1.03 175 !"#& #"!& #"#+
H02I12.1 0.31 0.78 0.47 124 #"+& #"&% #"!% 0.71 0.96 0.85 77 #")% #"!* #"#$
hmg-3/-4 0.92 0.75 1.00 0.91 80 #"'# #"!# #"#+ 1.34 0.28 0.72 159 #"$) #"+* #"*!
K02E7.11/Y51H7BR.3 0.96 0.71 0.94 0.83 100 #")( #"!& #"#( 0.52 0.67 0.59 88 #"(# #"#$ #"#%
K03F8.1 0.62 0.60 0.54 104 #"+' #"#% #"#& 0.48 0.99 0.88 61 #"$) #"&$ #"!(
klp-15 0.61 1.17 56 #")' #"*' #"&) 1.35 0.74 1.34 0.50 95 #"') #"%* #"&&
krs-1 0.20 0.62 0.35 82 #"*' #"&! #"!& 1.28 0.99 1.30 90 !"!' #"!$ #"!#
mcm-2 0.19 0.67 0.37 95 #"%! #"&+ #"!% 0.57 0.99 0.81 74 #"$' #"&! #"!&
nex-1 0.70 1.17 76 #"'* #"** #"&* 1.02 0.31 0.63 0.40 134 #"+' #"*& #"!(
pdl-1 0.58 0.53 0.47 85 #"+* #"#( #"#* 0.87 1.00 0.94 86 #"'% #"#$ #"#%
phb-2 0.86 1.20 0.69 71 #"'& #"&( #"!+ 0.73 0.34 0.45 0.36 87 #"%$ #"!) #"#'
ptr-19 0.88 0.97 0.94 87 #"'* #"#% #"#& 0.27 0.94 0.54 62 #"+) #"*% #"&#
R03D7.1 0.49 0.63 0.51 68 #"+% #"#) #"#% 0.55 0.98 0.69 80 #"$% #"&& #"!*
R05D11.4 0.57 1.24 61 #"'# #"%$ #"** 0.68 1.32 0.99 50 #"'' #"*& #"!)




Table S3: Comparative analysis between genetic screens and overlapping gene modifiers.
Table S2: Motility assays results for each modifier tested, per assay executed, with wt and Q35 animals.
RNAi Trial 1 Trial 2 Trial 3 Trial 4 Trial 5 n Mean SD SEM Trail 1 Trial 2 Trial 3 Trial 4 Trial 5 n Mean SD SEM
wt Assays (normalized to L4440 control) Q35 Assays (normalized to wt;L4440)
R05D7.2 0.60 1.22 79 !"#$ !"%% !"&$ 0.65 1.38 0.94 93 !"## !"&' !"($
rgl-1 0.43 0.48 0.40 54 !"%% !"!% !"!( 0.58 1.36 0.79 96 !"#$ !"%! !"(&
ril-1 0.81 1.36 64 $"!# !"&# !"() 0.93 0.32 0.70 74 !"*+ !"&$ !"$)
rnr-2 0.35 0.66 0.44 55 !"%) !"$* !"!# 0.46 0.96 0.74 76 !"'( !"(+ !"$+
rpa-1 0.53 0.53 0.35 80 !"%' !"$! !"!* 1.20 0.47 0.83 0.80 94 !")( !"&! !"$+
rpl-2 0.75 0.84 0.98 0.93 75 !")) !"$! !"!+ 0.68 1.11 1.00 89 !"#& !"(( !"$&
rpl-35 0.70 1.17 67 !"#% !"&& !"(& 0.94 0.95 75 !"#% !"!$ !"!$
rps-21 0.55 0.83 0.61 97 !"** !"$+ !"!) 1.93 0.83 63 $"&) !"') !"++
ruvb-1 0.82 1.33 66 $"!) !"&* !"(* 0.67 0.29 0.40 0.82 128 !"++ !"(% !"$(
smu-1 0.83 1.62 120 $"(& !"+* !"%! 0.47 0.85 0.53 69 !"*( !"($ !"$(
sri-57/-78 0.88 0.87 76 !")' !"!$ !"!$ 1.01 1.17 0.80 95 !"## !"$# !"$$
srz-53 0.98 0.88 96 !"#& !"!' !"!+ 1.39 0.71 1.01 1.11 126 $"!* !"() !"$%
T04D3.5 0.65 0.92 0.95 1.15 50 !"#( !"($ !"$! 0.82 0.95 0.90 108 !")# !"!' !"!%
T10H9.1 0.82 1.17 58 !"## !"(+ !"$) 0.23 0.54 0.48 185 !"%$ !"$* !"$!
T11F1.6 0.32 0.51 0.34 60 !"&# !"$! !"!* 1.30 2.05 1.36 85 $"+' !"%$ !"(%
T22B11.5 0.62 1.17 0.99 1.01 70 !"#+ !"(& !"$( 0.87 0.79 88 !")& !"!* !"!%
T24C4.1 1.06 0.92 0.92 1.00 62 !"#' !"!' !"!& 0.92 0.96 0.94 73 !"#% !"!( !"!$
tag-335 0.47 0.65 0.48 100 !"+& !"$! !"!* 0.86 1.20 1.12 74 $"!* !"$) !"$!
vab-19 0.46 0.71 0.49 60 !"+* !"$% !"!) 0.72 1.10 0.59 128 !")$ !"(* !"$+
viln-1 0.87 1.30 70 $"!# !"&$ !"(( 0.46 0.44 0.53 0.48 170 !"%) !"!% !"!(
W03B1.9/.5 0.86 0.93 63 !")# !"!+ !"!& 0.99 1.07 1.04 90 $"!& !"!% !"!(
W06H3.3 0.42 0.47 0.39 103 !"%& !"!% !"!( 0.81 0.79 168 !")! !"!( !"!$
xpo-1/imb-4 0.31 0.71 0.23 0.26 0.56 266 !"%$ !"($ !"!# 1.09 1.03 2.31 1.25 1.23 131 $"&) !"+& !"(%
Y110A7A.8 0.50 1.50 55 $"!! !"'$ !"+! 0.75 0.95 0.81 174 !")% !"$! !"!*
ZK430.7 0.88 0.93 0.94 67 !"#( !"!& !"!( 0.97 1.11 1.01 97 $"!& !"!' !"!%
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 Regulation of proteostasis and protein conformation represent a prominent challenge to cellular 
integrity, aging and disease. Much of our understanding on the consequences of protein misfolding and the 
activation of stress responses has come from studies at the cellular level and exposure to acute 
environmental  and physiological stress conditions. Here, we show in Caenorhabditis elegans that a 
physiologically relevant stimulation of cholinergic signaling at the neuromuscular junction, initiated by 
increase in expression of the L-type acetylcholine receptor, rescues post-synaptic protein folding. 
Cholinergic signaling causes calcium release via activation of the voltage-gated calcium channel, EGL-19, 
and the sarcoplasmic reticulum ryanodine receptor, leading to activation of HSF-1 and expression of 
cytoplasmic chaperones. The change in muscle proteostasis results in suppression of polyglutamine 
aggregation and toxicity, and stabilization of metastable proteins. This demonstrated the critical importance 
of cell  non-autonomous control of stress signaling pathways and revealed a novel  neuronal regulatory 
mechanism of proteostasis.  
INTRODUCTION
 A network of molecular interactions that coordinates synthesis, folding, trafficking and clearance of 
proteins in the cell is responsible for maintaining proteostasis [58].  When proteostasis is challenged by an 
acute environmental, chemical, or physiological stress, the cell  responds with a precise and rapid 
activation of stress responses, such as the heat shock response (HSR) or the unfolded protein response 
(UPR), to restore homeostasis [92]. In contrast, the chronic  expression of misfolded and aggregation-prone 
proteins, as occurs in conformational diseases such as Amyotrophic Lateral Sclerosis (ALS), Alzheimer’s 
disease, polyglutamine (polyQ) disorders, metabolic diseases, cancer, and muscular dystrophy represents 
a different challenge to the cellular quality control  machinery in that proteotoxicity does not abate 
compared to the response to transient stress [58,70,71,143].  
 Much of the understanding of the biology of protein conformational diseases has benefitted from 
genetic model systems to identify components of the proteostasis network that respond to protein 
aggregation and toxicity.  In particular, the invertebrate model organisms C. elegans and D. melanogaster 
expressing aggregation-prone proteins that recapitulate important features of conformational  disorders, 
have been used to identify genetic  modifiers of protein aggregation, cellular toxicity and behavioral 
phenotypes [119,122,133,144,161,205].  Among these are genetic pathways that promote protein solubility 
and clearance within the cell, including molecular chaperones, proteasome subunits, components of the 
autophagy machinery, and the FOXO and heat shock factor 1 (HSF-1) stress-induced transcriptomes 
[143]. Moreover, metazoans are representative of the orchestration of cellular functions and processes that 
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respond in an organized manner to diverse stress challenges in an organism. In contrast to cell-
autonomous regulators, tissue-specific genetic  modifiers affecting other tissues and organismal  processes 
have highlighted cell  non-autonomous regulatory mechanisms of folding and homeostasis, and reveal the 
presence of a system network of stress responses. In particular, the integration of neuronal and endocrine 
signaling cascades, transduced to muscle and intestinal cells, were shown to improve stress resistance, 
folding and even lifespan [143,164,165]. Also, tissue-specific mitochondrial  function, including the electron 
transport chain and the mitochondrial UPR were shown to affect the rate of aging [120]. Understanding 
how these cellular non-autonomous processes are integrated and regulated offers new genetic and 
pharmacological strategies to enhance protein homeostasis and health span.
 The C. elegans model for polyQ aggregation in body-wall muscle (BWM) cells exhibits a Q-length 
and age-dependent onset of aggregation and toxicity [119], that has been highly useful  as a folding sensor 
to monitor cellular homeostasis and to identify components of the proteostasis network [90,130,144,167]. 
In this study, we have used the C. elegans polyQ model, to characterize a new proteostasis genetic 
pathway, involving GEI-11, a negative regulator of cholinergic receptor activity at the neuromuscular 
junction (NMJ) [201]. Whereas cholinergic  and GABAergic  signaling at the NMJ control  muscle contraction 
[206], a dysregulation of signaling leading to overstimulation of the muscle by total absence of GABA, 
increases protein misfolding in the post-synaptic cells [167]. Here, we show that the genetic 
downregulation of gei-11 results in a distinct moderate increase in cholinergic  signaling and enhancement 
of protein folding capacity in post-synaptic  muscle cells. This revealed the existence of a critical range for 
modulation of cholinergic  and GABAergic  signaling at the NMJ that leads to activation of HSF-1 and 
expression of chaperones to restore post-synaptic proteostasis. 
RESULTS
Identification of GEI-11, a New Genetic Modifier of PolyQ Aggregation and Toxicity
 We performed a genome-wide RNA interference (RNAi) screen for suppression of polyQ 
aggregation in body wall muscle (BWM) cells, to identify new proteostasis modifiers. E. coli-expressing 
dsRNA corresponding to the genome of C. elegans [155], were fed to L1 (first larval stage, day 1) animals 
expressing Q35-YFP, the highly folding-sensitive polyglutamine aggregation reporter [119]. Animals were 
scored for reduction in the number of Q35 foci on day 6, corresponding to 3 days after onset of 
aggregation, relative to the empty vector RNAi control (Figure 1A). As a control for RNAi  efficiency, animals 
were treated with RNAi to yfp that reduced the fluorescence signal, as expected (Figure S1A). Here, we 
report on the modifier gene gei-11  that suppressed aggregation in Q35 animals (Figure 1A: II, IV, VI) and in 
two additional muscle protein aggregation models expressing Q37 (Figure S1E: I-IV) and mutant 
SOD1G93A (Figure S1E: V-VIII) [91]. Suppression of Q35 aggregation by gei-11 knockdown was not due to 
reduction in expression of Q35 mRNA or protein steady-state levels (Figure S1B-D).  
 Next, we examined whether the diffuse pattern of Q35 fluorescence observed in gei-11-treated 
animals (Figure 1A: VI vs. V) corresponded to soluble Q35 protein, using the dynamic  imaging method of 
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fluorescence recovery after photobleaching (FRAP) (Figure 1B). Whereas inclusion-localized Q35 is 
immobile and exhibits no fluorescence recovery (Figure 1B: Q35;vector) [144], Q35 fluorescence in gei-11 
RNAi-treated animals recovered completely upon photobleaching, indicative of a diffuse state 
indistinguishable from the soluble Q24 control  (Figure 1B). To address whether suppression of Q35 
aggregation affected toxicity, we examined muscle function, as aggregation reduces motility of 6 day old 
animals by 40% relative to wt animals (Figure 1C vector RNAi). gei-11  RNAi rescued the motility of Q35 
animals to 100%, without affecting the motility of wt animals (Figure 1C). As expected, motility was also 
fully restored by knocking down the polyQ transgene itself with yfp-RNAi (Figure 1C).  These results show 
that downregulation of gei-11 suppressed both aggregation and toxicity of the polyQ protein.
Knockdown of gei-11 Increases Cholinergic Signaling at the NMJ Through the L-AChR
 gei-11 encodes the GEX-3-interacting protein 11 (GEI-11), a member of the Myb superfamily of 
transcription factors, homologous to mammalian SNAPC4 (snRNA-activating protein complex subunit 4) 
[207]. gei-11 was suggested to be a negative regulator of the AChR in C. elegans BWM cells, being also 
expressed in head neurons, germ cells, somatic gonad and intestine [201,208]. At the NMJ of C. elegans, 
two types of ACh receptors are expressed, each with distinct subunit composition and pharmacology 
[181,209,210]. To test the specificity of GEI-11 regulation of AChR type, we monitored expression of AChR 
subunits of the L-type (levamisole-sensitive) AChR (unc-29, unc-38, unc-63 and lev-8) and of the N-type 
(nicotine-sensitive) homomeric  AChR (acr-16). Knockdown of gei-11 selectively increased the mRNA levels 
Figure 1: Knockdown of gei-11 
Suppresses PolyQ Aggregation 
and Toxicity. (A) gei-11 RNAi 
suppressed Q35 aggregation in 
BWM cells of 6 day old animals, 
shown by the diffuse fluorescent 
pattern in II, IV and VI, in contrast to 
a foci-like pattern in the vector 
control I, III, V. Scale bar: 0.1 mm for 
I-IV, 0.025 mm for V-VI (boxed areas 
correspond to magnified images 
below). (B) FRAP analysis shows 
relat ive f luorescence intensity 
recovery at each time point post-
photobleaching. Control Q35 foci 
( b l a c k ; v e c t o r ) r e v e a l e d n o 
fluorescence recovery, while gei-11-
treated animals showed complete 
recovery of fluorescence (blue), 
analogous to the soluble Q24 control 
(red). Each curve represents an 
average o f > 1 2 i n d e p e n d e n t 
measurements for gei-11 RNAi, and 
>5 for the controls. (C) Motility assay 
for 6 day old Q35 and wt animals fed 
with gei-11 or vector RNAi. yfp-RNAi 
is a positive control for suppression 
of motility defect (±SEM, Student t-
test **p<0.01, ***p<0.001). See also 
Figure S1.
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of all  three essential  subunits of the L-AChR (unc-29, unc-38, unc-63) by approximately 3-fold, while the 
levels of N-AChR acr-16 were unaffected (Figure 2A). We also determined that gei-11 RNAi did  not affect 
expression of the NMJ GABA receptor (GABAR unc-49, Figure 2A). These results suggest that GEI-11 is a 
specific modifier of L-type cholinergic receptor expression.
 The functional consequence of elevated expression of the three essential AChR subunits on 
receptor activity was addressed by measuring C. elegans sensitivity to the cholinergic  agonist levamisole, 
that selectively activates L-AChR and causes dose-dependent hyper-contraction, paralysis and death 
[211]. Adult wild-type (wt) animals treated with gei-11 RNAi showed increased sensitivity and rapid 
paralysis on 1 mM levamisole plates, relative to vector RNAi-treated wt animals (Figure 2B), consistent 
with increased number of functional L-AChR. We confirmed that the increased sensitivity to levamisole 
was due to L-AChR activity, by performing the same paralysis assay with loss-of-function receptor mutant 
animals (unc-38(e264), unc-63(x26), unc-29(e1072)) [181,206]. These L-AChR-deficient animals remained 
resistant to levamisole upon gei-11 RNAi treatment (Figure 2B), which supports the role of GEI-11 in the 
regulation of receptor activity. To further verify receptor specificity, we examined the sensitivity of gei-11-
treated animals to the agonist nicotine that targets N-AChR, and did not observe a change in sensitivity of 
wt or N-AChR mutant animals (acr-16(ok789)) (Figure S2A) [181,209,210], consistent with the expression 
data in Figure 2A. Taken together, these results demonstrate the specificity of GEI-11 as a selective 
negative regulator of the L-AChR. To establish the link between gei-11-mediated suppression of polyQ 
aggregation and increased cholinergic signaling, we employed (+)-Tubocurarine chloride (dTBC), a potent 
inhibitor of AChR activity [206].  dTBC prevented the suppression of Q35 aggregation by gei-11  RNAi in a 
dose dependent manner (Figures 2C, S2B), demonstrating that aggregation suppression in the muscle is a 
consequence of L-AChR activity. 
  To determine if aggregation suppression by gei-11 RNAi was a muscle-specific  event, we asked if 
gei-11 knockdown could suppress aggregation in another tissue, and found that it had no effect on 
aggregation of polyQ (Q44) expressed in the intestine (Figure S1F). To further examine if suppression of 
protein aggregation was a direct consequence of muscle-specific  expression of AChRs, we employed a 
mutant strain that only allows RNAi in muscle cells: Q35;WM118 [212,213]. As a negative control  we 
employed the strain Q35;WM27 that is completely impaired for RNAi (Figure 2D). Having confirmed 
muscle gei-11 knockdown (Figure 2D), we show that Q35 aggregation was suppressed by 50% relative to 
vector control in WM118 animals, but not in WM27 (Figure 2E).  Moreover, knockdown of gei-11  in WM118 
animals increased expression (>3-fold) and activity of the L-AChR, as seen by sensitivity to levamisole, 
comparable to whole-body gei-11 RNAi (compare Figure 2A, B with F, G). Taken together, these results 
suggest that suppression of protein aggregation is a consequence of gei-11 knockdown in muscle cells, 
through upregulation of AChR expression at the NMJ and increased cholinergic stimulation.
Modulation of Cholinergic Signaling Effect on Metastable Proteins and Health Span
 To address whether suppression of protein aggregation by cholinergic  signaling reflects a more 
global effect on post-synaptic  proteostasis, we examined the stability of four endogenous muscle-
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expressed metastable proteins [90]. These well-established endogenous sensors of the folding capacity in 
muscle cells are represented by temperature-sensitive (TS) mutations in the paramyosin ortholog UNC-15, 
the basement-membrane protein perlecan UNC-52, a myosin-assembly assisting protein UNC-45, and the 
myosin heavy chain UNC-54 [60,90,91,167]. At the permissive temperature (15°C), all four TS-proteins fold 
properly and are functional, whereas at the restrictive temperature (25°C) each protein misfolds and 
results in characteristic  muscle dysfunction phenotypes (Figure 3A control). For the purpose of the RNAi 
Figure 2: GEI-11 Negatively Regulates Cholinergic Signaling at the NMJ. (A) Real-time qPCR analysis of expression levels 
of AChR subunits unc-29, unc-38, unc-63, lev-8 and acr-16, and GABAR unc-49, in 6 day old wt animals fed with gei-11 RNAi. 
Data are normalized to the levels of each gene on vector-treated wt animals (±SD). (B) Cholinergic sensitivity assay: 5 day old 
animals treated with gei-11 or vector RNAi were scored for paralysis on plates containing 1 mM levamisole (±SD). L-AChR 
mutant animals unc-38(e264), unc-63(x26) and unc-29(e1072), and N-AChR mutant acr-16(ok789), were employed as controls. 
Two-way ANOVA and Bonferroni Test ***p<0.001 relative to vector control. (C) AChR antagonist dTBC (2.5mM at L4 stage) 
prevented gei-11 RNAi suppression of Q35 aggregation (±SD). Q35;unc-38(e264) is a control for AChR-dependent effect. 
Student t-test ***p<0.001. (D) Real-time qPCR analysis of gei-11 mRNA levels in wt, WM27 (impaired RNAi) and WM118 
(muscle-only RNAi) animals, treated with gei-11 or vector RNAi. Data are normalized to wt animals (±SD). (E) Knockdown of 
gei-11 suppressed aggregation by 75% in Q35 animals, and by 50% in Q35;WM118 animals (muscle-specific RNAi). Q35;WM27 
animals are the control for impaired RNAi. Foci count is relative to Q35;vector (±SD). Student t-test ***p<0.001, ns/not significant. 
(F) Real-time qPCR analysis shows AChR subunits unc-29, unc-38 and unc-63 upregulation by muscle-specific gei-11 RNAi in 
WM118 animals (6 day old), relative to vector control (±SD). (G) Cholinergic sensitivity assay: 5 day old wt, WM118 and WM27 
animals treated with gei-11 or vector RNAi were scored for paralysis on plates containing 1mM levamisole (±SD). Two-way 
ANOVA and Bonferroni Test ***p<0.001, **p<0.01, *p<0.05 relative to vector control. See also Figure S2.
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experiments, we employed an intermediate temperature (23°C) at which the TS mutant phenotypes 
remained highly penetrant (Figure 3A, 23°C vector control). Upon treatment with gei-11 RNAi, the stability 
of each protein was increased by 50% to 60% (Figure 3A). These results show that downregulation of 
gei-11 enhanced folding of multiple endogenous metastable proteins in muscle cells, suggesting an 
improvement in cellular folding capacity rather than a protein aggregation-specific effect.
 Since protein misfolding and decline in the capacity to maintain proteostasis are associated with 
aging [28,58,60,92], we examined if improvement in folding capacity by knockdown of gei-11 would affect 
lifespan.  We found that the mean lifespan of wt animals was increased by 13% upon treatment with gei-11 
RNAi (Figure 3B, Table S1), consistent with a modest improvement in organismal proteostasis and 
extended health span. In this assay, RNAi for hsf-1 and daf-2 were employed as positive controls for 
decrease and increase in lifespan, respectively [116,214,215], and the effect of gei-11  on mean lifespan 
was hsf-1-dependent (Figure 3B). Together, these results suggest that the increase in cholinergic signaling 
has beneficial consequences on muscle protein folding, and a modest overall  improvement on organismal 
proteostasis, as seen by the effect on lifespan.
Restoration of Post-Synaptic Proteostasis by Induction of Cytoplasmic Chaperones and Activation 
of HSF-1
 The proteostasis network is comprised of many pathways that affect the stability of the proteome, 
therefore, we sought to identify which components were responsible for the enhanced folding in the 
muscle. We examined if this effect was a consequence of HSR induction, by testing dependence on HSF-1 
and HSP-70. Double knockdown of gei-11 with hsf-1 or C12C8.1 (hsp-70) did not suppress Q35 
aggregation (Figure 3C), suggesting a role for the HSR. Next, we examined the expression of cytoplasmic 
chaperones regulated by the HSR. Upon gei-11 knockdown in wt animals, the expression of multiple heat 
shock genes of the HSP-70 family (C12C8.1, F44E5.4 and C30C11.4) and small  heat shock protein family 
(sHSPs hsp-16.1, hsp-12.6 and hsp-16.49) was upregulated (Figure 3D). The expression of these 
chaperones was not induced by gei-11 knockdown in the AChR mutant unc-29(e1072), or in the 
background of the hypomorphic mutant hsf-1(sy441) (Figure 3D), revealing that folding improvement by 
cholinergic  signaling is a consequence of HSR activation. In addition, hsp levels were also upregulated in 
WM118 animals (muscle RNAi) treated with gei-11 RNAi  (Figure 3E), underscoring that the effect on 
muscle proteostasis is a consequence of events occurring at the NMJ.
 To examine directly whether induction of chaperone expression by gei-11 knockdown is due to 
activation of HSF-1, we employed an electrophoresis mobility shift assay (EMSA) to directly monitor HSF-1 
DNA binding activity [216]. Knockdown of gei-11 induced HSF-1 DNA-binding activity (Figure 3F: lane 6), 
to a level equivalent to that of heat shock (lane 3). A similar level  of HSF-1 DNA binding activity was also 
observed in animals treated with hsp-1 (Hsc70) RNAi, a negative regulator of HSF-1 (lane 9) [40]. The 
specificity of HSF-1 binding was demonstrated by competition with excess unlabeled HSE (lanes 4, 7 and 
10) and by using a mutated HSE radiolabeled oligonucleotide (lanes 5 and 8), for which HSF-1 binding 
was not observed. These results establish that HSF-1 was activated by gei-11-mediated increase in 
cholinergic signaling, consistent with the up-regulation of cytosolic chaperones.
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 Finally, to distinguish between a generalized cell stress response and a selective induction of the 
HSR, we examined the expression of the UPR-regulated ER chaperones (hsp-3, hsp-4, dnj-7 and ero-1), 
metabolic  stress FOXO/DAF-16 regulated genes (sod-3 and mtl-1) and oxidative stress regulated genes 
(hsp-6, gst-4 and gcs-1). As shown in Figure S3, the expression of these stress responsive genes was not 
induced by gei-11  knockdown. Altogether, these results demonstrate that modulation of synaptic 
cholinergic  signaling leads to the selective activation of HSF-1, expression of cytoplasmic chaperones, and 
restoration of the folding environment in post-synaptic muscle cells.  
Figure 3: Cholinergic Signaling Rescue of Proteostasis through HSF-1 Activation and Upregulation of Chaperones. (A) 
gei-11 RNAi rescued folding of muscle TS mutant proteins as measured by the decrease in the TS phenotypes: UNC-15 
(paramyosin; unc/slow movement), UNC-52 (perlecan, stiff paralysis), UNC-45 (myosin assembly, egg laying defect) and UNC-54 
(myosin, paralysis). 15°C is the permissive temperature, 25°C is the restrictive temperature and 23°C is the temperature for RNAi 
(±SD, Student t-test **p<0.01).  (B) Survival curves for wt animals on RNAi bacteria from L2 stage throughout adulthood, at 20°C. 
Animals treated with gei-11 RNAi show 13% increase in mean lifespan relative to vector control RNAi. (p<0.001 Log-rank/Mantel 
Cox test). daf-2 RNAi is the control for extended lifespan, and hsf-1 RNAi is the control for shorter lifespan. See also Table S1. (C) 
gei-11 double knockdown with hsf-1 or C12C8.1 (hsp-70) abolished the suppressor effect on Q35 aggregation (±SD, Student t-
test ***p<0.001). (D) Real-time qPCR analysis of chaperone levels in wt or mutant unc-29(e1072) and hsf-1(sy441) animals, 
treated with gei-11 RNAi. Up-regulation of chaperones from the Hsp-70 family (C12C8.1, F44E5.4, C30C11.4) and small Hsps 
(hsp-16.1, hsp-12.6, hsp-16.49) by gei-11 is dependent on AChR (unc-29) and HSF-1. Data are relative to wt;vector (±SD). (E) 
Upregulation of hsp levels upon muscle specific gei-11 knockdown in WM118 animals. Real-time qPCR data relative to 
WM118;vector (±SD). (F) Gel mobility shift analysis shows that gei-11 RNAi induced HSF-1 DNA binding (lanes 6) in a similar way 
to heat shock at 35°C (lanes 3). hsp-1 RNAi (hsc-70) is a positive control for RNAi-induced HSF-1 activation (lane 9). Assay 
performed with a [32P]HSE oligonucleotide, HSEmutant refers to a mutated oligonucleotide in the HSE (lanes 5,8) and +self refers to 
competition with 100-fold molar excess of unlabeled oligonucleotide (lanes 4,7,10). Control (lane 2) refers to vector RNAi. See 
also Figure S3.
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Regulation of Cholinergic and GABAergic Signaling Modulates Post-Synaptic Proteostasis
 The NMJ integrates multiple pathways that regulate muscle contraction, including neuronal 
synthesis and release of ACh and GABA neurotransmitters, and receptor synthesis and function at the 
BWM cell membrane (Figure 4A) [217,218]. We systematically examined the role of each component in 
the suppression of protein aggregation by gei-11 (Figure 4B, C, G). Double knockdown of gei-11 with an 
essential subunit of the L-AChR (unc-38, unc-63 or unc-29), that inhibits receptor activity, no longer 
suppressed polyQ aggregation (Figure 4B). By comparison, knockdown with a non-essential  subunit 
(lev-1) that only reduces receptor function [181], only weakened the gei-11 effect on polyQ aggregation 
(Figure 4B). As expected from the genetics data (Figure 2A), double knockdown with acr-16  did not affect 
gei-11 suppression of aggregation (Figure 4B). We then examined whether increased AChR expression in 
post-synaptic  cells was balanced by neuronal  signaling, so as to affect post-synaptic protein aggregation. 
To address this, neuronal ACh synthesis and release into the synaptic  cleft was disrupted by co-
knockdown of either the choline acetyltransferase cha-1 (choline acetyltransferase, together with unc-17/
synaptic  vesicle ACh transporter), required for neuronal ACh synthesis, or the kinesin-like protein unc-104, 
required for ACh synaptic  vesicles transport (Figure 4A) [218], with gei-11. In both cases, the level of 
aggregation suppression was significantly less efficient than by gei-11 alone (Figure 4C). We also tested 
the role of neuronal  cholinergic  activity through the acetylcholine receptor ACR-2R (Figure 4A) [219]. 
Knockdown of ACR-2R subunits acr-3 and acr-12 almost completely abolished suppression of aggregation 
by gei-11 (Figure 4C). Collectively, these results indicate that suppression of polyQ aggregation in post-
synaptic  cells requires neuronal  cholinergic signaling, revealing a cell non-autonomous control of muscle 
proteostasis.
 To address the physiological relevance of cholinergic  regulation of muscle proteostasis, we asked 
whether upstream modulation of neuronal cholinergic  activity could also correct folding in post-synaptic 
muscle cells. This would be consistent with observations that post-synaptic  transcriptional regulation of 
AChR expression is controlled cell non-autonomously by nerve-supplied signaling factors [220,221]. To 
selectively activate neuronal cholinergic  signaling, we treated Q35 animals with muscarinic  cholinergic 
agonists Oxotremorine M and Arecolin [203,218,222,223], and found that muscle Q35 aggregation was 
suppressed by >50% (Figure 4D). This result corroborated that muscle homeostasis can be rescued by 
chemical modulation of neuronal activity, in addition to genetic regulation of muscle receptor expression.
 While upregulation of cholinergic  signaling at the NMJ suppressed misfolding and toxicity of 
multiple proteins in post-synaptic  muscle cells, in a previous study we have shown that complete inhibition 
of GABAergic  function, with a null mutation in unc-30 (Figure 4A), causes misfolding and aggregation in 
BWM cells [167]. This led to the hypothesis that, while overstimulation of the muscle has deleterious 
consequences on the folding environment [167], there is a range of cholinergic  signaling modulation with a 
beneficial effect on post-synaptic homeostasis. We used the L-AChR agonist ACh and levamisole to 
determine if there is a range of agonist concentrations that suppresses or enhances aggregation. Increase 
in cholinergic signaling with the receptor agonist ACh reduced Q35 aggregation by >50% at 1 mM, while 
levamisole suppressed aggregation by 40% at 5 µM (Figure 4E). The effect of both ACh and levamisole 
was dose-dependent (Figure S2C, D), and at a higher concentration of ACh (200 mM) or levamisole (50 
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Figure 4: Regulation of Cholinergic and GABAergic Signaling Effect on Post-Synaptic Protein Aggregation. (A) 
NMJ components required for motor neuronal signal, ACh and GABA synthesis/release: choline acetyltransferase 
(cha-1); ACh vesicle and transport (unc-17; unc-104, cho-1); motor neuron AChR (ACR-2R); L-type AChR (unc-38, 
unc-29, unc-63, lev-1, lev-8); N-type AChR (acr-16); vesicular GABA transport (unc-46, unc-47); GABAergic transcription 
factor (unc-30); GABAR (unc-49). (B) Suppression of Q35 aggregation by gei-11 RNAi was abolished by double-RNAi 
with L-AChR (unc-38, unc-63, unc-29, lev-1) but not with N-AChR (acr-16). Individual RNAi controls included. (C) 
Suppression of Q35 aggregation by gei-11 RNAi was prevented by disrupting ACh synthesis/transport (cha-1, unc-17, 
unc-104) and neuronal signal (acr-3, acr-12) with RNAi. (D) Increase in neuronal cholinergic signaling with muscarinic 
receptor agonists Arecolin (25 µM) and Oxotremorine M (50 µM) led to 50% reduction in Q35 aggregation. (E) Increase 
in cholinergic signaling with L-AChR agonists ACh and levamisole suppressed Q35 aggregation at 1 mM and 5 µM, 
respectively; but enhanced aggregation at 200 mM and 50 µM, respectively. Mutant AChR unc-38(e264) is a control for 
AChR-mediated effect. (F) Reduction in GABAR function with Lindane suppressed Q35 aggregation at 25 µM, and 
enhanced aggregation at 1 mM concentration. (G) Modulation of GABAergic signaling effect on Q35 aggregation: 
decrease in GABA by unc-49 and unc-47 RNAi, or eliminating GABA with unc-47 or unc-30 mutants. (H) Incubation with 
GABA 50-200 mM suppressed Q35 aggregation. GABA at 50 mM abolished the suppressor effect of gei-11, possibly by 
“re-balancing” the GABAergic-cholinergic signaling ratio. Student t-test *p<0.05, **p<0.01 and ***p<0.001; data and 
statistics are relative to Q35;vector control (±SD).
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µM), Q35 aggregation was enhanced by 50 to 60% (Figure 4E). As expected, these agonists did not affect 
aggregation of AChR mutant animals (Q35;unc-38(e264)) (Figures 4E).  These results are consistent with 
a range for cholinergic stimulation improvement of muscle proteostasis, beyond which overstimulation 
leads to an opposite deleterious effect.  
 We characterized further the range of ACh/GABA signaling at the NMJ that restores post-synaptic 
protein homeostasis. Suppression of Q35 aggregation by moderate increase in AChR activity (gei-11 
RNAi), was mimicked by a moderate decrease in GABAergic activity with the GABAR antagonist Lindane, 
at 25 µM (Figure 4F). However, a high concentration of Lindane (1 mM), corresponding to a stronger 
inhibition of GABAergic  signaling and overstimulation of BWM cells, led to enhancement of Q35 
aggregation, as reported previously (Figure 4F) [167]. We also tested genetically, if modulating expression 
of GABAR or GABA release would have opposite effects on post-synaptic protein aggregation, as seen 
with the AChR modulators. We “titrated” GABAergic signaling by using unc-30 (GABA synthesis), unc-47 
(GABA transport) and unc-49 (GABAR) (Figure 4A) RNAi dilutions and loss-of-function mutations. 
Knockdown of unc-47 and unc-49 suppressed Q35 aggregation, and the effect was less penetrant when 
RNAi was diluted 1:1 with vector RNAi (Figure 4G). However, unc-30(e191) and unc-47(gk192) mutants 
that eliminate GABA signaling had the opposite enhancer effect (Figure 4G), also as previously reported 
[167]. When combined, knockdown of unc-47  or unc-49 with gei-11, did not affect Q35 aggregation, as 
both contribute to increased cholinergic  stimulation of the muscle, representing the threshold above which 
it becomes deleterious (Figure 4G). To further test the effect of cholinergic/GABAergic balance on post-
synaptic  folding, we exposed gei-11 RNAi-treated Q35 animals to increasing concentrations of GABA. At 
low concentrations (≤50 mM) GABA cancelled the gei-11-mediated increase in cholinergic signaling and 
suppression of Q35 aggregation, in a dose-dependent manner (Figure 4H). However, at higher GABA 
concentrations (50 mM-200 mM), the equilibrium was shifted to the opposite direction leading to 
aggregation suppression by GABA (Figure 4H) [167].  
 We then examined HSR activation by modulation of cholinergic/GABAergic signaling. Consistent 
with the effect on protein aggregation, activation of chaperone expression (hsp-70: C12C8.1 and F44E5.4) 
was dependent on AChR activity, as shown with the antagonist dTBC (2.5 mM) or AChR mutants unc-29
(e1072) and unc-63(x26); and dependent on neuronal cholinergic  function, as shown with the double 
knockdown with cha-1 or unc-104, that abolished HSR induction (Figure 5A). Conversely, increase in 
cholinergic  signaling at the NMJ, by chemical  modulation with AChR agonists ACh (1 mM) and levamisole 
(5 µM), with the GABAR antagonist Lindane (25 µM), or with the neuronal cholinergic  muscarinic  agonists 
Oxotremorine M (50 µM) and Arecolin (25 µM), induced expression of hsp-70 chaperones (Figure 5B), 
reflecting rescue of the folding environment (Figure 4E, F).  We also show that treatment with muscarinic 
agonists upregulated expression of the AChR subunits unc-29 and unc-38 by >2-fold (Figure 5B), 
consistent with regulation of AChR transcription by neuronal cholinergic stimulation [220,221], and 
emphasizing the physiological  relevance of cell non-autonomous regulation of muscle proteostasis. 
Finally, we demonstrate that GABA reduction with unc-47 or unc-49 RNAi, equivalent to a moderate 
increase in AChR function, upregulated hsp-70 by <9-fold (Figure 5C) and restored folding (Figure 4G), 
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whereas overstimulation by eliminating GABA with mutants unc-47(gk192) or unc-49(e407) led to stress 
and upregulation of hsp-70 by >50-fold (Figure 5C), consistent with aggregation enhancement (Figure 4G).
 Taken together, the results demonstrate that modulation of synaptic activity, by shifting the balance 
between cholinergic/GABAergic signaling in either direction, can affect post-synaptic proteostasis, within a 
critical range that leads to activation of chaperone expression and rescue of protein folding. Here, we 
distinguish between the beneficial  consequences of moderate increase in cholinergic  stimulation of muscle 
cells, and the deleterious consequence on the cellular folding environment caused by overstimulation. 
Cholinergic Signaling Leads to EGL-19 Activation and Ca2+ Influx Upstream of HSF-1 Activation 
 ACh binding to receptors in BWM cells leads to activation of the voltage-gated calcium channel 
(VGCC), EGL-19, and the consequent flux of calcium (Ca2+) into the cytoplasm [224] (Figure 6A). We 
investigated whether Ca2+ influx promoted by increased cholinergic activity contributes to HSF-1 activation 
by using the cell  permeant Ca2+ chelator BAPTA [224]. BAPTA at 15 µM had no effect on Q35 aggregation, 
but together with gei-11 RNAi, prevented suppression of polyQ aggregation and induction of hsp 
chaperones (Figure S4A, B). To further explore the contribution of Ca2+ for the folding environment on 
muscle cells, we examined how genetic modulation of EGL-19 activity affected protein aggregation. We 
employed a partial loss-of-function mutant, with a 30% decrease in Ca2+ flux (egl-19(n582)), a weak 
hypermorphic  (egl-19(n582ad952)) and a hypermorphic mutant (egl-19(ad695)) in the background of Q35 
[224,225]. The results show that the magnitude of modulation of Ca2+ flux in the muscle had opposing 
Figure 5: Activation of Chaperone Expression by Regulation of Cholinergic/GABAergic Signaling. Real-time qPCR 
analysis of hsp-70 (C12C8.1, F44E5.4) levels in 5 day old wt animals (A) upon gei-11 RNAi and AChR antagonist dTBC co-
treatment, upon gei-11 RNAi in the background of AChR mutants unc-29(e1072) and unc-63(x26), upon treatment with ACh or 
levamisole, and upon gei-11 double RNAi with unc-104 or cha-1 genes (ACh synthesis and release) (±SD); (B) upon treatment 
with muscarinic agonist (Oxotremorin M or Arecolin) or the GABAR antagonist Lindane (±SD); (C) upon decrease in GABAergic 
signaling, by either RNAi or mutation of unc-47, unc-49 or unc-30 (±SD).
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effects. Whereas the stronger hypermorphic mutant ad695 enhanced Q35 aggregation, both the weak 
hypermorphic  n582ad952 and hypomorphic n582 mutants suppressed Q35 aggregation (Figure 6B) [167]. 
Animals where Ca2+-mediated enhanced aggregation was observed (ad695), also had a high upregulation 
of hsp-70 levels (C12C8.1, F44E5.4; 15-fold), consistent with cellular stress, compared to the moderate 
chaperone induction (3-fold) in animals where Ca2+ suppressed aggregation (n582 and n582ad952; Figure 
6C).  These results reveal that modulation of Ca2+ flux and cholinergic  signaling had an equivalent effect 
on muscle proteostasis, with a critical range for rescuing protein folding.
 We then treated Q35;egl-19 mutant animals with gei-11 RNAi, to determine if suppression of 
aggregation by gei-11 was dependent on Ca2+ flux through the VGCC (Figure 6B). In the hypomorphic 
n582 mutant, gei-11 knockdown did not suppress Q35 aggregation (Figure 6B) and did not induce hsp-70 
expression (Figure 6C), revealing that Ca2+ flux through EGL-19 is required for the gei-11 effect. This result 
was supported by using egl-19 RNAi and the EGL-19 inhibitor Nemadipine A [226], that also abolished the 
gei-11 effect on muscle proteostasis (Figures 6B, C and S4C). The effect of the weak hypermorphic mutant 
egl-19(n582ad952) was additive to gei-11 RNAi in folding rescue (Figure 6B, C), whereas the stronger 
hypermorphic  mutant ad695 increase in Ca2+ seems to be at the threshold for causing deleterious stress, 
as it did not affect aggregation but induced hsp-70 expression to higher level (Figure 6C). Taken together, 
the results show that EGL-19 and Ca2+ influx function downstream of cholinergic signaling and contribute 
to improvement in post-synaptic protein folding. Furthermore, as for cholinergic signaling, we found a 
critical range for modulation of Ca2+ flux that improves proteostasis.
Figure 6: The VGCC EGL-19 is Involved in HSR Activation and Suppression of Aggregation in the Muscle. (A) Cholinergic 
signaling activates EGL-19 and Ca2+ flux into the cytoplasm for muscle contraction. (B,C) We tested the effect of Ca2+ flux, with 
and without gei-11, on Q35 aggregation (B) and hsp-70 (C12C8.1, F44E5.4) induction in wt animals (C) by employing a 
hypomorphic mutant egl-19(n582), a weak hypermorph egl-19(n582ad952), a hypermorph egl-19(ad695), egl-19 RNAi or the 
specific antagonist Nemadipine A. gei-11 RNAi did not suppress Q35 aggregation (B) or induce hsp-70 levels (C) in hypomorphic 
mutant egl-19(n582) animals, in animals co-treated with Nemadipine A (0.75 µM at L2), or with egl-19 RNAi, showing dependence 
on EGL-19/Ca2+ for folding improvement. Student t-test *p<0.05, ***p<0.001, ns/not significant; data relative to vector control 
(±SD). See also Figure S4.
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Sarcoplasmic Reticulum Ryanodine Receptor Contributes to Ca2+ Effect on Muscle Proteostasis
 Activation of the VGCC and Ca2+ flux into the cytoplasm triggers the opening of the ryanodine 
receptor (RYR) at the sarcoplasmic reticulum (SR), that also releases Ca2+ into the cytosol (Figure 7C) 
[227,228]. We hypothesized that Ca2+ release by RYR could further amplify the signaling cascade from the 
AChR, and thus contribute to induction of the HSR. Therefore, we examined whether increased RYR 
activity could mimic  the effect of enhanced cholinergic  signaling at the NMJ. Ryanodine (Ryr), a plant 
alkaloid with high affinity to the RYR, is a pharmacological agent widely used to study intracellular Ca2+ 
signaling in muscle cells [227,228]. At low concentrations (nM range) ryanodine acts as an agonist and 
sensitizes RYR channels to activation by Ca2+ [229,230]. Incubation of Q35 animals with Ryr (50 nM) 
suppressed aggregation (Figure 7A), and was less effective in the background of the hypomorphic  mutant 
egl-19(n582) (60% vs. 40%) (Figure 7A), consistent with our hypothesis that the two Ca2+ channels 
function in the same pathway. These results show that flux of Ca2+ from the SR is a component of the 
mechanism triggered at the NMJ to improve the folding environment.
 Recognizing that Ca2+ regulates many signaling cascades, we examined the specificity of gei-11-
dependent Ca2+ release by the RYR, on induction of hsp-70 and suppression of polyQ aggregation by 
testing RYR agonists and antagonists. As for the natural agonist ryanodine, the clinically used activator 4-
Chloro-m-cresol (4-CmC) [231] up-regulated hsp-70 levels and significantly reduced Q35 aggregation by 
more than 60% (Figures 7A, B S4D). This emphasizes the contribution of Ca2+ release by the RYR to the 
improvement in folding. At the highest concentrations of 4-CmC (>1mM), we observed toxicity and no 
effect of aggregation (Figure S4D), consistent with a critical  range for Ca2+ that restores homeostasis in 
muscle cells.  We next tested dantrolene sodium (DS), a clinically used muscle relaxant that selectively 
targets RYR and blocks Ca2+ release from the SR during muscle contraction [232,233]. This antagonist 
prevented induction of hsp-70 and suppression of Q35 aggregation by gei-11 RNAi (Figures 7A, B, S4E). 
A similar result was obtained with the RYR mutant unc-68(kh30) (Figure 7B) [227], supporting a role for 
RYR-Ca2+ on the mechanism leading to HSR activation. Finally, treatment of EGL-19 hypomorphic  mutant 
animals (Q35;egl-19(n582)) with the RYR modulators had no significant effect on aggregation (Figure 7A) 
supporting the epistatic relationship of the two Ca2+ channels. Collectively, these results demonstrate that 
the downstream events of increased cholinergic signaling, involve Ca2+-dependent activation of the HSR 
and folding rescue in BWM cells. 
 The increased flux of cytoplasmic Ca2+ promoted the activation of HSF-1, leading us to propose 
that this could occur through activation of Ca2+-dependent kinases. Previous studies on HSR regulation 
have shown that HSF-1 activity is regulated by phosphorylation in multiple serine residues, implicating 
Ca2+ and Ca2+-dependent kinase activities [35,234-239]. Here, we have tested a large group of kinases 
known to be calcium regulated in C. elegans (Figure S5A), and we have identified the ortholog kinases to 
be required for HSR induction by gei-11 RNAi (Figure S5B, C): calmodulins cal-2 and cal-4; unc-43/CaMKII 
ortholog; pkc-1, pkc-3, and gsk-3. This overlap places these kinases at a critical step between Ca2+ flux 
and activation of HSF-1, and it will be interesting to further explore if they represent the direct link between 
increase in Ca2+ levels in the cytosol, triggered by increased cholinergic  signaling, and activation of HSF-1 
in C. elegans. 




 This study provides new insight on the role of synaptic signaling on cell non-autonomous control of 
proteostasis. A moderate increase in cholinergic signaling at the NMJ, either by genetic upregulation of L-
AChR activity (gei-11) or downregulation of GABA, led to selective activation of HSF-1, up-regulation of 
cytosolic chaperones and rescue of the folding environment in muscle cells (Figure 7C). The important 
distinction in the results presented here and the previous work describing the consequences of blocking 
GABA with an unc-30 null mutation [167] is that enhanced protein aggregation occurs when GABAergic 
signaling is completely inhibited, thus resulting in maximum cholinergic overstimulation of muscle cells. 
Here, we characterize the biological consequences of increased AChR expression (≤3-fold) and an 
Figure 7: RYR-Mediated Ca2+ 
Contribution to HSR and Folding 
Improvement. (A) The RYR agonists 
ryanodine (50 nM) and 4-CmC (10 
µM) suppressed Q35 aggregation in a 
similar way to gei-11 RNAi (at L2), but 
were less efficient in Q35;egl-19(n582) 
hypomorph i c mu tan t an ima ls . 
Treatment with the RYR antagonist 
DS (at L2) together with gei-11 RNAi 
prevented suppression of Q35 
aggregation. % Foci are relative to 
v e c t o r ( ± S D ) . S t u d e n t t - t e s t 
***p<0.001, n.s./no significance. (B) 
Real-time qPCR analysis of hsp-70 
(C12C8.1, F44E5.4) levels: RYR 
agonists Ryr (50 nM) and 4-CmC (10 
µM) up-regulated hsp-70 in wt animals 
but not in mutant egl-19(n582) 
animals. Chaperone induction by 
gei-11 RNAi was prevented in the 
RYR mutant (unc-68(kh30)) and by 
co-treatment with DS (±SD). (C) 
Model for GEI-11 modulation of 
p ro teos tas i s i n BWM. GEI -11 
negatively regulates cholinergic 
signaling at the NMJ, through L-AChR 
activity. [a] Knockdown of gei-11 leads 
to an increase in L-AChR activity and 
excitatory signaling into the muscle 
[b]. ACh binding to AChRs activates 
the VGCC EGL-19. [c] Depolarization, 
conformational changes and Ca2+ 
influx through EGL-19 triggers the 
opening of RYR at the SR and further 
release of Ca2+ into the cytosol [d]. 
Ca2+ activates signaling cascades to 
promote muscle contraction [e], HSF-1 
activation and expression of cytosolic 
chaperones that rescue protein folding 




intermediate level signaling response. We make the distinction between the beneficial and biologically 
relevant consequences of moderate increase in cholinergic stimulation, and the deleterious consequence 
on the cellular folding environment caused by overstimulation of the muscle cells. Therefore, we 
demonstrate a critical range for modulation of cholinergic/GABAergic  signaling at the NMJ that leads to 
rescue of protein folding. In agreement with our model, high cholinergic stimulation of the muscle with high 
concentrations of AChR agonists or complete inhibition of GABAergic  signaling was deleterious to muscle 
cells, as shown by enhanced protein aggregation. In contrast, a mild stimulation of muscle cells, either with 
low concentrations of AChR agonists or by dampening GABA signaling suppressed aggregation. As for 
cholinergic  signaling, modulation of Ca2+ flux to improve protein folding in muscle cells also occurs at a 
critical range. The activation of both EGL-19 and RYR channels, leads to increased cytoplasmic  Ca2+ to a 
level that was sufficient to activate HSF-1, but below the threshold that causes ER or mitochondrial  stress. 
These results shift the emphasis from extreme environmental  forms of stress to characterization of in vivo 
physiologically relevant stress signaling pathways. 
 In C. elegans, neurotransmitters are released in a graded fashion, such that the intensity of 
postsynaptic  currents correlates with the strength of neuronal stimulation [240]. This trait provides a broad 
dynamic range for neuronal  control of muscle function and protection against protein damage. There is a 
growing body of evidence for the neuronal  regulation of protein homeostasis; in particular that neuronal 
dysfunction impairs HSR capacity in somatic cells [164], induces post-synaptic muscle protein misfolding 
and proteolysis [166,167], and affects longevity [120]. Our studies have identified GEI-11 as a new genetic 
modifier of neuro-muscular regulation of proteostasis. In the proposed model  (Figure 7C), downregulation 
of gei-11 and subsequent increase in cholinergic stimulation of muscle cells, improved the folding of 
metastable proteins in muscle cells through the activation of HSF-1 and chaperone expression. The 
regulation of the HSR in a cell  non-autonomous manner by cholinergic  signaling at the NMJ represents an 
organismal  strategy that is likely to be of broad relevance for communication of proteostatic  imbalance 
across tissues.  Our results with neuronal cholinergic/muscarinic  agonists corroborate that muscle function 
and homeostasis can be rescued by chemical modulation of neuronal  activity, in addition to genetic 
regulation of muscle receptor expression. This is a relevant observation for complex pathologies such as 
neurodegenerative and neuromuscular disorders, where scenarios of protein misfolding initiated at one 
tissue have both autonomous and non-autonomous consequences on cellular and tissue function, 
organismal  health and lifespan. For example, selective neuronal degeneration leads to muscle weakness 
and paralysis in motor neuron disorders such as ALS, hereditary spastic  paraplegia, and spinal muscular 
atrophy [80]. Consequently, an understanding of the regulatory signaling cascades that trigger protective 
responses across tissues is of fundamental  importance to delay or prevent organismal collapse of 
proteostasis. Modulation of signaling events at the NMJ to rescue muscle function, such as described here 
for gei-11, represent new therapeutic  targets for genetic and chemical modulation of proteostasis 
maintenance.
 Our findings strongly suggest that cell non-autonomous control  of proteostasis, through neuronal 
signaling and Ca2+-dependent activation of the HSR in stressed cells, is a critical new mechanism in the 
cellular challenge to maintain homeostasis and proteome health. During aging and chronic  stress, as the 
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cellular quality control  systems are challenged by the persistent expression of misfolded toxic  proteins, an 
imbalance in neuronal  signaling may therefore lead to dysregulated proteostasis.  Fine-tuning of neuronal 
cholinergic  signaling, within a well-defined physiological range, represents a new target to re-shape the 
functional  properties of the proteostasis network. Our results contribute to the growing understanding of 
the organizational properties of stress response networks as an integrated organismal  response to diverse 




C. elegans Strains:  Animals were maintained according to standard methods, at 20°C on nematode growth media 
(NGM) with OP50 E. coli (Brenner, 1974).  The strains utilized in this work, and previously  described, are the following: 
wild-type (wt) Bristol strain N2; polyQ strains Q24 AM138 (rmIs130[Punc-54::q24::yfp]II), Q35 AM140 (rmIs132
[Punc-54::q35::yfp]I), Q37 AM470 (rmIs225[Punc-54::q37::yfp]II) (Morley  et al., 2002; Nollen et al., 2004); human 
SOD1G93A AM265 (rmIs177[Punc-54::sod1G93A::yfp]) (Gidalevitz et al.,  2009);  temperature sensitive (TS) mutant strains 
CB1402 [unc-15(e1402)],  CB1157 [unc-54(e1157)], HE250 [unc-52(e669su250)] and CB286 [unc-45(e286)] (Gidalevitz 
et al.,  2006); WM27 [rde-1(ne219)] and WM118 [rde-1(ne219);neIs9[myo-3::HA::RDE-1+pRF4(rol-6(su1006))]] (Bolz et 
al.,  2010; Qadota et al.,  2007); CB1072 [unc-29(e1072)], CB904 [unc-38(e264)], ZZ26 [unc-63(x26)], RB918 [acr-16
(ok789)], VC311 [unc-47(gk192)], CB845 [unc-30(e191)],  CB407 [unc-49(e407)] (Garcia et al., 2007), MT1212 [egl-19
(n582)],  DA952 [egl-19(n582ad952)], DA695 [egl-19(ad695)] (Jospin et al., 2002; Lee et al., 1997), HK30 [unc-68
(kh30)], PS3551 [hsf-1(sy441)]. Genetic crosses of mutant animals with Q35 were generated where indicated.
RNAi Assays:  RNAi gene knockdown in C. elegans was performed as described previously, using the commercial 
RNAi library  (GeneServiceTM, USA) (Kamath and Ahringer, 2003; Nollen et al., 2004). Briefly, animals were added to 
RNAi bacteria (in liquid or RNAi-seeded NGM plates) at the L1 stage (first larval, day  1), incubated at 20°C for 5 days 
and scored for reduction in the number of  aggregates at 6 days old (which corresponds to 3 days after the onset of 
Q35 aggregation), using the stereomicroscope Leica MZ16FA (Leica Microsystems, Switzerland). Aggregates were 
identified as discrete, bright fluorescent foci-like structures distinguishable from the surrounding fluorescence. As a 
negative control, animals were fed bacteria carrying the L4440 empty  vector (vector). Liquid RNAi treatment was 
performed in 96-well plates, with a total volume of  60 µl per well, consisting of  15-20 worms and RNAi bacteria. 
Bacteria was grown overnight (~16h), induced with isopropyl β-D-thiogalatoside (IPTG Sigma, 1 mM for 3 h at 37°C), 
pelleted and resuspended in S-medium complete (S-Basal supplemented with 3 mM MgSO4, 3 mM CaCl2, 10 mM 
KCitrate,  100 mg/ml Ampicillin and 1 mM IPTG) so that the final OD595nm was 0.9 in the well.  For RNAi assays on 
plates, NGM media was supplemented with 100 µg/ml ampicillin (Sigma), 1 mM IPTG and 12 µg/ml tetracycline 
(Invitrogen),  and seeded with overnight (~16h) RNAi bacteria cultures, pre-induced with IPTG (1 mM for 3 h at 37°C). 
For double knockdown experiments, equal volumes of  each RNAi bacteria were mixed (1:1 ratio) prior to plate 
seeding.  Q35 aggregation was scored in at least 50 animals, for each condition, always at 6 days of  age (n≥3). 
Fluorescent  microscopy images were taken using an Axiovert 200 microscope with a Hamamatsu digital camera 
C4742-98 (Carl Zeiss, Germany). All RNAi plasmids were sequenced to confirm correct and specific  gene-target 
identity. Gene knockdown by RNAi was confirmed by PCR.
FRAP Analysis:  Animals were mounted on a 3% (w/v) agar pad on a glass slide, immobilized with 2 mM levamisole 
(Sigma),  and subjected to FRAP analysis using the Zeiss LSM510 confocal microscope (Carl Zeiss,  Germany),  and 
the 63X objective lens at  5X zoom power, with the 514 nm line for excitation. An area of  0.623 µm2 was bleached for 
35 iterations at 100% transmission, after which time an image was collected every  123.35 ms. Relative fluorescence 
intensity (RFI) was determined as previously described (Garcia et al., 2007; Phair and Misteli, 2000). 
Motility Assays:  Six day  old animals grown on RNAi-seeded NGM plates were picked (~20 per assay) onto plates 
seeded with OP50 bacteria and equilibrated at 20°C. Their movements were digitally  recorded using a Leica M205 FA 
microscope with a Hamamatsu digital camera C10600-10B (Orca-R2, Leica Microsystems, Switzerland), and the 
Hamamatsu Simple PCI Imaging software. Videos of  45 s were recorded for a minimum of  75 animals per experiment 
and the animals were tracked using a custom ImageJ plugin wrMTrck (see Extended Experimental Procedures).  The 
average speed of  each animal was calculated by  dividing the distance of  each track, corrected for body length, by  the 
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duration (in seconds) of  the track (body  length per second BLPS). Motility  measurements are given as a percentage of 
wt motility in vector RNAi (100%) and n≥3.
Real-Time qPCR Analysis:  RNA from ~50 animals was extracted with Trizol (Invitrogen),  followed by  DNase 
treatment  (Applied Biosystems #AM1906). mRNA was reverse transcribed using the iScriptTM cDNA Synthesis Kit 
(Bio-Rad #170-8891). 10 ng of  cDNA were used for real-time PCR amplification using the iQ™ SYBR® Green 
Supermix (Bio-Rad #170-8880) and the iCycler system (Bio-Rad) (see Extended Experimental Procedures). 
Expression levels of  each gene were determined using the Comparative CT Method (Real-Time PCR Applications 
Guide, Bio-Rad), normalized to actin (act-1) in the same sample (internal control), and then determined relative to the 
non-treated or vector control sample. Measurements were performed for ≥3 biological samples.
Paralysis Assays with Cholinergic Agonists:  Five day  old animals grown on RNAi-seeded NGM plates at 20°C 
(≤40) were transferred onto fresh NGM plates, equilibrated at 20°C, containing 1 mM Levamisole (Sigma), 30 mM 
Nicotine (Sigma) or the solvent (water or ethanol, respectively). Sensitivity  to the drugs was followed by  visual 
inspection every  2 to 5 min and defined as paralysis,  or lack of  movement in response to prodding on the nose and tail 
of  the animal (n=3). Compound stock solutions: 800 mM levamisole (Sigma) in water, 300 mM nicotine (Sigma) in 
ethanol.
Compound Assays:  Compound assays were performed in liquid culture as described previously  (Voisine et al., 
2007), with 60 µl of  final volume per well, 15-20 animals (added in S-Basal complete), compound at the appropriate 
concentration and bacteria (OP50 or RNAi) at a final OD595nm of  0.9 (also resuspended in S-Basal complete). We 
included replicates of  each condition per assay  plate. Animals were incubated with each drug from L1 stage (ACh, 
levamisole,  GABA, Oxotremorine M, Arecolin), L2 stage (Lindane, Ryanodine, Nemadipine A, Dantrolene Sodium, 4-
CmC) or L4 stage (dTBC, BAPTA), until day  6 of  age, at 20°C (n≥3) (see Extended Experimental Procedures). At this 
time animals were transferred from liquid culture onto NGM plates for aggregate quantification (Leica MZ16FA), and/or 
collected for real-time qPCR analysis. 
Assay for TS Phenotypes:  Temperature sensitive (TS) mutant animals were age-synchronized to L1 stage, grown 
on RNAi-seeded NGM plates (~20 animals per plate) from day  1 at a sensitized temperature of  23°C (to maintain the 
RNAi suppressor effect on aggregation, used as control) and scored for phenotypes on day  5. For the 25°C restrictive 
temperature control experiment, L1 nematodes were grown on EV RNAi at 15°C until L4 stage to avoid embryonic and 
developmental phenotypes, then transferred to 25°C and scored 2 days later for the same phenotypes. For the 15°C 
permissive temperature control experiment,  L1 animals were added to RNAi plates, grown at 15°C and scored for 
phenotypes on day  6 (to account for slower but normal development at this temperature).  >50 animals were scored for 
each TS phenotype, per assy, as described previously: slow movement/paralysis assay  for unc-15(e1402) and unc-54
(e1157), stiff  paralysis for unc-52(e669su250),  and egg-laying phenotype for unc-45(e286) (partially  paralyzed animals 
with a large belly of accumulated eggs) (n=3) (Garcia et al., 2007; Gidalevitz et al., 2006). 
Gel Mobility Shift Analysis:  Native nuclear protein extracts were prepared from >200 µl of  pelleted worms (grown on 
NGM RNAi-seeded plates), with the commercial Thermo Scientific NE-PER Nuclear and Cytoplasmic Extraction Kit (# 
78835), as described previously  (Mah et al., 2007). Electrophoretic mobility  shift analysis (EMSA) was performed as 
before (Mosser et al., 1988) using a [32P]-labeled probe containing the proximal heat shock element (HSE) from the C. 
elegans hsp-70 (C12C8.1) gene promoter. Nuclear extracts (40 µg) were incubated with the [32P]-labeled probe (HSE 
or mutant) for 20 min at room temperature.  For heat shock treatment (HS) the samples were pre-incubated at 35°C for 
30 min. For competition experiments, a 100-fold molar excess of  the same unlabeled oligonucleotide was added to the 
mixture.  The samples were analyzed by  electrophoresis on a 4% (w/v) polyacrylamide native gel that was dried and 
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scanned using a PhosphorImager (Molecular Dynamics, Sunnyvale, CA). Oligonucleotide probes: HSE.F: 
taaattgtagaaggttctagaagatgccaga; HSE.R: tctggcatcttctagaaccttctacaattta; 
HSEmut.F: taaattgtaaaaggaaataaaagatgccaga; HSEmut.R: tctggcatcttttatttccttttacaattta.
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EXTENDED EXPERIMENTAL PROCEDURES
Motility Assays:  Videos of  45 s were recorded at 2x2 binning and 5 frames per second, and captured frames were 
merged into *.avi format and imported directly  into ImageJ. Using the LOCI bio-formats plugin and a custom stack 
deflicker plugin (http://www.loci.wisc.edu/bio-formats/imagej), light average intensity  was normalized for each frame. To 
enhance the definition of  the animals in the movies, the difference between each frame and the constant background 
was calculated, using the Maximum Z-stack projection.  The resulting movie was converted to binary  format using Otsu 
Thresholding 2.  Binary  objects representing the animals were tracked using custom ImageJ plugin, wrMTrck (based on 
“MTrack2” by  Nico Stuurman (Klopfenstein and Vale, 2004)). The average speed of  each animal was calculated by 
dividing the length of  each track (corrected to animal body  length) by  its duration (body  length per second, or BLPS). 
The wrMTrck plugin and scripts for automated analysis  are open-source and publicly  available at http://www.phage.dk/
plugins.
PCR Analysis:  Animal lysis and RNA extraction were accomplished by  vortexing with Trizol (Invitrogen). Chloroform 
was added to each sample,  followed by  vortexing and centrifugation at 13,500xg for 15 min (4°C). 2-Propanol was 
added to the aqueous layer and total RNA was spun down at 18,000xg (4°C) for 10 min. RNA pellets were washed 
with 75% (v/v) ethanol, air-dried and resuspended in nuclease free water. RNA aliquots of  10 µg were used for DNase 
treatment  (Applied Biosystems #AM1906), and purified RNA was used for cDNA synthesis (Bio-Rad #170-8891). For 
real time PCR analysis, 10 ng of  cDNA were used for PCR amplification with specific primers for each gene (see list 
below) and the iQ™ SYBR® Green Supermix (Bio-Rad #170-8880), in the iCycler system (Bio-Rad). For standard 
PCR, cDNA samples were amplified with the following primers: 
actin.F 5’-ATCACCGCTCTTGCCCCATC-3’; actin.R 5’-GGCCGGACTCGTCGTATTCTTG-3’; 
Q35-yfp.F 5’-GCTGCCCGACAACCACTAC-3’; Q35-yfp.R  5’-TGGCGATCTGATGACAGCGG-3’. 
Amplified products were ran on a 1% (w/v) agarose-TBE gel with ethidium bromide, and scanned with the UV scanner 
Alpha Imager EC (Alpha Innotech).
Primers used for real-time qPCR:
gei-11.F ctctcgatgcatcggttaagc; gei-11.R gttgttcgtcttcaaccagc; 
unc-29.F gaggaccaaccgactatcatgg;  unc-29.R cacattgatgagcaacaccaac; 
unc-38.F catgggatccagtgaattatggg; unc-38.R atactcttgaagattgctggtg; 
unc-63.F ggaccaaatgaccacggttttgc; unc-63.R gaacgtcaccacgagtgtctctc; 
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acr-16.F ctcatctcgtgcgcaattcttgc; acr-16.R cgtcaattatttgttggagggc; 
unc-49.F gttgccgcagtttgtacttcagtc;  unc-49.R cgacaatcaggacagatggtag; 
lev-8.F ggagagccacatatcacaatcac; lev-8.R gtttctccgtcattcgaccatcc;  
C12C8.1.F actcatgtgcggtatttatca; C12C8.1.R acgggctttccttgtttt; 
C30C11.4.F gcttcgtactattgtggaatctc; C30C11.4.R ggagatcttgcttgtagattcc;
F44E5.4.F gtcttgatgcaaagctattggtatc; F44E5.4.R cgtcgtccaatcaatccttttgcatc; 
hsp-16.1.F actttaccactatttccgtccagc; hsp-16.1.R gataatgtatgtccatccaaatta; 
hsp-12.6.F atgatgagcgttccagtgatggctgacg; hsp-12.6.R ccatgtgaatccaagttgctcttg; 
hsp-16.49.F ccatattggagaaatgctgatcac; hsp-16.49.R cttctggtagccgcctcattttg; 
mtl-1.F ggcttgcaagtgtgactgcaaaaacaagc; mtl-1.R ttaatgagccgcagcagttccctggtgttgatgg; 
sod-3.F gcttcaaagcttgttcaaccggttgcg; sod-3.R cagcgctggttggagagcaattgc; 
hsp-6.F caggccgttaccaactctgc; hsp-6.R gcagtttccttcatcttcatc; 
gcs-1.F gtgcaagtgtcgacgatcgtac; gcs-1.R gcgaatatgttttgccagtggctc; 
gst-4.F cgactccatttggccagc; gst-4.R  gatcagcgtcacttctag; 
hsp-4.F gcagatgatcaagcccaaaaag; hsp-4.R ggagacgattggttgaacaacag; 
hsp-3.F cctacggacttgacaagaaggac; hsp-3.R gaacggcacgattgtctttgc; 
dnj-7.F gagcacggatagtacggac; dnj-7.R gaggcaagccatccagtc; 
ero-1.F   cgacgaaatgcagtgaatatg; ero-1.R gtgtagcgttccggattcttcg;
Compound Assays:  Assays were performed in 96-well plates with 15-20 animals per well in a total volume of  60 µl, 
compound at the appropriate concentration and bacteria (OP50, vector RNAi or gei-11 RNAi bacteria). RNAi bacteria 
grown overnight (~16h) was induced with IPTG (1 mM for 3.5 h at 37°C), pelleted and resuspended in S-medium 
complete (S-Basal supplemented with 3 mM MgSO4, 3 mM CaCl2, 10 mM KCitrate, 100 mg/ml Ampicillin and 1 mM 
IPTG) so that the final OD595nm is 0.9 in the well. Compound stock solutions: 550 mM Acetylcholine (Sigma) in water; 
500 mM GABA (Sigma) in water; 1 mM Levamisole (Sigma) in water; 200 mM (+)-Tubocurarine Chloride (D-
Tubocurare/dTBC, Sigma) in water; 100 mM Lindane (Sigma) in 10% ethanol; 10 mM Oxotremorine M (Sigma) in 
water; 10 mM Arecolin (Sigma) in water; 5 mM Ryanodine (Tocris Bioscience) in 100% ethanol; 1 mM Nemadipine A 
(Nem.A,  Sigma) in 100% DMSO (dilutions in water); 5mM BAPTA (Invitrogen) in 100% DMSO; 10mM Dantrolene 
Sodium (DS, Sigma) in 100% DMSO; 20mM 4-Chloro-m-cresol (4-CmC, Supelco Analytical) in water.
SDS-PAGE and Western Blotting Analysis:  Six day  old animals (50 to 100 animals) grown on RNAi-seeded NGM 
plates at 20°C, were collected with M9 buffer,  pelleted at 3,000xg and resuspended in PELE buffer [20 mM Tris pH7.4, 
10% glycerol,  2% Triton X-100, 0.5 mM PMSF, 1 µg/ml leupeptin,  1 µg/ml pepstatin, 1 mM EDTA, 1 mM DTT, protease 
inhibitor cocktail tablet (Roche Diagnostics #11836170001)].  Lysis was accomplished by  a combination of  4 cycles of 
freeze-thaw, grinding with a motorized pestle (Kontes #749541-000 and #749520-0000), followed by  3 cycles of  2 min 
sonication (Sonicator Bath Branson 1510, Branson) and mixing. SDS was added to a final concentration of  5% (v/v) 
and samples were boiled for 5 min. Total protein concentration was determined using the Bradford assay  (Bio-Rad 
#500-0006). 16 µg of  total protein were loaded onto a 10% (w/v) SDS-PAGE followed by  Western blotting. For Q35-
YFP detection, blots were probed with the anti-GFP IR800 conjugated antibody  (1:5,000 dilution; Rockland 
Immunochemicals #600-132-215). For α-tubulin detection (55 KDa), the same blots were probed with the anti-α-tubulin 
primary  antibody  (1;4,000 dilution; Sigma #T-5168) followed by  the secondary  antibody  Alexa Fluor®680 goat anti-
mouse IgG (1:10,000 dilution; Molecular probes #A-21057). Antibody  binding was detected with the Odyssey  Infrared 
Imaging System (LI-COR Biosciences, USA) and intensity  of  the bands was measured using Adobe Photoshop 7.0. To 
determine relative Q35 protein levels, the ratio YFP/α-tubulin between band intensities was calculated (arbitrary  units) 




Figure S1: Suppression of Protein Aggregation in BWM cells by gei-11 RNAi, Related to Figure 1. (A) yfp-RNAi was a 
control for RNAi efficiency, causing a significant decrease in fluorescence. (B) RT-PCR amplification of q35-yfp (top panel). 
mRNA from wt animals was a negative control for transgene amplification (left); yfp-RNAi was a positive control for reduced q35 
mRNA levels. Actin (bottom panel) was the control for total mRNA. Band intensities were used to calculate relative mRNA levels 
to control (n=3). (C,D) SDS-PAGE and western blotting analysis of Q35 protein levels, with anti-YFP (top) and anti-α-tubulin 
(bottom) antibodies. Q35 protein levels relative to tubulin were calculated from band intensities on (C), and are shown as a 
relative percentage of the vector control (n=3, Student t-test ***p<0.001, ±SD). (E) gei-11 RNAi suppressed Q37 (I-IV) and 
SOD1G93A (V-VIII) aggregation in BWM cells of 5 day old animals, shown by the diffuse fluorescent pattern in III, IV, VII and VII in 
contrast to a foci-like pattern in the vector control I, II, V and VI. Panels II, IV, VI and VIII are high magnification images of the 
boxed areas in I, III, V and VII, respectively (scale bar 0.1 mm). (F) gei-11 knockdown did not affect polyQ aggregation in the 
intestine (iQ44), relative to control RNAi animals.
Table S1: Effect of gei-11 RNAi on lifespan of wt 
animals at 20°C. RNAi for hsf-1 and daf-2 are negative 
and positive controls, respectively, for extension of 
lifespan. Statistical p-value calculated with the Log-rank/
Mantel Cox test.
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Figure S2: Suppression of Aggregation 
by Cholinergic Signaling, Related to 
Figures 2 and 4. (A) Cholinergic 
sensitivity assay: 5 day old animals 
treated with gei-11 or vector RNAi 
were scored for paralysis on plates 
containing 30 mM nicotine (±SD). N-
AChR mutant acr-16(ok789) and L-
AChR mutant unc-38(e264) were used 
as controls for receptor specificity. 
Two-way ANOVA p>0.05 relative to 
vector control. (B-D) Dose-dependent 
effect of cholinergic antagonist dTBC 
and cholinergic agonists ACh and 
levamisole on Q35 aggregation (±SD). 
Student t-test *p<0.05, **p<0.01 and 
***p<0.001; data and statistics are 
relative to Q35;vector (±SD).
Figure S3: Effect of gei-11 Knockdown on Stress 
Responses, Related to Figure 3. Real-time qPCR 
analysis of wt animals treated with gei-11 RNAi did not 
show induction of UPR-regulated ER chaperones, 
metabolic stress FOXO/DAF-16 regulated or oxidative 
stress regulated genes (±SD, data normalized to the 
levels of each gene in vector control).
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Figure S4: Suppression of Q35 Aggregation by Increase in Ca2+ Flux, Related to Figures 6 and 7. (A,B) Suppression 
of Q35 aggregation and hsp induction by gei-11 RNAi are calcium dependent, and were prevented by co-treatment with the 
chelator BAPTA (15 µM at L4). Data are relative to Q35;DMSO control (±SD). (C) Dose-dependent effect of Nemadipine A 
on suppression of Q35 aggregation by gei-11 RNAi. Data are relative to Q35 in vector RNAi (±SD). (D,E) Dose-dependent 
effect of the RYR agonist 4-CmC and the antagonist DS on Q35 aggregation. % of foci are relative to Q35;water control for 
4-CmC and Q35;DMSO for DS (±SD). Student t-test ***p<0.001 and **p<0.01.
Figure S5: Ca2+-Dependent Kinases 
and Calmodulins Required for 
Folding Improvement, Related to 
Figure 7. (A) RNAi of Ca2+-
d e p e n d e n t k i n a s e s a n d 
calmodulins tested for effect on 
Q35 aggregation, with and without 
gei-11, by double RNAi (±SD). (B) 
Double knockdown of gei-11 with 
calmodulin cal-1, cal-2, or cal-4; or 
Ca2+-dependent kinase unc-43, 
pkc-1, pkc-3, or gsk-3, prevented 
suppression of Q35 aggregation 
(±SD). % of foci are relative to Q35 
in vector RNAi; Student t-test 
p<0.001. (C) Real-time qPCR 
analysis of hsp-70 levels in wt 
animals upon gei-11 double RNAi 
with the indicated genes (±SD). 
Data are relative vector-treated wt 
animals.











 As protein folding and homeostasis are essential for cellular function, they are kept under tight 
surveillance by a network of pathways that constitute the proteostasis  network. Yet, the stability of  the 
proteome is constantly put at risk by both intrinsic  factors (e.g. genetic mutations, aging) and extrinsic 
stress agents (e.g. drastic temperature change, exposure to toxins and pathogens) that disrupt 
homeostasis beyond the functional capacity of  the PN, and often leading to disease states (Figure 1). 
These include conditions that derive from the accumulation of  misfolded proteins in toxic  and 
aggregated aberrant conformations, such as Alzheimer’s, Parkinson’s and Huntington's  diseases, as 
well as  muscular distrophies, ataxias and some metabolic disorders. Although protein aggregation is 
a common characteristic among these pathologies, the events leading to cellular toxicity are quite 
more complex. In fact, great attention has been drawn to the identity of the “toxic species” causing 
disease, and evidence indicates that multiple misfolded and oligomeric  species may contribute to 
cellular toxicity by disrupting various cellular functions [86]. Although aggregates are found in the 
areas of the brain most affected by neurodegeneration, the highest content of  insoluble aggregates 
and amyloid plaques does not correlate with disease severity [102-104]. In fact, in model systems for 
disease, toxicity is often exacerbated when inclusions formation is prevented or reduced and in other 
cases, the presence of oligomers is a better predictor of  disease progression [98-101]. Recent work 
has demonstrated that oligomeric toxic  conformations have similar conformations (or epitopes) that 
are recognized by a specific  set of  antibodies designed to bind and reduce the toxicity  of  these 
species [111,112,241]. Altogether, it is clear that the cellular events involved in protein aggregation, 





Figure 1: Proteostasis network function 
(“balance”) dictates disease propensity and 
health span. Proteostasis is composed by a 
network of cellular processes responsible for 
maintaining homeostasis, resistance to stress and 
health-span/longevity. Expression of aggregation-
prone proteins poses a chronic insult to PN function 
(imbalance), leading to aging-related diseases. 
Genetic screens performed in model organisms 
have identified gene modifiers of proteostasis that 
increase folding capacity and protection against 




main reasons hindering the development of efficient therapeutics. 
 Another way of addressing the problem is by asking why the QC system cannot maintain 
homeostasis, or why the stress responses are not activated by the noxious proteins. It is currently 
understood that neurodegenerative and motor-neuron diseases derive from the toxicity of the misfolded 
species and not from their loss-of-function. Then, the determinant of disease becomes the proteostasis 
network itself, and its (lack of) ability to deal with these proteins, e.g. by to promoting degradation thus 
avoiding the accumulation of toxic  conformations. The absence of this response suggests that the 
functional  capacity of the PN becomes saturated and overwhelmed by the chronic  expression of 
aggregation-prone proteins, in a time-dependent manner. This is in part the reason why most of these 
diseases have a late onset. Here, we tested the hypothesis that the PN functional capacity can be 
modified to improve folding function, maintain homeostasis and delay/prevent disease-related cellular/
organismal  phenotypes. We have taken advantage of the metazoan C. elegans as a tractable genetic 
model system for expression of conformationally challenged proteins and for the ability to screen the 
genome for modifiers of protein folding. The power of genetics in model  systems is then complemented by 
small molecules to unravel  new regulators of proteostasis and new target pathways for development of 
therapeutics (Figure 2).
1. GENETIC SUPPRESSION OF PROTEIN AGGREGATION AND TOXICITY
 We took a genetic approach to examine whether the proteostasis network can be genetically 
modulated to increase capacity of protection against the toxicity of protein aggregation (Chapter II). This 
study was complementary to previous work that led to the identification of the QC components: molecular 
chaperones, ubiquitin-proteasome, autophagy, and the upstream stress response signaling pathways. 
Here, we employed a screening triage method that initially revealed genetic  modifiers that suppress 
aggregation of polyQ and are also effective with mutant SOD1, defining candidates of a core PN. Only a 
subset of the suppressors of aggregation (42%) also suppressed cellular toxicity, with approximately equal 
numbers having either no effect on toxicity or even enhancing toxicity. This demonstrated that aggregation 
and toxicity can be genetically uncoupled, supporting that aggregation and toxicity are not obligatory co-
linked genetic  traits. Furthermore, to examine if the monomeric  vs. oligomeric vs. aggregated state of the 
protein (polyQ) was correlated with the outcome in toxicity, we monitored the biophysical  properties of the 
polyQ protein upon suppression of aggregation with the dynamic imaging technique fluorescence 
correlation spectroscopy (FCS) (Appendix I). At the detection limit, suppression of aggregation led to mixed 
populations of protein species, including soluble monomers and oligomers. No discrete populations of 
oligomers were correlated with enhanced or suppressed toxicity, arguing against the concept that a single 
toxic  species causes the disease state. Even when aggregation and toxicity were both suppressed, 
heterogeneous populations of soluble polyQ proteins were still  detected. Similarly, on an age-dependent 
study, we found that the heterogeneous oligomeric  species pattern is also intensified at older age. We 
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concluded that multiple oligomeric states can co-exist in the cell  as inert oligomeric  and misfolded 
conformations, with potential  to turn into toxic  conformers and aggregates if the PN becomes “unbalanced” 
or saturated, as would be the case during aging or chronic expression of aggregating proteins.
 From a mechanistic perspective it is increasingly clear that a series of events are associated with 
the conversion of the nascent polyQ protein into different oligomeric  states and inclusion bodies. Likewise, 
the genetic suppression of aggregation can occur via a wide range of mechanisms. Each modifier gene 
functions within its own network of interacting partners, revealing an expanding network through which 
each modifier can suppress aggregation, with differential effects on toxicity as well, depending on the 
affected cellular function. We predicted that the modifiers could suppress aggregation in one of two ways: 
(1) either by directly interfering with the inter-molecular interactions, nucleation dynamics or recruitment of 
A3
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Figure 2: From genetic model organisms 
to the development of therapeutics. The 
model organism employed in the work 
described here was mainly C. elegans. 
Genetic screens using RNAi provided a list 
of modifier genes of PN function, that affect 
protein misfolding, aggregation and toxicity. 
Characterization of these genes allowed for 
the discovery of new mechanisms of 
proteostasis maintenance. Simultaneously, 
a large scale small molecule screen 
identified new small molecule regulators of 
proteostasis, followed by characterization of 
the mode of action in cellular models and C. 
elegans. Together, these two methods 
provide a platform to uncover important and 
targetable pathways within the PN, that 
could be tested in higher organisms and 
clinical trials for the development of 
therapeutics of conformational disorders.
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species into inclusions; or (2) indirectly by activating stress responses and chaperone expression, 
therefore enhancing proteostasis capacity and preventing formation of toxic species. It was our goal  to 
identify the aggregation modifiers that enhanced proteostasis function. We reasoned that modifiers that 
suppressed both aggregation and toxicity in the aggregation models would be strong candidates. We then 
identified 9 modifier genes that also improved the folding of multiple endogenous metastable proteins, 
revealing a core group of PN genes never before linked to quality control  nor to proteostasis. Perturbation 
of each of these 9 genes re-adjusts the PN to enhance its functional  capacity, activating distinct stress 
responses (not shown) that affect folding and health span. The study of these genes promised to reveal 
new mechanisms involved in protein homeostasis, both at the cellular and at organismal levels.
2. NEW REGULATORS OF HOMEOSTASIS: ACTIVATION OF STRESS 
RESPONSES TO RESCUE FOLDING
 The PN core modifiers that we identified either play a role in the mitochondrial  respiratory chain 
and TCA cycle, thus regulating metabolism, energy balance and prevention of oxidative stress, or are 
related to rRNA processing and transcription, processes that determine gene expression and the proteome 
load. Identification of these processes is an important contribution to understanding of the components that 
constitute the PN, beyond the “typical” QC machinery. In terms of the relevance of these functional classes 
to protein folding, reduction in ATP or ETC activity have been shown to slow down aging, possibly by 
delaying the age-dependent collapse in proteostasis [60], and compromised mitochondrial function can 
lead to the upregulation of multiple stress-response pathways that ultimately promote homeostasis and 
survival  [120,147,184,185]. Restriction in energy levels also hinders overall protein biogenesis, as 
synthesis, folding and clearance activities are ATP-dependent. Metabolic enzymes influence protein folding 
in the cell by providing organic/inorganic  solutes that affect polypeptide chain solvation and hence, 
solubility [58]. On the other hand, reduced RNA processing/gene expression (and protein synthesis) have 
been proposed to extend the organism lifespan by activating a physiological state with increased stress 
resistance, folding and repair capacities [186-188]. In addition to these predicted consequences on 
proteostasis, we characterized further the role of two of the modifiers.
 We then pursued the characterization of the genetic modifier gei-11 and found that its 
downregulation caused an increase in expression of the L-type AChR in muscle cells, leading to muscle 
cholinergic  stimulation. This, in turn, provoked Ca2+ influx through the voltage-gated calcium channel 
(EGL-19) and the ryanodine receptor (UNC-68) in the cytoplasm, as well as activation of HSF-1 and 
chaperone expression that ameliorate folding (Chapter III). This finding is complementary to an earlier 
study where a deletion mutant of unc-30 that regulates GABA expression in C. elegans neurons, results in 
enhanced polyQ aggregation in muscle cells [167]. An important distinction in the genetics that led to these 
discoveries must, however, be emphasized. Previously, enhanced protein aggregation was observed upon 
complete inhibition of GABAergic  signaling (due to the null mutation in unc-30), resulting in maximum 
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cholinergic  overstimulation of muscle cells. Whereas, in the current study, upon gei-11 knockdown, the 
effect of increased AChR expression is quite different from the complete inhibition of GABA signaling, in 
part because the signaling response occurs at an intermediate level. This makes an important distinction 
between the beneficial  consequences of a moderate increase in stimulation of the muscle, and the 
deleterious consequence to the folding environment of complete overstimulation. This distinction reveals 
the importance of a threshold for the level of induced stress, in this case by muscle cholinergic  stimulation 
(too much is bad but a little is good). This is not too far from the different consequences observed for other 
HSR inducers, depending on the “magnitude” of the stress. Mild heat shock treatment of cells and C. 
elegans has been shown to upregulate chaperones, cause thermo-adaptation, improve homeostasis and 
extend lifespan [38,146,242]. However, an acute heat shock treatment has deleterious consequences, 
such as cell cycle arrest and apoptosis [243]. This reveals that there is a critical range of signaling that 
leads to chaperone expression and improvement of the folding environment.  Moreover, the relevance of 
neuronal  control of post-synaptic  homeostasis is becoming increasingly evident. In particular, it has been 
shown that neuronal dysfunction impairs HSR capacity in somatic  cells [164], induces post-synaptic 
muscle protein misfolding and proteolysis [166,167], and affects longevity [120]. Therefore, the activation 
of post-synaptic  HSR and homeostasis by moderate increase in cholinergic  signaling at the NMJ (and 
muscle stimulation) is prone to be highly biologically relevant for pathologies such as neurodegenerative 
and neuromuscular disorders, i.e., scenarios where selective neuronal degeneration leads to muscle 
weakness and paralysis (ALS, hereditary spastic paraplegia, and spinal muscular atrophy) [80]. Fine-
tuning of neuronal  cholinergic  signaling, within a well-defined physiological range, represents a new target 
to re-shape the functional properties of the proteostasis network at the organismal  level. An understanding 
of the regulatory signaling cascades that trigger protective responses across tissues is of fundamental 
importance to delay or prevent organismal collapse of proteostasis during aging and disease. Together, 
these studies provide compelling evidence for the control of stress responses through tissue-specific 
signaling events and these findings could have only been discovered using an organismal model system. 
Moreover, because cholinergic  and GABAergic signaling are conserved, these results are of broad 
relevance to the study of muscle cell  function, neuronal stimulation of muscle cells, and muscle wasting 
diseases. Altogether, this work also shifts the emphasis from extreme environmental  forms of stress to in 
vivo physiologically relevant stress signaling and sensing. 
 We have also initiated the characterization of the gene let-607, which we show to affect cellular 
homeostasis in a cell-autonomous manner (Appendix II). LET-607 is predicted to be the C. elegans 
CREBH ortholog, involved in UPR [244] and activated for transcriptional function similarly to ATF-6 [46]. In 
mammals, CREBh is involved in immune response and hepatocyte’s homeostasis [52]. Knockdown of 
let-607 in C. elegans activated the UPR, the HSR, and expression of both ER and cytosolic  chaperones. 
Upon let-607 RNAi the dependence of HSR activation on UPR, through xbp-1 levels and splicing, 
suggested that compartmental  stress responses can “crosstalk” to reduce protein misfolding and rescue 
homeostasis. Very little is known about this type of interaction, although it has been shown that impairment 
of either UPR or HSR can exacerbate the toxic effects of ER or HS-type stress [245,246]. Characterization 
of the signaling cascade activated at the ER by let-607 knockdown, and transduced to the nucleus for 
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HSF-1 activation, promises to reveal new insights into the co-regulation of the ER and cytosolic  stress 
responses, as a measure to rescue proteostasis.
 The discovery of folding improvement by knockdown of let-607 and gei-11 are two examples of the 
valuable information provided by genetic  screens. In particular, the triage strategy implemented allowed us 
to select, from an initial  large number of hits, the gene candidates with higher probability of having a 
relevant role in the proteostasis network, by identifying modifiers of the folding capacity instead of protein 
aggregation-specific modifiers. These pathways within the network are strong candidates for therapeutics 
targeting.
3. GENETICS AND CHEMICAL BIOLOGY
 Despite the increasing understanding of the regulation of stress responses and the organization of 
the proteostasis network at the cellular and organismal, the inability of this system to prevent protein 
misfolding in disease and in late age are still  very intriguing. With the identification of core components of 
the PN from genetic screens and elucidation of the roles of key transcription factors in stress response 
(HSF-1, SKN-1/Nrf2 and DAF-16/FOXO), chaperone activation and proteome stability, it becomes 
prominent to identify novel small molecules that modulate their activity, in particular HSF-1, with the goal of 
developing efficient therapeutics for a large number of diseases that still go untreated (Figure 3). Several 
small molecule activators of HSF-1 are known, and some of these have shown protective effects in models 
of Huntington’s disease and ALS [35,169,170]. Despite the potential benefits shown, further development 
of these small molecules will  be necessary prior to their use as therapeutic  agents, mainly due to the high 
toxicity of some of these compounds [247,248]. Furthermore, while some small molecules like 
geldanamycin (GA) and other derivatives that inhibit Hsp90 are currently in pre-clinical and clinical  trials for 
the effective treatment of a number of cancers, their efficacy in diseases associated with protein misfolding 
seems to have limited therapeutic potential. An effort to find new small molecule regulators of proteostasis 
(proteostasis regulators, PRs) that represent strong therapeutic  candidates led to a new large-scale small 
molecule screen in human cells for HSF-1-dependent activators of chaperone expression (Appendix III). 
We discovered and characterized novel small molecule PRs that, by enhancing HSF-1 activity, restore 
proteostasis in multiple disease models, including cytosolic and compartment-specific conformation 
disorders. A further understanding of these PRs and their ability to activate the HSR and restore protein 
folding in multiple disease models through genetic studies, offers new strategies for development of small 
molecule chaperone therapeutics for protein conformational diseases. These PRs represent novel 
chemical series and, by comparison to previously identified small molecule activators of the HSR, they do 
not cause protein misfolding, proteasome inhibition, or Hsp90 inhibition. Interestingly, the novel PRs exhibit 
complex stress response signatures. In addition to inducing HSF-1 and the expression of multiple 
cytoplasmic chaperones, we have observed the induction of other major components of the PN, including 
the UPR and the antioxidant response genes (Figure 3). This activation of stress-signaling pathways, in 
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turn restores the stability and functionality of the proteome. The ability of these PRs to activate one or 
more stress response pathways suggests a mechanism that employs the cell’s biological response to 
damaged proteins to protect cells against chronic  disease. In other words, to face the challenges caused 
by chronic  stress and toxicity, the compounds target and enhance the properties of the same biological 
pathways that are already employed by the cell to manage proteostasis, under physiological conditions.
4. CONCLUSION AND PROSPECTUS
4.1. Concluding Remarks
 The main components of the folding machinery have been identified and characterized 
exhaustively, but when it comes to late-onset diseases of protein aggregation, it has been a difficult task to 
pin point what goes weary with this machinery. Therefore, we focused on identifying mechanisms causing 
the enhancement of the proteostasis network function to prevent disease-related events. Altogether, 
genetic screens for modifiers of disease-related phenotypes in multiple model  systems have provided a 
plethora of genes and pathways that can be modulated to delay and even prevent disease states. How 
Figure 3: Model depicting the proposed target stress pathways by which small molecules ameliorate conformational 
diseases. The small molecules PRs work by activating some of the major PN machineries, inducing components of the quality 
control machinery and other cytoprotective stress response genes. We have found PRs that suppress misfolding and toxicity in 
disease models that depend on HSF-1 and DAF-16/FOXO or SKN-1/Nrf2 transcription factors. Adapted from Appendix III.
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does research translate from basic  genetics to disease therapeutics? The answer is chemical biology. 
Advances in the small molecule synthesis, testing in cultured cells and model organisms, and elucidation 
of mechanism of action offer strong therapeutic options. 
 Here we show that the “fine-tuning” of PN pathways, that are already physiologically employed by 
the cell for keeping cellular function and homeostasis, enhances the efficacy of stress sensing, reducing 
misfolding and toxicity of metastable and disease-related proteins. Both GEI-11 and LET-607 modifiers act 
on specific cellular processes to activate a response that translates into chaperone expression and 
enhancement of folding. For GEI-11 in particular, we have not only identified a physiological  process of 
neuronal  control  of muscle function and homeostasis, but also we show for the first time that the 
neuromuscular junction is under a tight regulatory balance between cholinergic  and GABAergic  signaling, 
that can be targeted and modulated to restore folding in disease scenarios. We demonstrate that activation 
of the HSR and chaperone expression only rescues folding efficiently at a specific magnitude of muscle 
stimulation but not at more drastic overstimulation conditions. This is a very important aspect when 
targeting biologically relevant pathways that respond to stress to rescue folding instead of causing even 
more deleterious stress. We believe that this fits the motto “a little stress could be good”. On the other 
hand, small molecule PRs of the HSR provide a potentially powerful approach to obtaining proteome 
balance in both loss- and gain-of-function diseases by providing a superior corrective environment based 
on properties of the stress pathways. Besides the usefulness for potential  therapeutic  development, small-
molecule inducers of the HSR can be used as research tools for further dissecting the multi-step activation 
pathway of HSF-1. A better understanding of the regulation of HSF-1 activation pathway and signaling 
mechanisms could lead to the discovery of compounds that exhibit stress signatures that are HSF-1 
selective, rather than activators of multiple stress pathways. Drug target and mechanism of action studies 
have gained considerable attention, given that many small molecules are initially described to be specific 
and later found to have multiple additional  targets [249,250]. Considerable improvement has been made 
into drug design to increase specificity, but it is still crucial  for pharmacogenetics studies to determine all 
targets and potential side interactions for each compound. 
4.2. Future Work
 To complete the characterization of the PN gene modifiers identified and described in this thesis 
(Chapter II), we have initiated a genetic  approach to determined which stress pathways are activated by 
each modifier. We have asked how downregulation of genes that function primarily in cellular metabolism 
and RNA processing, alter the PN and through activation of which stress pathways. This approach is 
consistent with modulation of specific  cellular functions causing stress within a particular range, to activate 
protective mechanisms that ultimately improve folding capacity and restore homeostasis, without causing 
further cellular/organismal toxicity. This is well illustrated in the characterization of the gene modifier gei-11. 
Through this study we uncovered a novel  pathway that can be targeted for modulating neuronal  control  of 
muscle function. It will be extremely relevant to identify other components of the neuronal  circuitry, either 
involved in signal  magnitude, receptor expression or neurotransmitter synthesis/release, that can be 
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modulated to alter neuronal function and effect on post-synaptic cells homeostasis. This will  be especially 
relevant for diseases of neuromuscular dysfunction leading to muscle atrophy and early death.
 Moreover, we are currently completing the characterization of the modifier gene let-607, described 
in Appendix II, by determining the “type of stress” caused by let-607  downregulation at the ER, and how 
that stress is “communicated” to the cytosol  for activation of the HSR. We will also validate this mechanism 
of proteostasis maintenance in mammalian cells, using the ortholog CREBH.
 By employing tissue-specific and cellular compartment-specific  folding sensors, research is 
moving towards the characterization of both cell  autonomous and cell  non-autonomous processes 
responsible for proteostasis, as an integrated stress response system that is responsible for organismal 
health- and life-span. Altogether, genetic  and chemical modulation of the PN and direct or indirect 
activation of the HSR, for improvement of protein folding capacity, contribute to the identification of all 
factors composing the PN, as well as the nodes that can be targeted to promote the most robust 
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 Protein misfolding and aggregation are molecular events that become exacerbated with aging and 
are risk factors for neurodegeneration, metabolic disease, and cancer. Misfolding can lead to the 
appearance of multiple protein conformational states, including oligomeric  and aggregate species. Here, 
we employ fluorescence correlation spectroscopy (FCS) to analyze the diverse biophysical states of 
polyglutamine (polyQ) proteins expressed in a Caenorhabditis elegans model that exhibits age- and polyQ-
length dependent aggregation and toxicity. By employing FCS and fluorescence recovery after 
photobleaching (FRAP) methods, we detected mixed populations of protein species, including soluble 
monomers and oligomers, as well as large immobile aggregates, in strains carrying the longer lengths of 
polyQ and upon aging. Moreover, when RNAi genetic  modifiers suppressed aggregation, we detected 
different heterodisperse populations of soluble polyQ oligomers. These studies reveal that the transition 
from soluble monomers to immobile aggregates involves intermediate species, but does not support a 
model in which formation of a discrete population of oligomers is associated with toxicity.
INTRODUCTION
 Protein misfolding and aggregation have been implicated in a wide variety of diseases including 
Amyotrophic  Lateral Sclerosis, at least nine CAG-repeat diseases, Alzheimer’s disease and Parkinson’s 
disease [73,251]. Many models have been put forth to study the basis of cellular toxicity in these diseases, 
implicating different conformational and oligomeric states of mutant SOD1, TDP-43, huntingtin, ataxins, Aβ, 
tau, alpha-synuclein, and parkin, respectively. However, the events leading to aggregation and toxicity 
remain poorly understood. The majority of studies to elucidate the misfolding pathway have been 
performed in vitro and have proposed four general pathways that lead to aggregates: monomer directed 
conversion, nucleated polymerization, template assembly, and nucleated conformational conversion (Kelly, 
2000). These studies further suggest that more than one of these pathways can contribute to the kinetics 
of aggregation of specific proteins. For example, studies of Aβ suggest that both template assembly 
[252-254] and nucleated conformational  conversion [255,256] play a role in aggregation. Studies with 
polyQ suggest that nucleated polymerization [257,258] and template assembly are involved [259,260]. 
Techniques employing thioflavin T binding and turbidity measurements have indicated the presence of a 
lag time, growth phase and finally a plateau in formation of fibrils [257,261-263]. More recently, techniques 
including AFM (atomic  force microscopy), EM (electron microscopy), and dynamic light scattering have 
shown that, during the lag phase, proteins adopt multiple conformational states including oligomers and 
soluble aggregates [110,193,259,264,265]. 
 While in vitro  aggregation studies have provided the majority of the kinetics of aggregation data, 
they also have demonstrated that the kinetics and pathway of aggregation are highly dependent on the 
environment. Changes in pH, salt concentration, protein concentration and solvent characteristics can 
have a large effect on lag-time, secondary structures and the type of aggregate species formed [260]. 
Therefore, in vivo conditions may lead to different aggregation events due to the continual generation of 
monomers and the presence of other proteins such as chaperones that directly interact with misfolded 
proteins. In fact, dynamic imaging methods including FRAP and FLIP have revealed variability in the [266]
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packing structure of in vivo aggregates, as well  as dynamic interactions with Hsp70 and other molecular 
chaperones [93,94,163,192,193,266-269]. 
 A technique that offers excellent potential for the study of oligomers both in vitro and in vivo is 
fluorescence correlation spectroscopy (FCS), a detection method that can measure changes in diffusion 
rate at the single molecule level for fluorophore-tagged proteins [270,271]. The FCS analysis 
autocorrelation function, G(τ), measures the self-similarity of the fluorescent signal after a time (τ) interval 
[272-274]. Signal fluctuations, arising from changes in molecular physical parameters such as diffusion 
rate, size, concentration, and brightness intensity, can be determined with precision [95,198,274,275]. 
Specifically, FCS has been used to detect changes in particle mobility as a result of protein-protein or 
protein-DNA interactions, or changes in cellular localization [276-280]. FCS has also been used to 
measure changes in aggregation through detection of appearance of higher order oligomers [281,282], but 
has not been employed yet to resolve different populations of oligomeric states formed. 
 The goal  of these studies was to monitor the polyQ aggregation pathway in C. elegans, and the 
effect of genetic suppressors of aggregation on the polyQ biophysical properties, using multiple dynamic 
imaging techniques. Our approach consisted in utilizing FCS based techniques coupled with FRAP and 
fluorescence imaging to monitor the three main species of the aggregation pathway: monomers, oligomers 
and aggregates. We show all  three states co-exist in the C. elegans polyQ model for multiple Q-lengths 
and ages. We also show that for the aggregation suppressor modifiers tested, oligomers were maintained 
in a heterogeneous state, although the distribution varied between modifiers, independently of the effect on 
polyQ toxicity. 
MATERIALS AND METHODS
C. elegans Strains and Maintenance:  Worms were maintained according to standard methods, at 20°C on 
nematode growth media (NGM) with OP50 E. coli [138].  The polyglutamine strains, expressing different lengths of 
CAG-repeats fused with YFP, have been described elsewhere (Q0 AM134; Q24 AM138; Q35 AM140; Q37 AM470; and 
Q40 AM141 in CGC) [119].
Fluorescence Imaging and RNA Interference:  To obtain age synchronized populations of  L1 larvae (first larval state 
post  egg hatching) for the different polyQ strains, gravid adult animals were bleached with a NaOCl solution [250 mM 
NaOH and 1:4 (v/v) dilution of  commercial bleach] and the eggs were allowed to hatch in M9 buffer overnight at  20°C. 
Age synchronized L1 animals (day  1) were transferred onto NGM-OP50 bacteria plates and grown at 20°C for different 
time periods (see Figure 1). Fluorescent microscopy  images were taken using the Axiovert  200 microscope with a 
Hamamatsu digital camera C4742-98 (Carl Zeiss, Germany). RNA interference (RNAi) assays were performed using 
the commercial C. elegans RNAi library,  as previously  described (GeneServiceTM, USA) [154,283]. NGM plates 
supplemented with 100 µg/ml ampicillin, 0.5 mM isopropyl β-D-thiogalatoside (IPTG) and 12 µg/ml tetracycline were 
seeded with overnight RNAi bacteria cultures (~16 h), induced with 1 mM IPTG for 3 hours at 37°C. Age synchronized 
L1 larvae (day  1) animals were transferred onto NGM-RNAi seeded plates, grown at 20°C for 5 days, and assayed for 
aggregate count using the stereomicroscope Leica MZ16FA equipped for epifluorescence (Leica Microsystems, 
Switzerland) (detailed methodology in Chapter II). 
Motility Assays: See Chapter II Materials and Methods for detailed description of this assay. 
Fluorescence Recovery After Photobleaching (FRAP) Analysis:  Animals were mounted on a 3% (w/v) agar pad 
on a glass slide, immobilized with 2 mM levamisole and subjected to FRAP analysis using the Zeiss LSM510 confocal 
microscope (Carl Zeiss, Germany), with the 63X objective lens at 5X zoom power, and the 514 nm line for excitation. 
An area of  0.623 µm2 was bleached for 35 iterations at 100% transmission, after which time an image was collected 
every  123.35 ms. Relative fluorescence intensity  (RFI) was determined by  using RFI = (Tt/Ct)/(T0/C0); where T0 and C0 
represent  the intensity  of  the bleached and control unbleached regions, respectively, prior to bleaching, and Tt and Ct 
represent the intensity at time t after photobleaching for the bleached and unbleached region, respectively [202].
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Fluorescence Correlation Spectroscopy (FCS) 
 Sample Preparation and Data Collection: Six day  old animals (or at the time points indicated in Figure 2D) 
grown on RNAi or OP50 bacteria were collected and washed with M9 and re-suspended in native-lysis buffer [50 mM 
Tris pH 7.4, 5 mM MgCl2, 0.5% Triton X-100, 0.2 mM PMSF, 1µg/ml leupeptin, protease inhibitor cocktail tablet]. Lysis 
was achieved with 4 cycles of  freeze-thaw, followed by  grinding with a motorized pestle. The lysates were spun at 
1,000xg for 3 minutes to remove the larger aggregated species. Centrifugation conditions were determined based on 
approximation of  the sedimentation coefficient for the large visible aggregates at 150,000 S, so that these species 
were removed from the fraction analyzed by  FCS. Total protein concentration was determined using the Bradford 
assay  (Bio-Rad #500-0006). Protein lysates were aliquoted and only  thawed once, to ensure minimal effects on 
oligomers stability.  FCS measurements were collected on the Confocor3 system (Carl Zeiss, Germany) using the 
Apochromat 40x 1.2NA water immersion objective lens. Each sample was loaded into 3 wells of  a Nunc #1 coverslip 8-
chamber slide (Lab-Tek Chambered Coverglass w/ CVR #155411, Nalge Nunc International, USA) at a total protein 
concentration of  0.5µg/300µl. YFP was excited with the 514 nm laser line and emission signal was detected by  the BP 
530-610 IR filter. Each well was sampled for a total of  1500s (either 5x300s, or 50x30s). Each set of  measurements 
was performed twice and each experiment was done in duplicate (at least). This gives a minimum of  5 total hours of 
FCS data collection per sample, necessary  to obtain a large statistical sampling of  oligomers present in small relative 
concentrations. 
 Autocorrelation curves and fitting: Autocorrelation curves G(τ) were generated by  the Confocor3 software 
analysis (Carl Zeiss,  Germany) [273], and averaged over the different data collections to generate the final plot. Initially 
attempts were made to fit the data using the autocorrelation function (Equation 1) and fitting software provided by 
Zeiss. 
 Brightness Histograms: To generate the brightness histograms we used a program written in Python. Briefly, 
raw FCS data is examined for local maxima greater than 150 kHz. All peaks are output for further statistical analysis, 
performed using the Graphpad Prism software. The log of  the brightness of  the peak was taken, as there are log-fold 
differences in peak brightness. These values were then placed in bins of  width 0.2 on the log scale to generate the 
final brightness histogram. The x-axis  represents the bin center which relates to the Log (brightness), where brightness 
is photon counts per second. The y-axis  is the fraction of  oligomers (out of  1), at a given brightness range. Statistical 
analysis and significance between values was determined using the Bonferroni t-test (p<0.05).
 Purified Single Molecule FCS: To determine the hydrodynamic size of  the oligomers, data was analyzed using 
the “purified, single-molecule” FCS method, previously  described [284]. This technique uses single molecule 
fluorescence burst analysis. Specifically, bursts of  fluorescence (signal greater then 150kHz) are found along the time-
scale over which the burst occurs. The region to be analyzed is expanded around the burst by  10-fold the time-width of 
the burst on either side.  By  being restrictive in the data set analyzed, the method excludes other bursts within the 
region that would complicate analysis. Once the specific region has been extracted, the data can be fit with the 
standard autocorrelation function yielding information on the diffusion rate of  the bright species. Results from every 
burst  are plotted in a diffusion rate histogram, allowing the comparison of  the distribution of  diffusion rates for Qn::YFP 
in different backgrounds.
RESULTS
Multiple Aggregation States Co-Exist Across Diverse PolyQ Lengths and Ages 
 In transgenic C. elegans expressing different CAG-repeat (polyQ) lengths, Q35 represents the 
threshold length for time-dependent protein aggregation and toxicity with onset at young adult stage [119]. 
The age- and Q-length-dependent aggregation pattern was monitored using three methods: fluorescence 
microscopy, FRAP and FCS. 
 PolyQ aggregates were observed in Q35, Q37 and Q40 young adult animals but not in Q0 and 
Q24 animals (Figure 1A). For Q35 animals, the appearance of visible aggregates was age-dependent: 
Q35 remained soluble until  day 4, and the number of aggregates, detected as bright foci by fluorescence 
Equation 1
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microscopy, increased during adulthood (Figure 1D). The transition from soluble to aggregated state during 
aging (Figure 1E) is also associated with increased cellular toxicity [119]. A similar profile was observed for 
Q37 animals (not shown). By FRAP analysis the diffuse state of soluble Q35 and Q37 protein was 
indistinguishable from Q0 and Q24 (Figure 1B). In contrast, Q40 animals only have immobile aggregates, 
as measured by FRAP analysis (Figure 1B). The Q-length and age-dependent solubility transitions (Figure 
1A-B, D-E) were used to investigate the dynamics of protein aggregation. 
Characterization of the Soluble PolyQ Species by FCS
 To further characterize the population of soluble polyQ species expressed in the transgenic 
animals, we employed fluorescence correlation spectroscopy (FCS), to measure diffusion rates, brightness 
and concentration of the polyQ, and therefore, the distribution of the oligomeric population(s). 
 Analysis of the soluble fraction of the native protein lysates from different Q-lengths by FCS 
demonstrated the presence of oligomeric  species for Q35, Q37 and Q40, but not for Q24 and Q0 (Figure 
1C). This is shown by the diffusion rates (proportional  to 1/τDi) of the YFP-tagged molecules in solution. 
The Q0 (YFP) and Q24 autocorrelation (AC) curves (Figure 1C) overlap, indicating that the mobility of the 
Q24 species corresponds to a monomeric  state, indistinguishable from YFP alone (Figure 1C). For the 
longer aggregation-prone Q-lengths, Q35, Q37 and Q40, the autocorrelation curves shift towards the right, 
corresponding to decreased diffusion rates due to the presence of slow moving oligomeric  species (Figure 
1C). These results reveal the presence of larger oligomers, that were not distinguishable by FRAP 
measurements, and that co-exist with immobile aggregates. 
 FCS analysis of protein native extracts from Q35 animals (soluble faction only, see Experimental 
Procedures), between day 2 and day 6, revealed transition from monomeric  soluble species to oligomeric 
(Figure 1F). The AC curves of Q35 protein at day 2, 3 and 3.5 were indistinguishable from the Q0 curve, 
and suggest that Q35 is largely monomeric  through day 3.5 of age (Figure 1F). AC curves from day 4 
adults were shifted to the right, indicative of the formation of oligomeric species (Figure 1F), also 
consistent with the adulthood onset of visible aggregates. As animals continue to age through day 6, we 
observed a further increase in the size and concentration of the Q35 oligomeric  species, as shown by the 
further rightward shift of the curves, corresponding to lower diffusion rates (Figure 1F). 
 Efforts to extract additional information revealed that we could not fit the AC curves to a 1, 2 or 3 
component autocorrelation function for a majority of the samples due to large residuals, oscillations in the 
residual  curve, inconsistent fitting results, and diffusion rate and concentration parameters that did not 
coincide with known values for the monomer fraction. We interpret this to suggest that there is a 
heterogeneous distribution of both size and brightness in the samples. Therefore, we introduced two 
complementary analyses to provide more detailed information: Brightness Histograms that gives 
information on the number of Qn-YFP molecules per oligomer; and “Purified Single Molecule” FCS that 
measures the oligomeric hydrodynamic  size. For the brightness analysis, a simple and complementary 
non-correlation-based method measures the brightness of particles in samples where oligomer 
concentration is low and the species distribution is diverse in size and concentration [285]. The highest 
signal-to-noise light bursts from each fluorescent species transiting through the focal volume are used to 
determine the brightness distribution (τD) of the oligomeric  species . Likewise for “purified” FCS, these 
bursts were identified, and together with the surrounding data, fitted using the AC function. The fitting 
results were binned to generate a histogram of the τD distribution that relates to the hydrodynamic  size of 
the oligomers.
 Through the use of brightness analysis and “purified” FCS, we show that soluble polyQ, of different 
Q-lengths and from animals of different ages, exhibit a heterodisperse state (Figure 2). It was particularly 
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noteworthy that the histograms for Q35, Q37 and Q40 showed similar heterodisperse distribution of 
oligomers, revealing the absence of discrete sub-populations of Q-length-dependent species (Figure 2A, 
B). In Q35 animals the burst histograms revealed oligomers at day 2, 3 and 3.5, which were not detected 
by the AC curves (Figure 2C). We observed a higher concentration of dim species at day 2 and 3 that had 
decreased by day 4 together with a corresponding increase in brighter species (Figure 2C). Taken 
together, the brightness and τD analysis reveal that oligomers increase in both size and brightness as the 
animals age, but the heterodisperse distribution is maintained without detection of any prominent 
oligomeric sup-population (Figure 2C, D). 
 By employing complementary FRAP and FCS imaging methods we have demonstrated that 
populations of oligomeric species co-exist with both aggregates and monomers. Moreover, age-dependent 
Q35 aggregation occurs in parallel  with an increase in frequency and size of soluble oligomers, as 
detected by brightness analysis (Figure 2C). For the later age time points and longer Q-lengths, the 
oligomer brightness distribution was unaltered suggesting that the monomer-oligomer-aggregated species 
reach a dynamic equilibrium. 
Suppression of PolyQ Aggregation Is Genetically Uncoupled From Oligomeric Distribution
 Having identified the distribution of polyQ species associated with aggregation, we next asked 
whether suppression of polyQ aggregation by genetic  modifiers of proteostasis would affect the distribution 
of oligomers, specifically if it would lead to the appearance, increase or decrease in frequency of discrete 
species associated with toxicity. To accomplish this, we took advantage of a genome-wide screen for 
suppression of polyQ aggregation using RNA interference (RNAi) (Chapter II). We selected a subset of 
these modifiers (Figures 3A, S1, S2) to ask whether distinct modifiers alter the cellular environment in the 
same or distinct manner to prevent aggregation. Both fluorescence microscopy and FRAP analysis 
demonstrated that these modifiers suppressed the formation of large visible Q35 aggregates (Figure S1B, 
Chapter II). Knockdown of phb-2 (mitochondrial  prohibitin complex), col-61 (collagen-type protein), viln-1 
(actin regulatory villin-related protein), klp-15 (kinesin-like protein), C34B2.8 (cell death regulatory protein), 
C01G12.8 (CATP-4, Na+/K+ ATPase) and F59C6.5 (NADH-ubiquinone oxidoreductase) was accomplished 
by feeding RNAi to Q35 animals at the L1 larval  stage of development (day 1). As shown in Figures 3A and 
S1A, RNAi-treated animals showed a significant reduction in Q35 foci number relative to control. The 
fluorescence recovery curves indicate that the diffusion rate of soluble Q35 was similar to YFP alone, 
confirming the strong suppression of visible aggregates by these genetic modifiers (Figures 2B and S1A, 
B).
 While all the modifiers had the same suppressor effect on Q35 aggregation, we wanted to 
examine the effect on the distribution of oligomers. FCS analysis revealed heterodisperse populations of 
oligomeric  states upon genetic  suppression of aggregation (Figure 3B and S2A). Relative to the control 
Q35 curve, the AC curves for the aggregation suppressors did not shift in the same direction (Figures 3B, 
S2A). Some led to the appearance of increased (C01G12.8) or decreased (phb-2) diffusion rates, while 
other modifiers (klp-15, viln-1, col-61, C34B2.8) had no apparent effect on the diffusion rate (Figure 3B and 
S2A). These results further support our earlier conclusion that FRAP analysis cannot distinguish 
monomers from higher molecular weight soluble species. 
 The brightness histograms indicated that each aggregation suppressor-modifier generated 
heterodisperse populations of Q35 oligomers (Figures 3C and D and S2B), rather than leading to the 
conversion of a discrete oligomeric state. The Q35 oligomer populations, however, were not identical. For 
example, phb-2 and F59C6.5 RNAi decreased the concentration of specific  dim species in the bin center 
2.2, whereas C01G12.8 RNAi  increased the concentration of these species. Conversely, C01G12.8 RNAi 
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decreased the concentration at bin center 3.2, whereas phb-2 and F59C6.5 increased this concentration. 
FCS analysis not only confirms the heterodisperse nature of the Q35 oligomers, but it also provides 
quantitative information on the subpopulations of oligomers based on brightness intensity, for each 
aggregation suppressor tested. The largest group of modifiers tested, while suppressing polyQ 
aggregation, maintained the polyQ in an indistinguishable oligomeric states from the control Q35 (Figure 
S2A). Furthermore, “purified single-molecule” FCS, shows that Q35 species with similar brightness 
distributions correspond to different diffusion rates (Figure 3C-E). For example, while both phb-2 and 
F59C6.5 RNAi generated Q35 oligomers with similar brightness distributions, the TD values for the latter 
were shifted to the left relative to phb-2. This suggests tighter packing for F59C6.6 RNAi-generated Q35 
oligomers, or could reflect difference in the composition of phb-2-generated Q35-containing species. This 
type of comparison not only provides information regarding the molecular packing of oligomers, but also 
reveals possible existing heterotypic interactions with other proteins.
 The relationship between oligomeric states and cellular toxicity has been an area of great interest. 
Q35 animals exhibit a 40% reduction in motility relative to wt animals, associated to protein aggregation in 
the muscle cells (Figure S3). Of the aggregation suppressors examined in this study, there were three 
different toxicity outcomes, with decreased (klp-15 and C34B2.8), unaffected (col-61 and C01G12.8), and 
enhanced (phb-2, viln-1 and F59C6.5) motility defect (Figure S4). The modifiers phb-2 and F59C6.5  had 
similar effects on the oligomer distribution, but did not have the same effect on toxicity. Conversely, 
F59C6.5 and C01G12.8 did not affect toxicity, but had opposite effects on the oligomer distribution. These 
results begin to suggest that there is no simple relationship between oligomers and toxicity.
 Taken together, the use of FCS-based analyses has provided new resolution for the oligomeric  
states adopted by polyQ during aggregation, aging and in a cellular environment with suppressed 
tendency for aggregation. While some aggregation modifiers affected the heterodisperse oligomeric 
distribution, others had no obvious effect, while still suppressing visible aggregates. These results argue 
against the presence of discrete dominant species of oligomers associated with toxicity. 
DISCUSSION
 The methodology employed here provides information about the in vivo polyQ aggregation 
pathway, revealing that oligomers appear in a time-dependent manner leading to visible aggregates 
formation, consistent with a nucleation-dependent reaction similar to the kinetics resolved in vitro for many 
aggregation-prone proteins [109,261,286,287]. Interestingly, for the later time points and higher Q-lengths 
analyzed, the distribution of oligomers is maintained, suggesting that an equilibrium is reached perhaps 
through interactions with other cellular factors such as chaperones, or due to the continual  regeneration of 
monomer. The results with the genetic  modifiers of polyQ aggregation were consistent with the often 
contradictory observations regarding the effect of enhancement or suppression of aggregation on 
oligomers and toxicity (see Discussion in Chapter II). Our results suggest that the aggregation pathway is 
not solely linear, but that it can be driven in multiple directions depending on the genetic environment. In 
addition, suppression of aggregation does not appear to be a simple reversal  of the oligomerization/
aggregation events, and instead it results in multiple distributions and new oligomeric states suggesting 
once again a multitude of ways by which aggregation can be suppressed or prevented. 
 The work described here provides a novel way to assess the aggregation pathway, which can be 
employed to understand disease related events and aggregation-dependent toxicity. An important aspect 
of this work is that the tools are not limited to one misfolding disease or one model  system but can be used 
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in any misfolding system that can be fluorescently labeled. The new FCS analyses can provide information 
about the frequency, size and brightness of the oligomers. Recently others have also focused on 
developing tools to better study oligomers formed in vivo [288-290]. Together, these methodologies can 
provide valuable information about the misfolding pathway in different model systems and for different 
aggregating proteins. 
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FIGURES
Figure 1: PolyQ aggregation in C. elegans analyzed by fluorescence microscopy, FRAP and FCS. (A) Fluorescence 
microscopy images show Q-length dependent aggregation of polyQ::YFP in C. elegans muscle cells (5 day old animals). Scale bar is 
0.1 mm. (B) FRAP analysis of areas that appear either aggregated (foci) or soluble confirm that Q0 and Q24 are entirely soluble, 
whereas Q35, Q37 and Q40 contain both soluble and aggregated (foci) forms of the polyQ protein. (C) FCS autocorrelation curves 
from protein samples of 6 day old animals. Q35, Q37 and Q40 curves are shifted to the right as Q-length and aggregation propensity 
increase. Q0 (YFP) and Q24 maintain monomer-like diffusion rates. (D) Fluorescence microscopy images of a Q35 animal head 
show age-dependent aggregation (white arrows). Scale bar is 0.1 mm. (E) FRAP of Q35 animals confirms age dependent 
appearance of aggregates (foci). Q0 is used as a control for diffuse polyQ. (F) FCS autocorrelation curves of Q35 protein samples 
from different time-points show a gradual shift toward the right, reflecting a decrease in diffusion rate of the species formed. Q0 (grey 
dashed curve) is the control for monomeric state. 
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Figure 2: Brightness Histograms and “Purified Single Molecule” FCS analysis of Q-length and age-dependent changes in 
PolyQ. (A,C) Brightness intensity analysis determines the distribution of Qn::YFP species (fraction) into intensity bins (logarithmic 
scale), for various Q-lengths/ages. (B,D) “Purified single-molecule” FCS analysis determines the distribution and frequency of 
diffusion times (TauD) for Qn::YFP soluble oligomers (proportional to the hydrodynamic radius). 
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Figure 3: FCS based techniques detect changes in oligomeric state that occur when the aggregation pathway is modified. 
(A) Fluorescence microscopy images show suppression of visible Q35::YFP aggregates upon RNAi knockdown of specific genes in 
C. elegans muscle cells compared to control (5 day old animals). Scale bar is 0.1   mm (top) and 0.05 mm (bottom), and lower panels 
show a magnified imaged of the boxed area on top. (B) FCS analysis of protein samples from 6 day old RNAi-treated Q35 animals. 
Q24 and Q35 curves represent the monomeric and aggregated controls, respectively. Suppression of aggregation by RNAi leads to a 
change in amount and size of the soluble oligomeric molecules as shown by curves’ shift to the right (slower mobility/larger species 
for viln-1, phb-2) or left (faster mobility/smaller species for C01G12.8) of the Q35 control curve (black). (C, D) Brightness intensity 
analysis determines the distribution of Q35::YFP species (fraction) into intensity bins (logarithmic scale). The suppression of 
aggregation does not lead to the same oligomer distribution for all the modifiers. (D) Specifically, for the brightness bin centered at 3.2 
[Log(photon counts/Sec)] there is a statistically significant increase in oligomers of this size between phb-2 and F59C6.5 compared to 
C01G12.8. (E) “Purified single-molecule” FCS analysis determines the distribution and frequency of diffusion times (TauD) for 




Figure S1: Suppression of Q35 
aggregate formation by RNAi. (A) 
Fluorescence microscopy images show 
suppression of visible Q35::YFP 
aggregates upon RNAi knockdown of 
specific genes in C. elegans muscle 
cells compared to control (5 days old 
animals). Scale bar is 0.1 mm. (B) 
FRAP confirms that areas that appear 
soluble recover fluorescence.
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Figure S2: Oligomer distribution upon suppression 
of aggregation. (A) FCS analysis of protein samples 
from 6 day old RNAi-treated Q35 animals. Q24 and Q35 
dashed curves represent the monomeric and aggregated 
controls, respectively. The curves appear to be similar to 
Q35 control. (B) Brightness histograms for many of the 
modifiers do not significantly differ from each other or 
Q35 control.
Figure S3: Effect of genetic modifiers on toxicity. RNAi treated 
animals were assayed for motility, as a read-out for polyQ-induced 
muscle dysfunction. Control Q35 and WT (N2) animals were treated with 
the empty vector L4440. Motility is given as a relative percentage of WT 
motility (black). Error bars represent ±SEM, Student t-test *p<0.05, 
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RESPONSES IN C. ELEGANS
INTRODUCTION
 Protein homeostasis, or proteostasis, maintenance relies on a sophisticated network of pathways 
that ensure folding, quality and stability of the proteome. The folding environment is monitored within each 
compartment through tight regulation of molecular chaperones levels and function [29]. Perturbation of this 
environment by stress conditions, such as fluctuations in temperature, chemical insults, and infectious 
pathogens, or alternatively by chronic expression of mutant, misfolded and/or aggregated proteins, leads 
to the activation of protective stress response pathways. Whereas perturbation of the cytosolic folding 
environment selectively activates the heat shock response (HSR) and cytoplasmic  chaperone expression 
[35], interference with endoplasmic reticulum (ER) or mitochondrial folding preferentially activates 
expression of ER- and mitochondria-localized chaperones, respectively [28,46].
 In eukaryotes, the ER is the primary site for synthesis and checkpoint of secretory pathway 
proteins. The ER is also a major Ca2+ storage organelle and the site of lipid and oligosaccharide synthesis 
[244]. Key chaperones and folding sensors reside in the ER, including the Ig-binding protein (BiP)/glucose-
regulated protein 78 (GRP78), GRP94, calnexin, calreticulin and protein disulphide isomerase (PDI) [291]. 
When accumulation of unfolded proteins in the ER exceeds the folding capacity of these chaperones, an 
intracellular signal transduction pathway, designated unfolded protein response (UPR), is activated. The 
UPR is a transcriptional  and translational regulatory pathway that alters the expression of numerous genes 
of the secretory pathway, and affects cell fate and metabolism of proteins, amino acids and lipids [46]. The 
first level  of response to ER stress consists in a transient reduction in protein synthesis, to reduce protein 
load entering the ER. Sequentially, there is transcriptional  activation of UPR target genes, including those 
that function as part of the ER protein-folding machinery, to increase ER folding capacity. If homeostasis is 
not re-established then cell  death is triggered, which has been proposed to be a mechanism of organismal 
protection against cells affected by proteotoxicity. The three main ER stress transducers are the 
transmembrane proteins inositol-requiring protein-1 (IRE1),  the activating transcription factor-6 (ATF6), 
and the protein kinase RNA (PKR)-like ER kinase (PERK). Signaling is initiated by the transmembrane 
protein that senses folding requirements in the ER lumen, and transmits the information across the ER 
membrane to the cytosol and nucleus. On the ER lumen side, the chaperone BiP/GRP78 is predicted to 
retain these transmembrane proteins in an inactive state. When the critical  level of unfolded proteins is 
exceeded, BiP/GRP78 dissociates from IRE-1, PERK and ATF6, releasing them to initiate the ER stress 
response [46,292]. Activated PERK phosphorylates the translation initiation factor eIF2a, slowing down 
protein synthesis. Activated ATF6 translocates to the Golgi, where it is cleaved by proteases to form an 
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active transcription factor that enters the nucleus and upregulates the transcription of genes encoding ER 
chaperone proteins [293]. IRE-1 activation results in X-box-binding protein 1 (XBP-1) splicing and 
activation. The activated spliced form of XBP-1 acts as a transcription factor of genes involved in ER 
homeostasis, export and degradation of misfolded proteins [294,295]. In C. elegans, ire-1, pek-1, and atf-6 
regulate UPR, and are also required for growth and survival  (developmental UPR) [244]. Cell  growth and 
differentiation of specialized cells, and a high demand for protein synthesis during development, causes a 
constant low-level of ER stress, or basal/constitutive UPR.
 Despite the growing knowledge on the effectors of the UPR, there is limited understanding of 
possible co-regulation of different stress pathways across cellular compartments to promote cellular 
homeostasis. Nonetheless, recent studies in C. elegans have shown that XBP-1 and DAF-16 can function 
synergistically to activate genes that promote ER stress resistance and longevity in animals with 
compromised insulin/IGF-1 signaling [28,296]. It remains to be determined whether the IRE-1/XBP-1-UPR 
arm is modified during aging, which would impede coordination with other stress response factors and 
consequently impair the ER stress response [60]. Moreover, studies in S. cerevisiae have shown that 
HAC1/xbp-1 mRNA transcription levels are also regulated [246], in addition to IRE-1-mediated splicing 
activation, revealing an additional regulatory step. Whereas normal ER stress inducers, such as DTT 
(dithiothreitol, reducing agent) or tunicamycin (TM, glycosylation inhibitor/blocks the synthesis of all N-
linked glycoproteins), activate HAC1 mRNA splicing by IRE1; a concomitant increase in temperature (heat 
shock) led to an additional  up-regulation of HAC1 mRNA levels [246]. Strikingly, the regulation of HAC1 
mRNA levels were independent from the IRE-1 pathway, revealing a new transcriptional  program triggered 
to promote cell  survival upon acute and intensive stress. The combined upregulation of mRNA levels and 
splicing of HAC1 was designated “Super-UPR” [246]. Accordingly, it has been shown that IRE-1 and 
XBP-1 have additional divergent functions and  non-overlapping subset of downstream target genes under 
basal  conditions, separate from the “classical  UPR” [244]. Another study has also demonstrated that HSR 
activation can relieve ER stress [245]. That is, HSR by constitutively active HSF-1 can rescue the growth 
of ire-1 null cells, by restoring secretory pathway function. This is consistent with the finding that more than 
25% of the genes unregulated by HSR are common UPR targets. This work offered a strong evidence that 
HSR can relieve ER stress in UPR-compromised cells, suggesting a “crosstalk” between the two stress 
responses or at least a compensatory mechanism employed by the cell to promote survival [245].
 Here, we have employed the C. elegans polyglutamine (polyQ) model [119] to identify new genetic 
pathways involved in proteostasis maintenance and describe a new proteostasis modifier, let-607, that 
encodes a bZIP transcription factor homologous to mammalian CREBH [244]. The genetic  downregulation 
of let-607 by RNAi  resulted in activation of the UPR and the HSR, with upregulation of ER and cytosolic 
molecular chaperones that rescued folding and reduced toxicity of multiple misfolded proteins. This work 
suggests a new role for let-607, as a co-regulator of multiple stress responses to maintain cellular 
homeostasis.
RESULTS
LET-607 is a New Genetic Modifier of Protein Misfolding and Toxicity
 We performed a genome-wide RNA interference (RNAi) screen for suppression of polyglutamine 
(polyQ) aggregation in C. elegans body wall  muscle (BWM) cells, to identify new modifiers of protein 
misfolding. E. coli expressing dsRNA corresponding to the genome of C. elegans [155], were fed to L1 
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(first larval  stage, day 1) animals expressing Q35-YFP [119]. Animals were scored for reduction in the 
number of Q35 foci on day 6, that corresponds to 3 days after onset of aggregation, relative to the empty-
vector RNAi control (Figure 1A). As a control for RNAi efficiency, animals were treated with RNAi to yfp 
that reduced the fluorescence signal, as expected (see Chapter II). Here, we report on the modifier gene 
let-607 that suppressed aggregation in Q35 animals, in animals expressing Q37 and in animals expressing 
mutant SOD1G93A (Figure 1A). Suppression of Q35 aggregation by let-607 RNAi was not due to reduction 
in expression of Q35 mRNA or protein steady-state levels (see Chapter II). We tested if knockdown of 
let-607 at a later time point would still be effective in suppressing aggregation and found that upon RNAi at 
L4 stage (day 3), the aggregation suppressor effect was even stronger and the animals appeared 
healthier. From here on we present data with RNAi always at L4 stage.
 To address whether suppression of polyQ aggregation affected toxicity, we examined the motility 
defect associated to Q35 aggregation in the muscle of 6 day old animals. Whereas Q35 animals display a 
40% reduction in motility relative to wt animals, let-607 RNAi rescued motility to near 100%, without 
affecting the motility of WT animals (Figure 1B). As expected, motility was also fully restored by knocking 
down the polyQ transgene itself with yfp-RNAi (Figure 1B). These results show that knockdown of let-607 
suppresses both aggregation and toxicity of the polyQ protein.
 To determine if the effect of let-607  on polyQ aggregation and toxicity reflects a more global effect 
on folding capacity, we examined the stability of four endogenous muscle-expressed proteins represented 
by temperature-sensitive (TS) mutations in the paramyosin ortholog UNC-15, in the basement-membrane 
Figure 1: RNA interference screen for suppression of protein misfolding and toxicity. (A) We identified a new 
genetic modifier, let-607 that when knocked down suppressed aggregation of polyQ (Q35 and Q37) and mutant SOD1G93A 
proteins in 6 day old C. elegans muscle cells. The control refers to vector RNAi treatment. (B) Motility assay for 6 day old 
Q35 and WT animals fed with let-607 or vector RNAi. yfp-RNAi is a positive control for suppression of muscle dysfunction. 
(±SEM, Student t-test ***p<0.001). (C) let-607 RNAi rescued the TS phenotype of muscle mutant proteins by >80%: 
UNC-15 (paramyosin; unc/slow movement), UNC-52 (perlecan, stiff paralysis), UNC-45 (myosin assembly, egg laying 
defect) and UNC-54 (myosin, paralysis). 15°C is the permissive temperature, 25°C the restrictive temperature and 23°C 
an intermediate temperature for RNAi efficiency (±SD, Student t-test ***p<0.001). 
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protein perlecan UNC-52, in the myosin-assembly assisting protein UNC-45, and in the myosin heavy 
chain UNC-54 [90]. At the permissive temperature (15°C), all four TS-proteins fold properly and are 
functional, whereas at the restrictive temperature (25°C) each protein misfolds and results in characteristic 
muscle dysfunction phenotypes (Figure 1C control, see Chapter II). For the purpose of the RNAi 
experiments, we employed an intermediate temperature (23°C) at which the TS mutant phenotypes 
remained highly penetrant (Figure 1C, 23°C control), but upon let-607 RNAi, the stability of each protein 
was increased by >80% (Figure 1C). These results show that downregulation of let-607 not only prevented 
protein aggregation, but also enhanced the folding of multiple endogenous metastable proteins, 
suggesting an improvement in protein folding capacity in muscle cells.
Induction of the UPR by let-607 Downregulation 
 The gene let-607 was previously described as a new component of the inducible UPR, both in C. 
elegans and mammals [244]. This gene encodes a bZIP transcription factor of the CREB/ATF family, 
homologous to the mammalian CREBH (Figures S1, S2). Both basal and inducible levels of let-607 
expression have been shown to be xbp-1/ire-1 and atf-6 dependent, but not pek-1-dependent [244]. 
LET-607 seems to be also required for developmental UPR, since the null mutant is lethal, and RNAi 
against let-607 from L1 stage causes some developmental morphological phenotypes (not shown). 
 Given the predicted role for LET-607 in the UPR, we tested how let-607 knockdown affects the ER 
quality control and stress response machinery. Animals treated with let-607 RNAi  showed activation of a 
specific arm of the UPR, with upregulation of ire-1/xbp-1, hsp-4 (ER hsp70), and ero-1, a sensor for ER 
stress, in an xbp-1-dependent manner (Figure 2A). Activation of IRE-1/XBP-1 led to increase in xbp-1 
splicing, as we observed by semi-quantitation of the spliced form on a DNA gel (Figure 2B and C). 
Concomitant upregulation of xbp-1 levels and splicing by let-607, was consistent with UPR transcriptional 
activation and hsp-4 expression. We also found that the levels of let-607 are dependent on the UPR 
transducers IRE-1/XBP-1 and ATF-6, but not PEK-1 or calnexin, as predicted (Figure 2D). Knockdown of 
either isoform of the ER Hsp70, hsp-4 or hsp-3, or treatment with TM, resulted in UPR activation and 
let-607 upregulation (Figure 2D), strengthening the predicted role of let-607 in UPR. Together, the results 
demonstrate that downregulation let-607 activated the ER stress response through IRE-1/XBP-1, and 
enhanced protein folding in the cytosol.
Restoration of Protein Folding by Induction of Cytoplasmic Chaperones and Activation of the HSR
 Although let-607 is involved in ER stress response, the master regulator of protein folding in the 
cytosol is the HSR. So, we asked if enhanced folding of metastable proteins and suppression of 
aggregation by let-607 downregulation was a consequence of activation of the HSR. Hsp70 (C12C8.1p-
GFP) reporter animals incubated with let-607 RNAi, showed increase in GFP fluorescence, consistent with 
an up-regulation of Hsp70 expression (Figure 3A). Next, we examined the expression of cytosolic 
chaperones regulated by HSF-1, and found that upon let-607 RNAi, the expression of multiple heat shock 
genes of the Hsp70 family (C12C8.1, F44E5.4 and C30C11.4) and small Hsp family (hsp-16.1, hsp-12.6 
and hsp-16.49) were upregulated in WT animals (Figure 3C). To examine whether induction of chaperone 
expression was due to activation of HSF-1, we took a genetic approach. Double knockdown of let-607 with 
hsf-1, or on hsf-1(sy441) hypomorphic mutant animals, only caused a slightly lower upregulation of 
chaperone expression (Figure 3C), and aggregation was still  suppressed (Figure 3B). Nonetheless, 
upregulation of hsp70 (C12C8.1) was absolutely required for let-607-mediated suppression of aggregation 
(Figure 3B). Together, these results establish that the HSR was activated by let-607 knockdown, consistent 
with the up-regulation of chaperones leading to enhanced protein folding. Yet, the effect is not fully HSF-1 
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dependent, indicating other contributing factors. Since LET-607 is predicted to be the C. elegans CREBH, 
an ER protein translocated to the nucleus upon stress (Figure S1) [244], we postulated that the events 
occurring at the ER by let-607 knockdown were transmitted to the cytoplasm/nucleus for HSF-1 
activation. 
Activation of the UPR Occurs Up-Stream of the HSR
 Knockdown of let-607 activated two distinct stress responses, usually thought to be independent 
and confined to the respective organelles. We asked if let-607 could function as a negative regulator of the 
HSR by directly inhibiting C12C8.1 transcription at the gene-promoter level. This did not seem to be the 
case as we found that upregulation of let-607  expression (by TM) did not impair C12C8.1 expression upon 
heat shock treatment (not shown). To examine whether activation of each stress response was 
independent or dependent on the other, we started by asking if other UPR inducers could cause a similar 
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Figure 2: The effect of let-607 
knockdown on UPR. (A) Real-
time qPCR analysis of WT 
animals treated with let-607 RNAi 
or co-treated with let-607 and 
xbp-1 RNAi from L4 stage (RNAi 
bac te r i a d i l u t i on con t ro l s 
included), showing up-regulation 
o f UPR genes by le t -607 
knockdown, in a xbp-1-dependent 
manner (crt-1/calreticulin; cnx-1/
calnexin; T05E11.3 /Grp94 ; 
T14G8.3/Hsp70 member; T24H7.2/
Hsp70 member). Data are relative 
to EV control RNAi (±SD). (B,C) 
DNA gel analysis of xbp-1 splicing 
by let-607 RNAi. RNAi for hsp-3 
and TM treatment are positive 
controls for UPR induction and 
xbp-1 splicing, and ire-1 RNAi is 
the control for specificity. The 
levels of hsp-4 were used as 
control of UPR induction. (C) 
shows semi-quantitation of the 
xbp-1 spliced form (by measuring 
the intensity of the 201 bp band 
relative to total xbp-1 and actin). 
(D) Real-time qPCR analysis of 
let-607 mRNA levels upon 
knockdown of each ER-UPR and 
quality control components. (E) 
The efficiency of RNAi knockdown 
was measured by qPCR (±SD).
Efficiency of
knockdown
effect on cytosolic  chaperones as let-607. To induce UPR, we employed hsp-3 RNAi or the chemical  TM. 
In animals treated with TM, the HSR was not induced and cytosolic chaperones were not upregulated 
(Figure 4A). However, when animals were treated with hsp-3 RNAi, both the UPR (seen by the levels of 
hsp-4 that compensates for the absence of the isoform hsp-3) and the HSR (C12C8.1, F44E5.4, hsp-16.1) 
were activated, to a similar magnitude or higher as for let-607 RNAi (Figure 4A). This suggested that UPR-
mediated activation of the HSR is not the simple result of ER stress caused by disruption of the secretory 
pathway (TM result), but may be specific to the disruption of the ER chaperone machinery. Supporting this 
hypothesis, we found that let-607-mediated upregulation of cytosolic chaperones, was strongly dependent 
on xbp-1 (Figure 4B). Co-downregulation of let-607 and xbp-1  abolished chaperone induction (Figure 3C, 
4B). These results suggest that induction of the UPR through xbp-1 is epistatic  to the activation of the HSR 
in the cytosol, revealing a new “crosstalk” between stress pathways, mediated by let-607. This is 
consistent with the requirement of xbp-1 for hsp-3/hsp-4 expression and subsequent up-regulation of 
cytosolic chaperones. In turn, let-607 seems to function like a “switch” that communicates to the cytosol 
the folding ‘status’ in the ER upon stress.
 To determine if the “crosstalk” between ER and cytosolic stress responses is specific  to let-607, we 
examined the relationship between the two canonical stress responses in C. elegans. Is HSF-1 function 
required for UPR activation? Is intact UPR required for HSR activation? We tested HSR induction in 
impaired UPR animals by knocking down the UPR transducers atf-6 and xbp-1. In both cases, heat shock 
treatment caused hsp-70 and shsp upregulation to the same level as in the control animals (Figure 5A). 
Then, we tested UPR induction in hsf-1(sy441) hypomorphic mutant animals, and found that TM-mediated 
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Figure 3: Induction of the heat shock 
response by let-607 knockdown. (A) 
Fluorescence images show activation of 
the C12C8.1p::GFP reporter. (B) 
Suppression of aggregation in Q35 and 
Q37 animals is dependent on C12C8.1 
chaperone levels, but not dependent on 
HSF-1. Foci number is shown relative to 
the total number of foci in each strain in 
vector conditions (±SD). (C) Real-time 
qPCR analysis of WT and hsf-1(sy441) 
animals treated with  let-607 RNAi showed 
upregulation of cytosolic chaperones from 
the HSP-70 family (C12C8.1, F44E5.4, 
C30C11.4), small HSPs (hsp-16.1, 
hsp-12.6, hsp-16.49), and the stress-
inducible protein sip-1. This up-regulation 
showed contribution by HSF-1 but not total 
dependence. Data are relative to 
WT;vector RNAi (±SEM).
up-regulation of hsp-4 levels was reduced by half (from 20-fold to 10-fold) in hsf-1 mutant animals (Figure 
5B). Moreover, whereas HS treatment activated UPR (hsp-4 levels, Figure 5A), TM did not activate the 
HSR (Figure 5B). This once again pointed towards a “crosstalk” between pathways for a robust protection 
against stress, but also corroborated that the UPR requirement for HSR induction is a let-607 specific 
observation (Figure 4B, 5A, 6).
Another Layer of Stress: DAF-16 Nuclear Translocation Upon let-607 Knockdown
 To examine exhaustively how let-607 knockdown affects cellular homeostasis and protein folding, 
we tested all  known stress-inducible pathways, as we hypothesized that enhancement of protein folding 
was a consequence of stress response activation and consequent upregulation of chaperones. In addition 
to the UPR and HSR, we found that let-607 RNAi treatment of a daf-16p::DAF-16::GFP reporter strain 
increased DAF-16 nuclear localization, as shown by GFP fluorescence (Figure 5C). This results showed 
that let-607 knockdown at the ER activated DAF-16 (FOXO) nuclear translocation and possibly 
transcriptional activity, which still  needs to be tested. We also examined the effect of let-607 knockdown in 
a daf-16(mu86) mutant strain and found that cytosolic  chaperones were strongly up-regulated (Figure 5D). 
These results suggest a compensatory effect between pathways that lead to chaperone expression and 
proteostasis maintenance (Figure 6).
DISCUSSION AND FUTURE DIRECTIONS
 In mammals, CREBH (or CREB3L3) is a liver-enriched transcription factor closely related to LZIP. 
CREBH has a transmembrane (TM) domain and it localizes to the ER. Under ER stress, proteolytic 
cleavage by site-1 and site-2 proteases (S1P, S2P) removes the TM domain and  liberates the CREBH 
amino-terminal fragment that translocates to the nucleus to activate transcription of hepatic  gluconeogenic 
Figure 4: Real-time qPCR analysis of the stress responses induced by let-607 knockdown in WT animals. (A) 
Induction of UPR by hsp-3 RNAi, but not by TM treatment, up-regulated cytosolic chaperones’ expression in a similar 
manner to let-607 RNAi. (B) Upregulation of cytosolic chaperones (Hsp70 and sHsp) and sip-1, by let-607 RNAi is 
dependent on xbp-1 but also results from HSF-1 activity as shown by reduced induction in the hypomorph  hsf-1(sy441) 
(data are relative to levels in vector control, ±SD). 
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enzymes and acute phase response (APR) genes (Figure S2) [297-299]. CREBH activates transcription by 
binding to the cAMP-responsive element (CRE), box B and ATF-6-binding element of target genes [298]. 
CREBH is up-regulated by pro-inflammatory cytokines and fatty acids, that also induce UPR, and is a 
growth suppressor that becomes aberrantly down-regulated in liver cancers (Figure S2B) [298]. CREBH 
establishes a link between ER stress and growth, innate immunity and nutritional regulation [300]. In C. 
elegans, ATF-6 and XBP-1 are predicted to be upstream regulators of let-607 during inducible UPR [244], 
and LET-607 seems to have a role in development. Otherwise, the physiological role and downstream 
targets of this predicted transcription factor are largely unknown.
 Here, we found that C. elegans UPR induction by let-607 downregulation is xbp-1 dependent, and 
occurs upstream of HSR activation (Figure 6). Moreover, the effect of let-607 RNAi  as a UPR and HSR 
inducer is not common to other UPR inducers, such as TM or DTT  (not shown), and is reminiscent of the 
“Super UPR” previously described [246]. We then asked how the effect of let-607 on the UPR/HSR 
“crosstalk” compared to the relationship between these two canonical  pathways. HSR induction did not 
require intact UPR components, but induction of UPR by TM was slightly lower when HSR was impaired 
Figure 5: Potential “crosstalk” between cellular stress pathways, mediated by let-607. (A,B) Real-time qPCR analysis 
of cytosolic (C12C8.1, F44E5.4, hsp-16.1) and ER (hsp-4) chaperones upon (A) heat shock (HS) treatment of WT animals 
with impaired UPR response (xbp-1 and atf-6 RNAi). HS induction of chaperones did not require functional UPR. (B) UPR 
induction by TM treatment of WT or HSR-deficient (hsf-1(sy441)) animals, showed that in the hsf-1 hypomorphic mutant, 
UPR was less robust. Data are relative to WT animals in EV control (±SD). (C) DAF-16 protein reporter shows nuclear 
localization upon let-607 RNAi. (D) Real-time qPCR analysis of chaperone expression in the daf-16(mu86) mutant 
background, by let-607 RNAi (relative to WT;control animals ±SD).
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(mutant hsf-1). It remains to be determined whether XBP-1 is a direct transcriptional activator (promoter 
binding activity) of cytosolic  chaperones or even HSF-1. From a preliminary analysis, we found that the 
C12C8.1 promoter region contains 3 XBP-1-binding elements (not shown), which would be consistent with 
the hypothesis of XBP-1-dependent HSR activation. We also found that the let-607 promoter region 
contains 1 XBP-1/ATF-6 binding element (TGACGT) and 3 DAF-16 binding sites (TGTTTAC, CTTATCA, 
TATTTAC) (not shown). Together, gene promoter analysis may strengthen the hypothesis of co-regulation 
of multiple stress pathways for overall homeostasis (Figure 6).
 We list here a number of questions we intend to see answered in order to characterize the role of 
let-607 in proteostasis maintenance:
• It will  be crucial to demonstrate that LET-607 is an ER resident protein, and for that we are generating a 
LET-607::GFP reporter strain. 
• Under physiological conditions, what is the stimuli that activates LET-607 translocation to the nucleus? 
Cleavage of LET-607 at the ER/Golgi  and translocation to the nucleus can be monitored by western blot 
with an antibody against human CREB3L3 (host rabbit, polyclonal, Orbigen PAB-10965) that recognizes C. 
elegans LET-607 [297,299]. 
• Does it have nuclear transcriptional activity? What are the transcriptional downstream targets and what is 
the promoter binding element (does it bind to CRE)? 
• Is LET-607 a new ER-stress transducer in C. elegans? According to sequence alignment predictions, 
LET-607 strongly resembles mammalian CREBH with an ER transmembrane domain (Figure S1, S2). 
Elucidating whether LET-607 is cleaved and activated similarly to ATF-6 under ER stress, and identifying 
the downstream transcriptional  targets will  broaden our understanding of the UPR components and 
physiological relevance. 
• We will  also employ electrophoresis mobility shift (EMSA) to look at HSF-1 and XBP-1 transcriptional 
activation upon let-607 downregulation.
 Finally, CREBH has been described to be involved in nutrient sensing and metabolism [300]. It will 
be important to determine if the effect of let-607 on protein homeostasis is a consequence of reduced 
Figure 6: Working model for the 
“crosstalk” between ER and cytosolic 
stress responses through LET-607. (A) 
Under physiological conditions LET-607 is 
a member of the UPR, with a role in 
constitutive and developmentally required 
UPR. (B) When let-607 is down-regulated, 
it activates the IRE-1/XBP-1 UPR pathway 
and up-regulates the expression of ER 
chaperones. Through this pathway, ER 
stress “signals” are transmitted to the 
cytosol for HSF-1 activation and HSR. 
This translates in expression of multiple 
cytosolic chaperones. Altogether, these 
stress pathways work to maintain 
proteome stability and cellular proteostasis.
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synthesis and metabolism, known to affect proteostasis. We will  test if the levels of synthesis components 
are altered by let-607 RNAi  (e.g. Abu genes, fatty acid metabolic enzymes, amino acid transporters and 
peptide transporters). In fact, a set of genes involved in ER stress from the Abu family (abu/pqn) have 
been proposed to be involved in protein folding and longevity [301], supporting a link between ER 
homeostasis and overall cellular and organismal health and lifespan.
MATERIALS AND METHODS
C. elegans Strains. Animals were maintained according to standard methods, at 20°C on nematode growth media 
(NGM) with OP50 E. coli [138]. The strains utilized in this work were: wild-type (WT) Bristol strain N2, polyQ strains 
(Q24 AM138; Q35 AM140) [119]; Q37-YFP strain (AM470, see Chapter II); SOD1 strains (SOD1G93A AM265; SOD1wt 
AM263) [91]; reporter strains C12C8.1p::gfp reporter fusion (AM446) [Morley  2004];  daf-16p::DAF-16::GFP (TJ356); 
temperature sensitive (TS) mutant  strains unc-15(e1402), unc-54(e1157), unc-52(e669su250) and unc-45(e286) 
(CB1402, CB1157, HE250 and CB286, respectively) [90]; and the mutant hsf-1(sy441) (PS3551).
RNAi Assays. A genome-wide RNAi screen for suppression of  Q35 aggregation in C. elegans  muscle cells was 
performed as described in Chapter II, using the commercial RNAi library  (GeneServiceTM, USA) [155]. Briefly, animals 
were added to RNAi bacteria at the L1 or L4 stage  (day 1 or day  3, respectively), incubated at 20°C for 5 or 2 days, 
respectively, and scored for reduction in the number of  aggregates at 6 days old  using the stereomicroscope Leica 
MZ16FA (Leica Microsystems, Switzerland). As a negative control, animals were fed bacteria carrying the L4440 
empty  vector. For RNAi assays on plates, NGM media was supplemented with 100 µg/ml ampicillin, 1 mM isopropyl β-
D-thiogalatoside (IPTG, Sigma) and 12 µg/ml tetracycline, and seeded with overnight RNAi bacteria cultures, pre-
induced with IPTG (1 mM). For double knockdown experiments, equal volumes of  each RNAi bacteria were mixed (1:1 
ratio) prior to plate seeding. Fluorescent microscopy  images were taken using an Axiovert 200 microscope with a 
Hamamatsu digital camera C4742-98 (Carl Zeiss, Germany). For all experiments, efficient gene knockdown was 
confirmed by qPCR, and all RNAi plasmids were sequenced to confirm target specificity. 
Motility Assays. Animals grown on RNAi-seeded plates (6 days old, ~25) were picked onto OP50-NGM plates 
equilibrated at 20°C and their movements digitally  recorded using a Leica M205 FA microscope with a Hamamatsu 
digital camera C10600-10B (Orca-R2, Leica Microsystems, Switzerland), and the Hamamatsu Simple PCI Imaging 
software (see Chapter II for detailed methodology). The average speed of  each animal was calculated by  dividing the 
distance of each track, corrected for body length, by the duration of the track (body length per second, BLPS). 
Assay for TS Phenotypes. Temperature sensitive (TS) mutant animals were age-synchronized to L1 stage, grown on 
RNAi-seeded plates at a sensitized temperature of  23°C for RNAi efficiency (the permissive temperature is 15°C, and 
the restrictive temperature 25°C), and >50 animals scored for each specific phenotype 4 days later as described 
previously (n=3) [90,167] (see Chapter II for detailed methodology). 
Reverse Transcriptase PCR Analysis. RNA was extracted with the Trizol reagent (Invitrogen), followed by  DNase 
treatment  (Applied Biosystems #AM1906). mRNA was reverse transcribed using the iScriptTM cDNA Synthesis Kit 
(Bio-Rad #170-8891). cDNA was used for real-time PCR amplification with the iQ™ SYBR® Green Supermix (Bio-Rad 
#170-8880) and the iCycler system (Bio-Rad) (see Chapter II). The relative expression levels of  each gene were 
determined using the Comparative CT Method (Real-Time PCR Applications Guide, Bio-Rad). Measurements were 
performed for ≥3 biological samples of  each condition. For standard PCR analysis, cDNA was amplified with Taq 
Polymerase (NEB) followed by electrophoresis on a 2% (w/v) agarose-TBE gel.
ER and Cytosolic Stress Induction.  For DTT (Dithiothreitol 2.5 mM in water, Sigma) and TM (Tunicamycin 28 µg/ml 
in methanol; Sigma) treatment, drug solutions were poured onto the plates where the animals were growing, covering 
the entire plate surface, and incubated at 20°C for 4h. Then, animals were washed with M9 buffer, allowed to recover 
on new OP50 plates for 1h, and finally  collected for mRNA extraction. For heat shock (HS) treatment, animals were 
incubated in M9-OP50 at 33°C for 15 min, allowed to recover for 30 min on OP50 plates at 20°C, and then collected 
for mRNA extraction.




Figure S1: Sequence alignment between C. elegans 
LET-607 and the human ortholog CREB3L3 (CREBH), 
obtained with the CLC DNA Workbench software. 
Highlighted are the predicted domains of CREBH.
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Figure S2: (A) Predicted LET-607/CREBH domains based on sequence similarity and alignment. ERM is the ER retention membrane 
proximal determinant, and S1P and S2P are the sites for RIP (regulated intramembrane proteolysis) for ER-to-nucleus translocation. 
(B) Overview of CREBH upstream and downstream regulatory pathways, in mammalian cells. HNF4α is the nuclear hormone 
receptor; PPARα is the peroxisome proliferator-activated receptor alpha; APR stands for acute phase inflammatory response genes. 
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ABSTRACT  
 Protein homeostasis (proteostasis) is essential for cellular and organismal health. Stress, aging, 
and the chronic  expression of misfolded proteins, however, challenge the proteostasis machinery and the 
vitality of the cell. Enhanced expression of molecular chaperones, regulated by heat shock transcription 
factor-1 (HSF-1), has been shown to restore proteostasis in a variety of conformational disease models, 
suggesting a promising therapeutic approach. We describe the results of a ~900,000 small molecule 
screen that identified novel classes of small  molecule proteostasis regulators (PRs) that induce HSF-1-
dependent chaperone expression and restore protein folding in multiple conformational  disease models. 
The beneficial  effects to proteome stability are mediated by HSF-1, DAF-16/FOXO, SKN-1/Nrf-2, and the 
chaperone machinery through mechanisms that are distinct from current known small  molecule activators 
of the HSR. We suggest that modulation of the proteostasis network by PRs represents a promising 
therapeutic approach for the treatment of a variety of protein conformational diseases.
INTRODUCTION
  
 Proteostasis regulates the functional  properties of the proteome to minimize the damage of 
misfolded and aggregated proteins through a network of pathways for protein synthesis, folding, trafficking 
and degradation [5,58]. Loss of proteostatic control has been implicated in aging and multiple disorders of 
protein misfolding including metabolic diseases, cancer, and neurodegenerative diseases [5,58,92]. 
Eukaryotic cells have developed compartment-specific  quality control mechanisms for proteome 
maintenance, to guide protein folding and transport, and to direct faulty proteins for refolding or clearance. 
Likewise, each compartment induces a cell  stress response to detect and restore balance: the heat shock 
response (HSR) for cytoplasmic  folding and misfolding, and the unfolded protein responses (UPR) in the 
endoplasmic reticulum (UPR-ER) [46] and mitochondria (UPR-MT) [302]. Across these compartments are 
other stress responses that detect specific  classes of protein damage caused by metal stress and 
antioxidants (ARE) [92,303,304].
 The cytosolic  HSR is governed by a family of heat shock factors (HSFs) of which HSF-1 is 
essential for proteotoxic  stress and regulation of heat shock proteins (Hsps) [35]. Many Hsps are molecular 
chaperones that guide the conformation of proteins during biogenesis and prevent misfolding and 
aggregation that interfere with cellular function [305]. Induction of the HSR not only prevents protein 
damage from persisting, but also restores the cell  to the pre-stress condition. Despite these essential 
cellular stress pathways, the chronic expression and accumulation of misfolded, oxidized and aggregated 
proteins, as occurs in aging and disease, leads to cellular dysfunction when the quality control  machineries 
become compromised [59,90]. There is increasing evidence that misfolded proteins expressed in diseases 
of protein conformation are not efficiently counterbalanced by a compensatory induction of cellular stress 
responses such as the HSR [59]. Enhancing the activity of HSF-1 and the levels of molecular chaperones 
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by genetic techniques or pharmacological  manipulation has been shown to restore proteostasis in several 
models of disease [214,306-313]. 
 Given the prominent roles of HSF-1 to maintain cellular proteostasis by upregulation of chaperone 
expression, there has been substantial effort to identify novel small molecule PRs that modulate HSF-1 
activity. Several small  molecule activators of HSF-1 are known [35,169], including proteasome inhibitors 
and compounds that selectively bind to the chaperone Hsp90, including radicicol, geldanamycin (GA), and 
17-AAG. Another plant-derived compound, the triterpenoid celastrol, identified from a consortium screen 
for molecules with protective effects in models of Huntington’s disease and ALS was shown to potently 
activate the HSR in mammalian cells. Most recently, a yeast-based high-throughput screen for small 
molecule activators of HSF-1 identified the compound HSF1A that was shown to activate HSF-1 without 
associated proteotoxicity [309]. 
 Despite the potential  benefits, as shown in multiple cellular and animal models of diseases of 
protein conformation, further development of these small  molecules will be necessary prior to their use as 
a therapeutic  agent [247,248]. For example, although GA and other derivatives that inhibit Hsp90 are 
currently in pre-clinical and clinical  development for the effective treatment of a number of different cancers 
[314], their use for diseases associated with protein misfolding may have limited therapeutic potential. 
Given the imminent challenges facing the care of individuals afflicted with protein conformational diseases, 
and the lack of effective therapeutics, we propose that further investigation into small molecule PRs that 
activate HSF-1 is urgent. Here, we describe the discovery and characterization of novel small molecule 
PRs that, by enhancing HSF-1 activity, restore proteostasis in multiple diseases of protein conformation. 
We propose that modulation of the proteostasis network by HSF-1 PRs represents a new therapeutic 
approach for the treatment of both cytosolic and compartment-specific conformation disorders.
RESULTS 
Cell-based HTS for Small Molecule Activators of the HSR  
 We developed a high-throughput screen (HTS) that measures the activation of the HSR in HeLa 
cells stably transfected with a heat shock-inducible reporter containing the proximal  human Hsp70.1 
promoter sequence upstream of a luciferase (luc) reporter gene (Fig. 1a) [170,315]. To assess the 
sensitivity and robustness of the cell-based assay before undertaking the HTS campaigns, we established 
dose-response profiles using three positive controls, celastrol, cadmium chloride (CdCl2), and MG132 (Fig. 
1b). The derived EC50 values for celastrol and MG132 were ~3 and 5 µM respectively, in agreement with 
previous reports [169]. Optimization and miniaturization of the HTS formats were carried out independently 
at the Scripps Research Institute Molecular Screening Center (SRIMSC, Florida) and at the Southern 
Research Institute (SRI) (Supplementary Table 1). MG132, due to its sigmoidal profile, and CdCl2, because 
of its ability to strongly induce the reporter (Fig. 1b), were subsequently employed as positive controls at 
the SRIMSC and Southern Research Institute, respectively (Supplementary Table 2). Assessment of 
critical variables of the assay was carried out during the miniaturization and optimization steps to achieve 
384 and 1,536-well plate formats (Supplementary Table 1). The Z’ values for the miniaturized cell-based 
assays were ≥0.6, indicative of consistency and reproducibility. The HeLa-luc assay was validated by pre-
screening two different libraries, the 1,280-molecule Library of Pharmacologically Active Compounds 
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(LOPAC) from Sigma at the SRIMSC, and a 2,000-compound set of known biologically active compounds 
from MicroSource Discovery Systems at Southern Research Institute. 
Identification of Novel Classes of Small Molecule PRs
 Two primary screens of 803,587 and 100,000 compounds were performed independently at the 
SRIMSC and at SRI, respectively.  The small molecule libraries consisted of: (i) 607,408 compounds from 
the Scripps Drug Discovery library and 196,179 compounds from the Molecular Libraries Probe Production 
Center Network (MLPCN) library, both run at the SRIMSC; and (ii) 100,000 compounds from the National 
Institute of Neurological Disorders and Stroke (NINDS) library, run at the Southern Research Institute. 
Assay performance was consistent across plates, with robust Z’ factors and signal-to-background ratio 
(Supplementary Fig. 1 and Supplementary Table 2). The data obtained from the primary screens was 
normalized to each positive control set as 100% activation. The screen performed at the SRIMSC 
identified 759 primary hits, whereas 37 primary hits were identified at SRI (Supplementary Table 2). 
 False-positive hits were excluded by performing a triplicate run on the primary hits that yielded 263 
confirmed compounds (Supplementary Table 2). Although the more stringent conditions elicited by CdCl2 
led to a lower number of primary hits, these conditions also identified a smaller fraction of false positives, 
as demonstrated in the confirmatory secondary assays (Supplementary Table 2). Confirmed hit 
compounds were reordered as dry powders from commercial vendors (ChemDiv, Enamine, ChemBridge, 
and Asinex) or re-synthesized for retesting in a full dose response. The active compounds were clustered 
by structure with a 0.8 Tanimoto (Butina, 1999 cutoff followed by manual inspection to merge clusters 
sharing a common scaffold. This analysis resulted in 233 hits grouped into seven clusters (A through G, 
Fig. 1c) that did not show structural  similarities with the remaining 30 hits. Many compounds contained 
reactive moieties known to activate the HSR, such as reactive α,β-unsaturated carbonyls [316,317], but 
other series had no obvious reactive groups. 
 The two primary screens performed with different positive controls, chemical libraries and 
compound concentrations, independently identified three common scaffolds (C, E and F, Fig. 1c and Table 
1), providing cross-validation of the cell-based screen. These active compounds were subsequently tested 
in the HeLa-luc  cells to establish dose-response curves and compound toxicity. EC50 and CC50 values 
were determined: most hits exhibited a sharp activation profile, with only few compounds displaying 
sigmoidal dose-response curves. Subsequent studies were initially performed with fourteen representative 
compounds (A1, A2, A3, B1, B2, B3, C1, C2, D1, E1, F1, F2, G1 and G2, Table 1) belonging to the largest 
clusters A-G (Fig. 1c). The dose-response activity and toxicity profiles for the selected compounds are 
shown in Supplementary Figure 2. We refer to these compounds as small molecule proteostasis regulators 
(PRs). 
Induction of Hsps and Activation of HSF-1 by the PRs 
 The results of the HTS screen were further validated by direct demonstration that the expression 
of endogenous Hsp mRNAs and proteins were induced by representative PRs. Exposure of HeLa cells to 
the PRs induced Hsp70 mRNA levels from 2 to 5-fold (Fig. 2a and Supplementary Fig. 3a). Likewise, 
western blot analysis (Fig. 2b) showed that the levels of multiple chaperones (Hsp70, Hsp40 and Hsp27) 
were induced from 2 to 6-fold, similar to the positive controls, respectively (Fig. 2b and Supplementary Fig. 
3b). 
 The elevated expression of multiple Hsp genes by the PRs can be most directly explained by 
induction of the HSR and activation of HSF-1. To address this, we employed electrophoretic  gel  mobility 
shift assays (EMSA). Of the fourteen PRs previously tested for chaperone induction (Fig. 2a and b), 7 
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compounds representative of each chemical cluster were selected for this study (A1, A3, B1, C1, D1, E1, 
F1). Incubation of HeLa cells with the PRs strongly induced HSF-1 DNA-binding activity (Fig. 2c). The 
specificity of HSF-1 induction (lanes 3-7 and 18-23) was demonstrated by competition with excess 
unlabeled HSE oligonucleotide (lanes 8-12) and by anti-HSF-1 antibody supershift experiments (lanes 
13-15 and 24, 26-29). The results of EMSA analysis were further confirmed by chromatin 
immunoprecipitation (ChIP) experiments. The PRs that most strongly induced HSF-1 activation in the gel 
mobility shift assay (A1, A3, C1, D1 and F1, Fig. 2c) were selected for ChIP analysis and the results 
showed occupancy of HSF-1 to the endogenous Hsp70.1 (Fig. 2d and Supplementary Fig. 3c), Hsp40 and 
Hsp27 promoters (Supplementary Fig. 4), but not to the negative control promoter. 
 From a chemical mechanism perspective, many previously identified small molecule inducers of 
the HSR have been suggested to activate HSF-1 by causing direct protein thiol oxidation. Compounds A1, 
A3, C1, D1 and F1 contain cysteine reactive moieties such as unsaturated-carbonyls (Supplementary 
Table 3). No close analogs of these five compounds that lacked these reactive groups were present in the 
HTS libraries, and therefore they were not tested. To determine whether the PRs A1, A3, C1, D1 and F1 
caused protein thiol  oxidation, we tested if their activity could be inhibited by treatment with reducing 
agents such as N-acetyl cysteine (NAC) and dithiothreitol  (DTT). Induction of the HSR by celastrol was 
inhibited by NAC (2 mM) and DTT  (250 µM) treatment, as expected (Supplementary Fig. 5f and l). Only the 
activity of PR F1 was completely inhibited by NAC and DTT treatment, indicating that F1 may cause 
oxidative damage by modifying protein cysteine residues (Supplementary Fig. 5e and k). In contrast, the 
activities of C1 and D1 were only slightly less affected (Supplementary Fig. 5c-d and i-j) and activation of 
the HSR by A1, and A3 was unaffected (Supplementary Fig. 5a-b and g-h), indicating that these PRs do 
not act through this mechanism. 
PR Activity on Hsp Genes Requires HSF-1 and the HSE 
 Activation of HSF-1 by the PRs correlates with enhanced expression of chaperone genes, but 
does not formally demonstrate a requirement for a wild type HSE sequence or a dependence upon HSF-1. 
To directly address this, we tested the five PRs for their ability to induce luciferase expression in HeLa cells 
transfected with a mutated HSE sequence fused to a luciferase gene. As expected, cells lacking a wild 
type HSE failed to induce luciferase expression (Supplementary Fig. 6), indicating that an intact HSE is 
necessary for activation of the HSR by the PRs. We then treated wild type (WT) and hsf-1 null  (hsf-1-/-) 
mouse embryonic fibroblasts (MEFs) with the PRs and showed that PR-induction of Hsp70 mRNA was 
detected only in WT cells and not in hsf-1-/- cells (Fig. 3a and Supplementary Fig. 7a). These results 
provide conclusive evidence that PR induction of chaperone expression is dependent upon activation of 
HSF-1. 
PRs Activate Multiple Proteostasis Network Pathways 
 We next examined the gene signature of the PRs using a multiplex gene expression analysis to 
identify additional proteostasis mechanisms regulated by the PRs. We asked whether the PRs could 
activate other stress responsive proteostasis network (PN) pathways such as the unfolded protein 
response (UPR) and the antioxidant stress response, in addition to the HSR. Therefore, we monitored the 
expression of the UPR-inducible gene GRP78/BiP, the antioxidant responsive genes heme oxygenase 1 
(HO1) and the regulatory subunit of glutamate-cysteine ligase (GCLM), and the proapoptotic  growth arrest- 
and DNA damage-inducible gene 153 (GADD153, also known as CHOP). WT and hsf-1-/- MEF cells were 
treated with PRs and the positive controls MG132 (MG) and geldanamycin (GA) that induce the HSR, 
oxidative stress, and the UPR; tunicamycin (Tm) that induces the UPR; and sulphoraphane (Sul) that 
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activates the antioxidant response (Fig. 3b and g). Untreated (Unt) and DMSO-treated cells served as 
negative controls (Fig. 3b and g). 
 The PR stress response signatures were established in WT and hsf-1-/- MEF cells (Fig. 3c-f and h-
k). At a range of concentrations of PRs A3, C1, D1, and F1, Hsp70 mRNA levels were induced from 9 to 
30-fold in WT MEF cells (Fig. 3c-f). Compound D1 (Fig. 3e) was selective and only induced the expression 
of Hsp70, whereas A3 and C1 strongly induced Hsp70, in addition to a 3-fold increase in BiP (A3 and C1) 
and HO1 (A3 only) expression (Fig. 3c and d). Likewise, compound F1 induced multiple responses and 
strongly induced Hsp70, the oxidative stress response genes (HO1 and GCLM), and a 2.5-fold 
upregulation of BiP (Fig. 3f). 
 In performing parallel  experiments on hsf-1-/- cells (Fig. 3h-k), we noticed that the level of 
induction of HO1 was dramatically enhanced from 12 to 130-fold, whereas the expression of GCLM and 
BiP was comparable to WT MEF cells (Fig. 3h-k). These results suggest that up-regulation of an anti-
oxidant stress response compensates for HSF-1 deficiency. At the highest PR concentrations, induction of 
the cell death pathway (GADD153) was also observed. Our previous experiments employing DTT 
treatment indicates that PRs A1, A3, C1 and D1 did not activate the HSR by causing oxidative stress, yet 
we observed potent induction of the antioxidant responsive gene HO1 in absence of HSF-1 (Fig. 3h-k). 
There may be at least two explanations for this apparent discrepancy. First, if the induction of HO1 by the 
PRs were due to the generation of oxidative stress, then we would expect a concerted upregulation of the 
antioxidant GCLM gene, as occurs for compound F1. This, however, is not observed in WT cells. In 
addition, transcriptional regulation the HO1 gene indicates that expression is regulated by multiple stimuli, 
and not solely dependent upon oxidative stress [318]. 
PRs Protect Cells Against Severe Stress and Apoptosis  
 Activation of the HSR and induction of molecular chaperones has been shown to protect cells from 
the deleterious consequences of protein damage and apoptosis. Therefore we tested if the PRs A1, A3, 
C1, D1 and F1 displayed cytoprotective properties. Pretreatment with either 42°C heat shock or the PRs 
A3, D1 and F1 significantly protected cells from cell death induced by a 35 min severe heat shock 
(Supplementary Fig. 8a). On the contrary, the PRs A1 and C1 did not display any cytoprotective properties 
and instead increased the fraction of cell death after the 45°C treatment compared to the DMSO control. 
 We next determined if the PRs protected against apoptotic cell death induced by oxidative stress.  
Assessment of cellular apoptosis and necrosis was performed by staining HeLa cells with Annexin V and 
propidium iodide (PI).  In agreement with the cytoprotection data, treatment with the PRs A3, D1 and F1 
led to a two-fold protection from H2O2–induced apoptosis, as indicated by the reduced number of Annexin 
V-stained cells compared to the untreated cells (Supplementary Fig. 8b).  On the contrary, cells pretreated 
with PRs A1 and C1 exhibited both an apoptotic  (A1 and C1) and necrotic pattern (C1), (Supplementary 
Fig. 8b).
Proteostasis Restoration in Models of Conformational Disease  
 In addition to its well-established role in maintaining cytoplasmic  proteostasis, HSF-1 has also 
been recently shown to ameliorate ER stress [245]. We therefore asked whether the PRs, by enhancing 
chaperone expression, would reduce protein misfolding in diseases in which expression of mutant proteins 
accumulates in either the cytoplasm or the ER. 
 As a representative cytosolic model, we examined the effects of the PRs on Huntingtin 
aggregation in PC12 cells, conditionally expressing human Huntingtin (htt) exon 1 containing an expansion 
of 74 glutamines, fused to green fluorescent protein (GFP) (httQ74-GFP) [319]. In these cells, httQ74-GFP 
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aggregates are detected after 48 hours of induction. PC12 cells were treated with the PRs and visually 
monitored for aggregate formation. Incubation with A1, D1 and F1 caused a reduction (from 2 to 3-fold) of 
httQ74-GFP protein aggregates without altering the levels of httQ74-GFP protein (Fig. 4a and b and 
Supplementary Fig. 9a-f), whereas PRs A3 and C1 had no effect, although Hsp70 levels were induced 
(Fig. 3c and d). 
 We next investigated the PRs on a cellular model of cystic fibrosis. This model corresponds to a 
human bronchial epithelial  cell  line (CFBE41o-) stably co-expressing the ΔF508 mutation of the CFTR and 
a halide-sensing mutant of YFP (H148Q/I152L-YFP). ΔF508-CFTR is defective both in trafficking from the 
endoplasmic reticulum to the plasma membrane and in channel gating [320]. Correction of ΔF508-CFTR 
trafficking by the PRs would lead to increased level of active protein at the cell  surface, affording increased 
flow of extracellular halides into the cell, resulting in reduction of YFP fluorescence intensity.
 The same PRs tested in the Huntington’s disease cell model  were also tested in ΔF508-CFTR 
expressing cells and positive results were obtained for A3, C1 and F1 (Fig. 4c  and Supplementary Fig. 
10a). The extent of YFP quenching detected was comparable to that seen with corrector 4a, a commonly 
used positive control  for this assay (Fig. 4c). It is worth noting that compound F1 represents the first 
characterized small  molecule capable of enhancing the correct folding of proteins expressed in two 
different cellular compartments.
 To further confirm that the PRs A3, C1 and F1 rescued ΔF508-CFTR trafficking, we monitored the 
processing of ΔF508-CFTR. Treatment of CFBE41o- cells expressing ΔF508-CFTR with the PRs 
generated higher molecular mass forms of ΔF508-CFTR, consistent with full  glycosylation (Fig. 4d-f and 
Supplementary Figs. 10b and 11), indicating that the PRs partially rescued the cell-surface expression and 
maturation of ΔF508-CFTR. In addition, we show that rescue of ΔF508-CFTR trafficking by the PRs 
coincides with Hsp70 upregulation, suggesting that the PR action depends on HSF-1 and the induction of 
molecular chaperones. 
Suppression of Aggregation and Toxicity in C. elegans 
 We asked whether the efficacy of the PRs to reduce protein aggregation could be also observed in 
a C. elegans model for expression of expanded polyglutamines (35 glutamines fused to YFP, Q35::YFP) in 
body wall muscles, that displays age-dependent aggregation and toxicity [119]. This model exhibits many 
characteristics of polyglutamine diseases, such as Huntington’s disease, and has been a valuable tool in 
the identification of genetic and chemical modifiers of aggregation and toxicity [144,167]. 
 Age-synchronized Q35 animals were treated with the PRs and the effects on aggregation and 
toxicity scored at 6 days of age. We used 17-AAG as a positive control inducer of the HSR that induces 
chaperone expression and reduces polyQ aggregation [306,312]. Treatment of C. elegans with 17-AAG 
induced the HSR (Fig. 5d), and showed a marked reduction in protein aggregates and toxicity (Fig. 5a-c). 
Treatment with PRs A1, D1 and F1 suppressed Q35 aggregation (Fig. 5a and b) without affecting overall 
levels of Q35 protein (Supplementary Fig. 9g and h). Suppression of polyQ aggregation also ameliorated 
aggregation-associated toxicity. Expression of Q35 in the body wall muscles reduces motility by 50% 
relative to WT, and PR treatment of Q35 animals restored (80%-100%) motility to near WT (Fig. 5c). These 
results reveal that the PR-induced suppression of aggregation also prevented polyQ toxicity.
 We then confirmed that the effect of the PRs on polyQ aggregation and toxicity was associated 
with expression of molecular chaperones and induction of the HSR (Fig. 5d). Chaperone expression was 
HSF-1-dependent (Fig. 6a-c) and moreover downregulation of HSF-1 by RNAi abrogated the PR-induced 
protection against Q35 aggregation (Fig. 6d). 
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PRs Stabilize the Folding of Metastable Proteins
 To begin examining the basis for PR induction of the HSR, we asked whether these small 
molecules caused protein damage and therefore activated a HSR, or alternatively that the PRs activated 
specific homeostasis regulators to induce chaperone expression. To address this, we used C. elegans 
strains harboring temperature-sensitive (TS) mutations in specific endogenous muscle proteins, including 
the basement-membrane protein perlecan UNC-52, and a myosin-assembly protein UNC-45. These 
conditional  mutations do not interfere with folding and function at the permissive temperature (15°C), but 
cause a complete loss of function at the restrictive temperature (25°C), resulting in distinctive muscle 
dysfunction (Fig.6e, DMSO 15°C and 25°C). These metastable proteins therefore serve as folding sensors 
that monitor changes in cellular proteostasis [90]. To determine whether the PRs induce protein misfolding, 
we incubated both unc-52(e669su250) and unc-45(e286) animals with PRs A1, D1 and F1 (10 µM) at 
15°C. We reasoned that enhancing misfolding would unmask the TS phenotypes at the permissive 
condition, which was not observed. Alternatively, to determine whether the PRs enhanced the folding 
environment, we incubated animals with PRs, transferred them to 25°C, and scored for TS phenotypes 2 
days later (Fig. 6e). While PR A1 caused an intermediate 35% suppression of the unc-45(e286) TS 
phenotype, the most potent effect was observed with F1, that suppressed both unc-52(e669su250) and 
unc-45(e286) phenotypes by 80% and 90% respectively (Fig. 6e). These results suggest that the PRs do 
not activate the HSR by interfering with cellular protein folding in general, but rather promote folding of 
metastable proteins. 
PRs Depends on the Folding and Quality Control Machinery
 The striking improvement in protein homeostasis, following treatment with the PRs, prompted us to 
investigate the requirements for other regulatory components of the PN such as DAF-16 (FOXO ortholog, 
insulin/IGF-1-mediated signaling transcription factor) and SKN-1 (oxidative stress response transcription 
factor). We simultaneously treated Q35 animals with the PRs and RNAi to knockdown the stress regulators 
DAF-16 and SKN-1. We examined the effects on induction of hsp-70 (C12C8.1, F44E5.4) and small HSP 
hsp-16.1 and show that A1 and D1-mediated chaperone expression requires both HSF-1 and DAF-16 (Fig. 
6a and b), whereas F1 activity is dependent upon HSF-1 and SKN-1 (Fig. 6c). 
 We explored the role of these stress responses on PR-regulated folding by monitoring the 
expression of downstream targets of SKN-1 and DAF-16, and other protein folding components including 
HSP-90 and co-chaperone genes, ubiquitin, and components of the ER HSP-70 (UPR). Compounds D1 
and F1 elicited induction of sod-1 (SKN-1 target), hsp-4 (UPR-ER) and hsp-90 and its co-chaperone 
(ZC395.1) (Fig. 6f). Meanwhile, A1 induced ER hsp-70 levels, and ubiquitin protein ubq-2 (Fig. 6f and 
Supplementary Fig. 12). We examined the expression of a number of oxidative stress, UPR, mitochondrial-
UPR and lifespan/aging regulators (Supplementary Fig. 12), and observed that only genes encoding 
folding and chaperone components were affected (Fig. 6f). These results indicate that the pathways that 
are activated to enhance the folding environment depend on HSF-1, DAF-16 and SKN-1 and the 
chaperone and quality control machinery.
PRs are not Inhibitors of the Proteasome or Hsp90
 Having demonstrated that the PRs themselves do not cause protein misfolding, we examined 
whether the PRs activated the HSR via inhibition of the proteasome or Hsp90 function. For these 
experiments, we selected the PRs A1, A3 and F1 because A1 and F1 suppressed aggregation in cellular 
and C. elegans models of conformational diseases and stabilized folding of TS mutant proteins, and A3 
and F1 improved the folding stability of mutant CFTR. Exposure of HeLa cells to MG132 and lactacystin for 
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3 and 6 hours (Fig. 7a and Supplementary Fig. 13a), reduced proteasome activity to 20 percent relative to 
DMSO-treated cells (Fig. 7a) and increased the levels of polyubiquitinated substrates (Fig. 7b). By 
comparison, treatment with the PRs A1, A3 and F1 neither inhibited proteasome activity nor increased 
polyubiquitinated proteins (Fig. 7a and b). 
 We next monitored the effects of the PRs on Hsp90 by assessing Hsp90 client protein degradation 
[239]. The levels of three well  characterized Hsp90 client proteins, Cdk4, Raf-1, and Akt, were quantified 
by western blot analysis of PR-treated HeLa cells. Relative to the DMSO-treated control cells, a reduction 
in the levels of the Hsp90 client kinases was observed with the PR A1 (10 µM) after 6 hours of treatment 
(Supplementary Fig. 13b), whereas treatment with the other two PRs had no effect. The clearance of these 
Hsp90 clients was even more dramatic  after 16 (Supplementary Fig. 13c) and 24 h (Fig. 7c  and 
Supplementary Fig. 7b) of PR treatment, and was comparable to the inhibitory effects of 17-AAG on Hsp90 
function. 
 Since classical Hsp90 inhibitors such as geldanamycin, 17-AAG and radicicol  bind competitively to 
the ATP site of Hsp90, we investigated whether the PRs A1, A3 and F1 had a similar mode of action. We 
therefore tested whether the PRs could compete in vitro with geldanamycin for binding to the ATP binding 
pocket of Hsp90. Whereas the positive control  17-AAG competed effectively with geldanamycin, none of 
the three PRs disrupted the interaction between geldanamycin and Hsp90 even at concentrations in 
excess of 100-fold (Supplementary Fig. 13d).
 Although the competition assay may suggest that the PRs A1 is not an inhibitor of Hsp90 activity, it 
is also possible that the compound acts through a different mechanism compared to known Hsp90 
inhibitors. To further confirm that the previous results were not due to a direct inhibition of Hsp90, we 
performed a chaperone-dependent protein refolding assay. Refolding of denatured luciferase was 
monitored in rabbit reticulocyte lysates (RRL) by measuring luciferase activity. In the presence of DMSO, 
luciferase recovered 40-45% activity, whereas 17-AAG (2 µM) caused only about a 25% recovery (Fig. 7d). 
Incubation of RRL with the PR A1 (10 µM) did not inhibit luciferase refolding (Fig. 7d). These results 
indicate that A1 is not a direct inhibitor of Hsp90 activity. Although PR A1 did not directly inhibit Hsp90 
activity, we offer possible explanations for the increase in client protein degradation by PR A1. A1 could 
disrupt the interaction between Hsp90 and its co-chaperone Cdc37 implicated in shuttling kinase clients to 
Hsp90, or A1 could inhibit Hsp90 activity by binding to a site different than the ATP binding pocket. 
 
DISCUSSION 
 In this study we describe the results of a large-scale small  molecule screen in human cells for 
HSF-1-dependent activators of chaperone expression. We identified 263 PRs that chemically induce the 
HSR and result in the activation of HSF-1 and elevated expression of multiple chaperone gene families. 
The PRs described here represent novel  chemical series and, by comparison to previously identified small 
molecule activators of the HSR, do not cause protein misfolding, proteasome inhibition, or Hsp90 
inhibition. A further understanding of these PRs and their ability to activate the HSR and restore protein 
folding in multiple disease models offers new opportunities and strategies for small molecule chaperone 
therapeutics for protein conformational diseases with novel specificities and reduced toxicity. 
 An intriguing observation is that the PRs exhibit complex stress response signatures. In addition to 
inducing HSF-1 and the expression of multiple cytoplasmic  chaperones, we have observed the induction of 
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other major components of the PN including the UPR and the antioxidant response genes. Our PR 
strategy is based on the proposition that small  molecules can mimic  the molecular signals recognized by 
the cell associated with a proteostatic  imbalance (Supplementary Scheme 1). This activation of stress-
signaling pathways, in turn restores the stability and functionality of the proteome. The ability of these PRs 
to activate one or more stress response pathways suggests a therapeutic  approach that employs the cell 
biological response to damaged proteins to protect cells against chronic  disease. By this approach, we are 
employing our growing understanding of stress biology to promote the health of the cell. In doing so, we 
are using compounds to enhance the properties of biological pathways that are already employed by the 
cell  to manage proteostasis, even when challenged by stress and disease. We suggest that this systems 
and network approach represents an alternative for drug discovery as we harness the protective abilities of 
cellular stress responses to protect the cell  against the multitude of deficiencies that occur during chronic 
proteotoxicity and stress.
 The central role for HSF-1 in maintaining and restoring proteostasis makes this transcription factor 
and the HSR an attractive target for therapeutic intervention in conformational  diseases. The observation 
that diverse chemical  types have in common the ability to induce the HSR, despite their broad activities, 
supports our proposal that HSF-1 is a stress network hub that integrates multiple stress signaling 
pathways to coordinate regulatory responses to maintain proteostasis in health, aging, and disease. Of the 
263 hits identified in this study that activate HSF-1, we have focused our attention on the 7 major clusters 
represented by the chemical series: β-aryl-α,β-unsaturated-carbonyls (cluster A), β–nitrostyrenes (cluster 
B), β-Cl-α,β-unsaturated-carbonyls (cluster C), nitrobenzofurazans (cluster D), nitrofuranylamides (cluster 
E), unsaturated barbituric acids (cluster F), and 2-cyanopentadienamide (cluster G). These chemical  series 
exhibit a broad range of pharmacological  indications and diverse mechanisms of action and, to our 
knowledge, have not been previously linked to proteostasis and the HSR. For example, compounds in 
cluster A are chalcone and curcumin analogues and have antibacterial, antioxidant and cancer 
chemopreventive activities [321,322]. These compounds are known to inhibit NF-κb and modulate the 
Keap1-Nfr2 complex [323,324]. Nitrobenzofurans (cluster E) have antitubercular activity, and nitrofuran 
antibiotics, i.e. nitrofurantoin, are currently used as second-line agents for urinary tract infections. The 
nitroimidazole antibiotics are structurally related; for example, metronidazole, is a widely used antibiotic  for 
treatment of anaerobic bacterial and protozoan infections [325]. Compounds belonging to cluster F are 
barbiturate analogs associated with anti-inflammatory side effects; in particular thiobarbiturates reduce 
activation of NF-κb. Thiopental, but not the oxy-analogue pentobarbital, is the only barbiturate suggested 
to activate the HSR and this property has been attributed to thiopental reactivity with protein thiols [326]. Of 
interest, barbiturate analogues have been previously reported as potentiators of defective ΔF508-CFTR 
channel gating [327]. Our results reveal unexplored mechanisms by which these chemical classes exert 
their beneficial effects, and suggest new pathways involved in activation of HSF-1. We propose that the 
ability of barbiturate analogs to rescue mutant CFTR defective channel gating can now be linked to the 
activation of the HSR and/or of the UPR. Likewise, the neuroprotective effects attributed to curcumin [328], 
a chalcone analog, may be due to the induction of chaperone expression [329]. Taken together with the 
data presented here, we propose that compounds of the same chemical  classes identified in our HTS can 
be reclassified as PRs. 
 We describe a first generation series of tool compounds that, by activating HSF-1 and other cell-
protective stress responses, demonstrate efficacy in cellular and animal  models of protein conformational 
diseases. Although we have shown that the PRs are effective in multiple misfolding disorders, i.e. cystic 
fibrosis and Huntington’s diseases, these molecules may have a broader efficacy. For example, PRs that 
restore proteostasis by simultaneously inducing the HSR and the UPR should be able to enhance the 
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folding, trafficking and activity of mutant enzymes in a variety of diseases, including lysosomal  storage 
diseases (i.e. Tay-Sachs, Gaucher and Pombe’s diseases) and retinitis pigmentosa, that require both ER 
and cytoplasmic  proteostasis [330-333]. Likewise, PRs selective to the HSR may be beneficial  for diseases 
in which the expression of the affected protein is primarily cytoplasmic and nuclear, as in ALS and in the 
multiple forms of spinal cerebellar ataxia. Considering that the pathogenesis of many diseases, such as 
Alzheimer’s, Parkinson’s, ALS and cystic  fibrosis disorders, is also associated with oxidative stress, the 
activation of the ARE pathway in conjunction with the HSR may be highly beneficial. In support of this, we 
show that the small  molecule PR F1, that simultaneously induced both stress-protective pathways, was the 
only PR that restored proteostasis in distinct cellular compartments. 
 In conclusion, we propose that the adjustment of the proteostasis network by small  molecule PRs 
of the HSR provides a previously unexploited and potentially powerful  approach to obtaining proteome 
balance in both loss- and gain-of-function diseases by providing a superior corrective environment based 
on the principle of proteome balance. Besides the usefulness for potential therapeutic  development, small-
molecule HSR inducers can be used as pharmacological tools for further dissecting the multi-step 
activation pathway of HSF-1. We believe that a better understanding of the regulation of HSF-1 activation 
pathway and of its signaling mechanisms could lead to the discovery of compounds that exhibit stress 
signatures that are HSF-1 selective or activate multiple stress pathways that can be effective in the control 
of diseases of protein conformation. 
MATERIALS AND METHODS
Cell-based High-throughput Assays. HeLa-luc cells were used to screen three compound libraries consisting of 
903,663 structurally  diverse small molecules. A library  of  100,000 compounds (NINDS library, http://www.ninds.nih.gov/
funding/areas/technology_development/HTS_Facility.htm) was screened at the Southern Research Institute and two 
libraries of  607,408 and 196,179 compounds (Scripps Drug Discovery  library  and MLPCN library, http://mli.nih.gov/mli/
mlpcn/) were screened at the SRIMSC. Detailed protocol and analysis are described in Supplementary Methods. 
Reverse Transcription-PCR. RNA was purified using the RNeasy  Mini kit  (Qiagen, Valencia, CA) according to the 
manufacturer's instructions. After the reverse transcription reaction, PCR was performed using PCR primers specific 
for Hsp70 and GAPDH. The human Hsp70 primers were: 5′-AGAGCCGAGCCGACAGAG-3′ (forward) and 5′-
CACCTTGCCGTGTTGGAA-3′ (reverse); the mouse Hsp70 primers were: 5'-CACCAGCACGTTCCCCA-3' (forward) and 5'-
CGCCCTGCGCCTTTAAG-3' (reverse); the human GAPDH primers were: 5′-GTCGGAGTCAACGGATT-3′ (forward) and 5′-
AAGCTTCCCGTTCTCAG-3′ (reverse);  the mouse GAPDH primers were: 5'-TGCACCACCAACTGCTTAG-3' (forward) and 5'-
GGATGCAGGGATGATGTTC-3 (reverse). PCR products were amplified with Taq polymerase (Promega, Madison, WI) by 
using standard cycling conditions.
Western Blot Analysis. Analysis of  chaperone expression was carried out using HeLa cells that were treated with the 
indicated compounds for 8 h. Cells were lysed in a buffer containing 20 mM HEPES (N-2-hydroxyethylpiperazine-N'-2-
ethanesulfonic  acid; pH 7.9), 25% (vol/vol) glycerol, 0.42 M NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM 
phenylmethylsulfonyl fluoride, 0.5 mM dithiothreitol and 2 mg/ml of  complete protease inhibitor cocktail (Roche, 
Switzerland) for 30 min on ice. 15 µg of  whole cell extracts were run on 7.5% SDS-PAGE gels  and transferred to 
nitrocellulose.  Primary  antibody  incubations were for 12 hours at  4°C in 10% BSA. The following primary  antibodies 
were used: a rabbit polyclonal HSF-1 #47 [170], a mouse monoclonal Hsp70 antibody  (4g4, Affinity  Bioreagents Inc., 
Golden, CO), a mouse monoclonal Hsp40 (αHdj-1 clone 25) [170], a mouse monoclonal Hsp27 (MA3-0015, Affinity 
Bioreagents, Inc., Golden, CO). All primary  antibodies were used at a dilution of  1:10,000, except for the Hsp27 
antibody, which was diluted 1:500. The anti-β-tubulin antibody  (Sigma, St. Louis, MO) was diluted 1:5,000 and used to 
verify  equal protein loading. The secondary  antibody  was an Alexa Fluor 680 goat anti mouse IgG diluted 1:5,000 
(Invitrogen, Carlsbad, CA). Western analysis was performed with the Odyssey system (Li-COR, Lincoln, NE). 
Gel Mobility Shift Analysis (EMSA). Detailed protocol is described in Supplementary Methods. 
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Chromatin Immunoprecipitation Assays (ChIP). ChIP was performed essentially  as described previously 
(Westerheide et al., 2004). Detailed protocol is described in Supplementary Methods. 
Effect of NAC and DTT on the PR Activity. HeLa-luc cells were seeded in a white 96-well plate at a density  of 
10,000 cells/well. Cells were pretreated with either 2 mM NAC or 250 µM DTT for 1 h before addition of  the positive 
control celastrol (Cel; 2.5 and 5 µM) or the selected small molecule PRs (A1, A3, C1, D1 and F1; 2.5,  5 and 10 µM). 
Cells  were incubated with compounds for 24 h before luminescence signal acquisition. DMSO-treated cells were used 
as negative control. 
Multiplex Gene Expression Analysis.  WT and hsf-1-/- MEFs were treated with serially  diluted compounds in a 7-
point dose dependent manner. Cell lysates were pooled with mouse 8-gene multiplex probe sets and with 8 different 
sets of  magnetic capture beads (Luminex Technology, Austin, TX) in a 100 µl/well volume. Fold changes in gene 
expression were obtained for each gene per well by normalizing the raw data first to the DMSO control and then to the 
TATA-box binding protein (TBP) housekeeping gene. Detailed protocol is described in Supplementary Methods.
Protein Aggregation Analysis in PC12 Cells. PC12 cells expressing httQ74-GFP were seeded in tissue culture 
treated 96-well plates as 7,500 cells/well and induced with doxycyclin (1 µg/ml). Compounds A1, A3, C1, D1, and F1 
were used at  concentrations ranging from 0.75 to 25 µM. GA (200 nM) was used as positive control. Final DMSO 
concentration was 0.5%. Fluorescence images were taken with a Zeiss Axiovert 200 fluorescence microscope (Carl 
Zeiss,  Germany) at 20x magnification and images deconvoluted with the Axiovision software. For quantification of 
fluorescence microscopy analysis, approximately 500 cells were counted for each treatment.
ΔF508-CFTR YFP Quenching Assay. Human bronchial epithelial cells (CFBE41o-) stably  expressing ΔF508-CFTR 
as well as H148Q/I152L-YFP (CFBE41o- -YFP) were treated with the indicated concentration of  compounds in 
complete growth media and incubated at  37oC, 5% CO2 for 24 h. Cells were subsequently  stimulated with a final 
concentration of  10 µM forskolin (fsk) and 50 µM genistein (gen) for 15 min prior to addition of  PBS + NaI (replacement 
of  NaCl with 137 mM NaI). Fluorescence was monitored every  second for a total of  30 seconds (3 seconds prior to 
addition of  NaI and 27 seconds after addition of  NaI). Detailed protocol and analysis are described in Supplementary 
Methods.
ΔF508-CFTR Transport Assay. CFBE41o-cells  stably  expressing ΔF508-CFTR were treated with the indicated 
concentration of  compound in complete growth media and maintained at 37oC, 5% CO2 for 24 hrs. Cells were lysed 
on ice and the supernatant was collected for analysis.  Equal amount of  total protein (15 µg) was separated by  SDS-
PAGE (8% gel) and transferred to nitrocellulose. The blot was probed overnight at 4oC for CFTR (3G11 rat monoclonal 
antibody  at 1:500 dilution) and indicated chaperone proteins. Detailed protocol is described in Supplementary 
Methods.
C. elegans Assays for Aggregation and Motility Defects. The treatment with chemical compounds was performed 
in a 96-well plate format,  in liquid culture. The animals were scored for changes in aggregation (number of  fluorescent 
foci) using the stereomicroscope Leica MZ16FA equipped for epifluorescence (Leica Microsystems, Switzerland). For 
the motility  assay, animals’ movement  was digitally  recorded using a Leica M205 FA microscope with a Hamamatsu 
digital camera C10600-10B (Orca-R2, Leica Microsystems, Switzerland), and the Hamamatsu Simple PCI Imaging 
software. Detailed protocol is described in Supplementary Methods.
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Figure 1. Identification of small molecule proteostasis regulators (PRs) by high-throughput screening. (a) HeLa-luc cells were 
used to screen compound libraries to identify small molecule PRs. The Hsp70.1pr-luc construct is diagrammed. The sequences of the 
upstream region of the human Hsp70.1 promoter from +1 to -188 are represented by a line. The locations of transcription factor 
binding sites are depicted as boxes and their corresponding genetic elements are indicated in the boxes. The transcription factors 
that bind to these regions are indicated above the boxes. The nucleotide sequence of the HSE is shown and the inverted nGAAn 
repeats, to which HSF-1 binds, are labeled with arrows and marked 1 through 5. (b) HeLa-luc cells were treated with celastrol, 
cadmium chloride and MG132 at the indicated concentrations and luciferase activity was measured after 24 h. Each experiment was 
performed in triplicate. The standard deviation is shown. (c) Confirmed hits (263) were clustered accordingly to their chemical 
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Figure 2. The small molecule PRs induce Hsp expression by activating HSF-1. (a) HeLa cells were treated with DMSO, celastrol 
(Cel, 3 µM), MG132 (MG, 10 µM), CdCl2 (Cd, 50 µM) and selected PRs for 4 h. Similar results were obtained in two independent 
experiments. Densitometric measurements of Hsp mRNA levels normalized to GAPDH in relation to control DMSO-treated cells were 
performed using ImageJ software. (b) Western blot analysis of HeLa cells treated with DMSO, celastrol (Cel, 3 µM), MG132 (MG, 10 
µM) and selected PRs. Fold induction was calculated as the ratio of normalized Hsp values between a compound-treated sample and 
the untreated control. Densitometric measurements of Hsp levels normalized to tubulin were performed as in (a). (c) Gel mobility shift 
assay was performed with a [32P]HSE oligonucleotide and HeLa cell whole cell extracts. DMSO: lanes 2 and 17; celastrol (3 µM): 
lanes 3 and 18; MG132 (10 µM): lanes 4 and 19; small molecule PRs (10 µM): lanes 5-7 and 20-23. Lanes marked self (lanes 8-12) 
contained a 200-fold molar excess of unlabeled complementary oligonucleotide. Lanes marked +Ab (lanes 13-15 and 24-29) 
contained a HSF-1 antibody. (d) HeLa cells were treated with DMSO, celastrol (3 µM) and selected PRs (10 µM) for 30 and 60 min 
and then chromatin was cross-linked, harvested, and immunoprecipitated with HSF-1 antibody (+Ab). The samples were then 
analyzed by PCR with primers specific for the Hsp70.1 and the dihydrofolate reductase (DHFR) promoters. The controls include input 























Figure 3. The PRs are HSF-1-dependent. (a) Wild type (hsf-1+/+) and HSF-1 null (hsf-1-/-) mouse embryonic fibroblasts (MEFs) 
were treated for 4 h with DMSO vehicle, celastrol  (3 µM) or indicated PRs (10 µM). RNA was extracted and reverse-transcribed. PCR 
reactions were performed on cDNA for the indicated transcripts. GAPDH RNA levels were assayed to determine equal loading. (b-f) 
WT and (g-k) hsf-1-/- MEFs were treated for 4 h with either DMSO, MG132 (MG, 1 µM), geldanamycin (GA, 1 µM), tunicamycin (Tm, 
1 µM), sulphorahane (Sul, 1 µM) or selected PRs (A3, C1, D1 and F1) at the indicated concentrations. Relative levels of multiple 
cytoprotective genes were measured by real-time PCR (qPCR) with tubulin serving as a reference gene. 
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Figure 4. The PRs restore proteostasis in cell-based models of cytoplasmic and compartment-specific conformational 
diseases. (a) PC12 cells expressing httQ74-GFP were treated either with DMSO (panel I), geldanamycin (GA, 200 nM, panel II) or 
with selected PRs (panels III-V). The representative fluorescence pattern of httQ74-GFP after 72 h of induction is shown. Scale bar: 
10 µm. (b) Quantification of results shown in panel (a). Cells containing aggregates were counted and are shown as a percentage of 
the total number of cells counted. The data shown are derived from three independent experiments. (c) CFBE41o- YFP cells were 
treated with 0.1% DMSO (black), the positive controls 5 µM SAHA (purple), 10 µM Corrector 4a (Corr4a) (grey) and the PRs A3 (dark 
blue), C1 (royal blue) and F1 (cyan) at 10 µM for 24 h. Fluorescence quenching is indicative of restored ΔF508-CFTR trafficking 
(mean ± s.e.m.; n = 3). Color-coded asterisks indicate statistically significant differences from DMSO control at the 30 s time point. (d) 
CFBE41o- cells were treated with 0.1% DMSO, SAHA (S, 1µM) and selected PRs at the indicated concentrations for 24 h. ΔF508-
CFTR trafficking was analyzed by monitoring the band B and C glycoforms (fold increase relative to DMSO band B ± s.e.m.; n = 3) at 
the various concentrations of PRs. The level of Hsp70 was also monitored by western blot as an indicator of HSF-1 activation. 15 µg 



















Figure 5. The PRs reduce aggregation/toxicity in C. elegans models of diseases associated with polyQ expansions.  (a) C. 
elegans expressing YFP-tagged Q35 protein were treated with either DMSO (panel I) or PRs (panels III-V) at different concentrations 
(1, 5, 10 and 15 µM) for 4 days.  17-AAG was used as positive control (50 µM, panel II).  Fluorescence microscopy images show the 
PRs that reduced Q35 aggregation at a concentration of 10 µM in 6-day old animals.  Panels VI-X show higher magnification images 
of the boxed areas on the top panels. Scale bar: 0.1 mm.  (b) PRs suppress Q35 aggregation as shown by the quantification of 
fluorescent foci in 6-day old animals, relative to DMSO control.  (c) Rescue from polyQ-associated toxicity was determined by 
comparing the motility of Q35 animals treated with either DMSO alone or the candidate PRs compounds (10 µM) to that of WT 
animals in DMSO.  17-AAG (50 µM) was used as positive control.  Standard error of the mean is shown. (t-test ***p-value<0.001). (d) 
The PRs up-regulate mRNA expression of cytosolic chaperones (HSP-70 family members and small Hsps) at the concentrations 
needed to suppress aggregation and toxicity.  Real-time qPCR was performed on samples extracted from animals treated with either 
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Figure 6. Chaperone expression and reduction in polyQ aggregation in C. elegans is HSF-1-dependent.  (a-c) For each of the 
PRs, chaperone up-regulation is HSF-1 dependent.  Wild type (control) and HSF-1 mutant (hsf-1(sy441)) animals were treated with 
each of the PRs or the positive control 17-AAG, and real-time qPCR was performed to show that both HSP-70 (C12C8.1, F44E5.4) 
and small Hsps (hsp-16.1) induction does not occur in the hsf-1 mutant background. For compounds A1 and D1, DAF-16 also 
contributes to chaperone up-regulation, as SKN-1 does for F1.  Standard deviation is shown. (d) Suppression of Q35 aggregation by 
the PRs (shown as % of fluorescent foci) is HSF-1 dependent and is not observed when hsf-1 is down regulated by RNAi. (e) Animals 
carrying temperature sensitive mutations in muscle proteins UNC-52 (perlecan, stiff paralysis) and UNC-45 (myosin assembly, egg 
laying defect) were incubated with the PRs. At the restrictive temperature of 25°C, F1 suppressed the muscle dysfunction 
phenotypes, indicating improved folding of UNC-52 and UNC-45. (f) Stress related genes up-regulated by each of the PRs relative to 
control (DMSO): hsp-4 (ER HSP-70), sod-1 (oxidative stress), daf-21 and ZC395.10 (HSP-90 and co-chaperone) and ubq-2 

























Figure 7. The PRs are not proteasome or Hsp90 inhibitors. (a) HeLa cells were incubated with either DMSO, MG132 (10 µM), 
lactacystin (lactacys., 6 µM) and the PRs A1, A3 and F1 (10 µM) for 6 h. Proteasome-associated chymotrypsin activity was assessed 
using the fluorogenic substrate Suc-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin (suc-LLVY-AMC) as described in Materials and 
Methods. (b) HeLa cells were either left untreated or treated with DMSO, the proteasome inhibitor MG132 (10 µM), or the PRs A1, A3 
and F1 (10 µM) for 16 h. Whole cell extracts of HeLa cells were separated by SDS-PAGE, transferred to membranes, stained with 
Ponceau S to visualize total protein and probed using a rabbit polyclonal antibody to detect ubiquitin. (c) HeLa cells were treated with 
either DMSO, 17-AAG (2 µM), MG132 (10 µM), lactacystin (lactacys., 6 µM) or the PRs A1, A3 and F1 (10 µM) for 24 hr. Protein 
levels of various Hsp90 client proteins (Cdk-4, Raf-1 and Akt) in equal amounts of whole-cell lysates were assessed by western blot 
analysis. GAPDH was used as loading control. Densitometric measurements of Hsp90 client protein levels normalized to GAPDH in 
relation to control DMSO-treated cells were performed using ImageJ software. (d) Refolding of chemically-denatured firefly luciferase 
was assessed in RRL containing 2 mM ATP in the presence of either DMSO (◊), 17-AAG (2 µM, ■) or the PR A1 (10 µM, ✕). 
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Supplementary Scheme 1. Model Depicting the Proposed Mechanism by which the Small Molecules PRs Ameliorate 
Conformational Diseases. The small molecules PRs work by activating some of the major PN machineries therefore inducing 
components of the quality control machinery and other cytoprotective stress response genes.
 
Supplementary Figure 1. Graphical representation of 
the results of the miniaturized HeLa-luc assay 
screened against a collection of 607,408 
compounds of the Scripps Drug Discovery 
library. Each of the 476 different 1,536-well plates 
run for this assay contained both positive (black 
dotted line) and negative internal controls (not 
shown). The red dotted line represents the activity 
cutoff, which was calculated at 15.86% activation. 
Compounds with percent activation higher than the 
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Supplementary Figure 2. Dose-response activity and toxicity profiles for the selected small molecule PRs. HeLa-luc cells 
were treated with increasing concentrations (0.5, 1.5, 5, 12.5 and 25 µM) of the selected PRs (A1, A2, A3, B1, B2, B3, C1, C2, D1, 
E1, F1, F2, G1 and G2) for 24 h. Celastrol was used as positive control. Compound activity (black columns) and toxicity (white 
columns) were measured as described in Supplemental Materials and Methods.
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Supplementary Figure 3. Original gel pictures for PCR, western blots and ChIP experiments. (a) RT-PCR results as in Fig. 2a. (b) 
Western blot analysis of Hsps as in Fig. 2b. (c) ChIP analysis of HSF-1 binding to its promoter as in Fig. 2d.
Supplementary Figure 4. Original gel pictures for PCR and western 
blots experiments. (a) RT-PCR results as in Fig. 3a. (b) Western blot 
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Supplementary Figure 5. The PRs induce HSF-1 
binding to the Hsp40 and Hsp27 promoters. 
Chromatin immunoprecipitation experiments show that 
both celastrol and selected PRs induce HSF-1 binding 
to the Hsp40 and Hsp27 promoters ex vivo. HeLa cells 
were treated with DMSO, celastrol (3 µM) and selected 
PRs (10 µM) for 60 min and then chromatin was cross-
linked, harvested, and immunoprecipitated with an 
antibody specific for HSF-1 (+Ab). The samples were 
then analyzed by PCR with primers specific for the 
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Supplementary Figure 6. Effect of the reducing agents NAC 
and DTT on the PR activity. HeLa-luc cells were treated with 
either DMSO, 2.5 µM of celastrol (Cel) or 2.5, 5, and 10 µM 
selected PRs for 24 h in the absence or presence of either 2 mM 
NAC (a-f) or 250 µM DTT (g-l). Celastrol and DMSO were used as 
positive and negative controls, respectively.
Supplementary Figure 7. The PRs do not 
activate a reporter gene lacking the 
correct HSE sequence. HeLa cells were 
transfected with a luciferase reporter gene 
fused to either a wild type or mutant HSE 
promoter. Cells were treated with DMSO 
(negative control), celastrol (3 µM) or the 
indicated PRs (10 µM) for 8 h before 
measuring luminescence. Only cells 
expressing the wild type promoter were able 
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Supplementary Figure 8. The PRs protect cells 
from stress-induced cell death.
HeLa cells were either left untreated or pretreated 
with heat shock (42°C) or the indicated PRs for 1 h, 
washed three times and given fresh medium, and 
then recovered for 8 h prior to a 35 min 45°C heat 
shock treatment. 24 h later, the percentage of cell 
death was determined by Calcein AM assay. The 
differences in group means were compared by the 
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Supplementary Figure 9. The PRs suppress expanded polyQ aggregation without altering the levels of soluble and total 
protein. (a) Treatment of cells with the indicated PRs for 48 h reduced the insoluble form of the protein compared to the DMSO- 
treated samples. Nitrocellulose slot-blot was used to detect total (T), soluble (S) and pellet (P) forms of HttQ74-GFP. Equivalent 
amounts of protein were loaded. (b) Quantification of total HttQ74-GFP protein from (a) with respect to tubulin loading control was 
done by densiometric analysis. The DMSO-treated samples were arbitrarily set as 100. (c) Insoluble HttQ74-GFP was detected by 
slot-blot using a cellulose acetate membrane (filter trap assay). (d-e) Soluble (S) and insoluble (P) HttQ74-GFP was detected by 
western blot. Open and closed arrowheads indicate, respectively soluble and insoluble HttQ74-GFP protein (detected in the stacking 
gel portion of the western blot). (f) Quantification of soluble HttQ74-GFP protein from (e) with respect to tubulin loading control was 
done by densiometric analysis. The DMSO-treated samples were arbitrarily set as 100. (g) Western-blot of total polyQ protein from C. 
elegans extracts. (h) Quantification of total polyQ protein from (g) with respect to tubulin loading control was done by densiometric 
analysis. The control samples were arbitrarily set as 100.
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Supplementary Figure 10. Dose-response curve for 
the PRs A3, C1 and F1 and enzymatic digestion of 
C F T R G o l g i - p r o c e s s e d g l y c o f o r m b y 
Endoglycosidase H. (a) CFBE41o- YFP cells were 
treated with 0.1% DMSO (diamonds), the positive 
control 5μM SAHA (triangles) and the indicated PRs at 
2.5 (open circles), 5 (grey circles) and 10μM (black 
circles) for 24 h. Fluorescence quenching is indicative 
of restored ΔF508- CFTR trafficking (mean ±	  s.e.m.; n 
=	   3). The open, grey and black asterisks indicate 
statistically significant differences from DMSO control 
at the 30s time point. The SAHA treatment yields a 
significant difference from DMSO (see Figure 5c). (b) 
Endoglycosidase H resistance assay was used to 
confirm that band C in the CFTR analysis represents a 
Golgi modified glycoform. The blot confirms that the ER 
derived band B glycoform is completely sensitive to 
EndoH indicated by the appearance of the faster 
migrating band A, whereas the band C, which is 

























Supplementary Figure 12 
Supplementary Figure 12. Real-time 
qPCR measurement of stress related 
gene levels upon treatment with the 
PRs A1, D1 and F1. Data are relative 
to the negative control (DMSO). The 
genes tested are grouped according to 
stress response or pathway (indicated 
at the bottom of the figure): DAF-16/
FOXO pathway, oxidative stress, ER 
and mitochondrial UPR, Hsp90 (daf-21) 
c h a p e r o n e a n d c o - c h a p e r o n e 
(ZC395.10), and UPS components. 






Supplementary Figure 11 
Supplementary Figure 11. Western blot analysis of CFTR and 
Hsp70 in CFBE41o- cells. Cells were treated with DMSO or the 
indicated dose of PRs A3, C1, F1 and the positive control SAHA for 
24 h. Blots were cut at the appropriate MW and immunoblotted (IB) 
with the indicated antibody.
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Supplementary Figure 13. (a) HeLa cells were incubated with either DMSO, MG132 (10 µM), lactacystin (6 µM) and the PRs A1, A3 
and F1 (10 µM) for 3 h. Proteasome- associated chymotrypsin activity was assessed using the fluorogenic substrate Suc-Leu-Leu-
Val-Tyr-7-amido-4-methylcoumarin (suc-LLVY-AMC) as described in Materials and Methods. (b-c) HeLa cells were treated with 
DMSO, 17-AAG (2 µM), MG132 (10 µM), lactacystin (6 µM) or the PRs A1, A3 and F1 (10 µM) for 6 (b) and 16 h (c). Protein levels of 
various Hsp90 client proteins (Cdk-4, Raf-1 and Akt) in equal amounts of whole-cell lysates were assessed by western blot analysis. 
GAPDH was used as loading control. (d) Purified Hsp90β (2 µg) was incubated with either DMSO, 17-AAG (1 µM) or the indicated 
PRs (10 and 100 µM) for 30 min at 4°C before addition of 1 µM geldanamycin-biotin for 1 h at 4°C. Hsp90 bound to geldanamycin-
biotin was captured with neutravidin-agarose beads and analyzed by immunoblotting.
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Supplementary Table 1.  Assay protocol in 384 and 1,536-well plate formats.  
 Order Step Condition Comments 
1 Cell dispensing 20 µL/well 1,875 cells/well 
2 Primary incubation time 16-18 h 37°C, 5%CO2 
3 Compound addition 50 nL/well 
in 5 µL 
medium 
Test concentration:  
2 µg/mL; final DMSO 
concentration: 0.2% 
4 Secondary incubation time 24 h 37°C, 5%CO2 
5 Luciferase detection reagent 
addition 
25 µL/well  





























    
1 Cell dispensing 5 µL/well 3,750 cells/well 
2 Primary incubation time 4 h 37°C, 5%CO2 
3 Compound addition 50 nL/well Test concentration: 10 
µM; final DMSO 
concentration: 1% 
4 Secondary incubation time 16 h 37°C, 5%CO2 
5 Luciferase detection reagent 
addition 
5 µL/well  


































































Number of compounds 607,408 196,179 100,000 
Compound concentration 10 !M 10 !M 2 !g/ml 
Positive control MG132 (30 !M) MG132 (30 !M) CdCl2 (50 !M) 
Plate format 1,536 wells 1,536 wells 384 wells 
Z’ value 0.63 0.62 0.68 
Primary hit cut-off (%) 15.86 15.86 5 
Primary hit rate (%) 0.11 0.04 0.04 
Number of primary hits 677 82 37 
Number of confirmed hits 218 12 33 
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SUPPLEMENTARY METHODS
Compounds. All the compounds were obtained from the commercial vendors indicated below and were used without 
further purification. A1: (2E,6E)-2,6-Bis(4- pyridinylmethylene)-Cyclohexanone, CAS 871361-88-5, ChemDiv: 
C151-0032; A2: (3E,5E)-3,5-Bis[(2,4-dimethoxyphenyl)methylene]-1-methyl-4-Piperidinone,  CAS 1207456-48-1, 
Enamine T0514-8318; A3: 2-(2-Benzoxazolyl)-3-(3-pyridinyl)-1-(3,4,5- trimethoxyphenyl)-2-Propen-1-one, CAS 
496011-51-9, ChemBridge 7355596; B1: 6- Bromo-2-(4-ethoxy-3-methoxyphenyl)-8-methoxy-3-nitro-2H-1-
Benzopyran, CAS 448189-54-6, ChemBridge, 8880788; B2: 1,4-Dimethoxy-2-methyl-5-(2-nitroethenyl)- Benzene, 
CAS 25505-64-0, ChemBridge 6561455; B3: 2-Ethoxy-6-iodo-4-(2- nitroethenyl)-Phenol, CAS 662160-43-2, 
ChemBridge 7251856; C1: 4-Chloro-3-nitro-1- (phenylmethyl)-2(1H)-Quinolinone, CAS 385387-83-7, ChemBridge 
6935964; C2:  4,5- Dichloro-2-(4,6-dimethyl-2-pyrimidinyl)-3(2H)-Pyridazinone,  CAS 78403-59-5,  T0507- 9111; D1:  7-
Chloro-N-(4-chlorophenyl)-4-nitro-2,1,3-Benzoxadiazol-5-amine, CAS 313966-69-7, ChemBridge 5241454; E1: N-(4,5-
Dichloro-2-benzothiazolyl)-5-nitro-2- Furan-carboxamide, CAS 797776-58-0, Asinex BAS 08207501; F1: 5-[3-(4- 
Methoxyphenyl)-2-propen-1-ylidene]-2,4,6(1H,3H,5H)-Pyrimidinetrione, CAS 100872-83- 1, ChemBridge 5772104; F2: 
5-[[5-(3-Bromophenyl)-2-furanyl]methylene]- 2,4,6(1H,3H,5H)-Pyrimidinetrione, CAS 331464-02-9, Asinex BAS 
00336306; G1: 2- Cyano-5-(2-nitrophenyl)-N-phenyl-2,4-Pentadienamide, CAS 733044-10-5, Enamine T0516-4089; 
G2: 2-Cyano-N-cyclohexyl-5-(2-nitrophenyl)-2,4-Pentadienamide, CAS 737819-53-3, Enamine T0516-8259.
Cell Cultures. Mammalian cell lines used in this study  were HeLa cells,  a stable HeLa cell line containing a heat 
shock-inducible reporter construct that consist of  the Hsp70.1 promoter sequence fused to a luciferase reporter gene 
(HeLa-luc)1, WT and hsf-1-/- MEF cells2, inducible PC12 cells expressing HttQ74-GFP3 and human bronchial epithelial 
cells  stably  expressing the ΔF508-CFTR as well as the H148Q-YFP mutant4 (CFBE41o- -YFP). HeLa and HeLa-luc 
cells  were maintained in Dulbecco’s modified Eagle’s medium (DMEM, Invitrogen, Carlsbad, CA) with phenol red 
buffered with HEPES and supplemented with 10% v/v  fetal bovine serum (FBS), 1% L-glutamine, and 100 U/ml 
penicillin/streptomycin. HeLa-luc cells were also supplemented with 100 µg/ml of  G418. WT and hsf-1-/- MEFs were 
maintained on DMEM supplemented with 10% FBS, 0.1 mM nonessential amino acids,  100 U/ml penicillin/
streptomycin, and 55 µM 2-mercaptoethanol. HttQ74-GFP PC12 cells were previously  described3 and were 
maintained on DMEM supplemented with 5% v/v  Tet-approved FBS, 10% v/v  horse serum, 100 µg/ml G418, 75 µg/ml 
hygromycin B, and 100 U/ml penicillin/streptomycin. Cells  co-expressing ΔF508-CFTR and CFBE41o- -YFP were 
grown in α-MEM containing 100 U/ml penicillin/streptomycin, 10% v/v  FBS, 2 mM L-glutamine, 2 µg/ml puromycin and 
0.75 mg/ml G418. Cells were maintained at  37°C with 5% CO2 atmosphere until they  were ready  for passage or 
harvest.
Cell-based High-throughput Assays. The automated primary  screens were performed according to the following 
steps.  For the 100,000 compound library  screened at the Southern Research Institute, the assay  was optimized for a 
384-well plate format and resulted in a Z’-value >0.6 using CdCl2 as positive control (50 µM). HeLa-luc cells were 
dispensed into white tissue culture treated 384-well plates at a density  of  1,875 cells/well in 20 µL assay  medium using 
a WellMate with a small bore cassette head (Matrix Technologies Corp., Thermo Fisher Scientific, Hudson, NH). The 
assay  plates were incubated for 16-18 hours at  37°C and 5% CO2 before compound addition.  Compound addition was 
performed in a two step process with the positive control added to control wells and an equal volume of  medium added 
to remaining wells with a Biomek FX liquid handling system (Beckman Coulter Inc., Brea, CA). The compounds were 
then delivered without dilution in 50 nL with 5 µL medium at a concentration of  2 µg/mL using an Echo 550 liquid 
handler (Labcyte Inc., Sunnyvale, CA). After 24 h incubation with compounds, the assay  plates were equilibrated to 
room temperature before endpoint  addition. 25 µl of  Bright-Glo Luciferase Assay  System (Promega, Madison, WI) was 
added to the plates using a Multidrop dispenser (Titertek Instruments Inc., Huntsville, AL) and luminescence signal 
was read using an Envision multi-label plate reader (Perkin Elmer, Waltham, MA). The assay  was run in three 107-
plate batches run in serial.  Every  step of  the assay  process, along with every  reagent and instrument used throughout 
the assay  process was tracked using a Uniflow Laboratory  Information Management System to ensure consistency 
between screening runs and to facilitate any  trouble shooting that may  arise along the way. Following each screening 
batch, data was imported into IDBS ActivityBase data management system. Because of  the low hit rate and the 
relatively  low response elicited by  the library  compounds when compared to the response to CdCl2, the hit  criteria was 
defined as >5% signal induction of  the positive control.  Using this criterion, 37 compounds were identified as hits 
(0.04% hit rate). Dose-response experiments were then performed in triplicate using a 1:2 serial dilution of  the hit 
compounds in DMSO starting from 20 µg/ml. Because of  the narrow active concentration range of  compounds tested 
in dose response (data not shown), the list  of  compounds to be tested in dose response was expanded to 169 based 
on structural relationships to the hits identified in the primary  screen. The majority  of  the compounds screened in dose 
response demonstrated very  narrow concentration ranges for which they  were active. Therefore the criterion for 
confirmed activity  was defined as a compound demonstrating maximum % activation >10% of  CdCl2. Using this 
criterion, 56 compounds (33%) demonstrated confirmed activity  in the dose response screen. Of  the 56 confirmed 
active compounds, 33 were hits selected from the primary  screen, resulting in a hit confirmation rate of  89%. For the 
607,408 Scripps Drug Discovery  unique compound library  and for the 196,179 compound MLPCN library  screened at 
the SRIMSC, the assay  was optimized for a 1,536-well plate format and resulted in a Z’ coefficient  >0.6 using MG132 
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(30 µM) as positive control.  A detailed description of  the protocols used is available on the PubChem website (http://
pubchem.ncbi.nlm.nih.gov/; PubChem AIDs 1203 and 1252).
Cytotoxicity Assays. For the hit compounds identified at the Southern Research Institute, the following procedure 
was used. HeLa cells were plated at a density  of  10,000 cells per well in black 96-well plates in 100 µl of  DMEM 
supplemented with 10% FBS and 1% Pen/Strep/Neo.  Plates were incubated for 16 hours at 37°C, 5% CO2 and 95% 
relative humidity  before compound addition. 1 µL of  hit  compounds in DMSO or DMSO alone were added to the 
sample or control wells, respectively. Plates were then placed back in the incubator for 24 hours. After incubation, cells 
were washed 2x with 200 µl of  PBS and 200 µl of  a solution of  1 µg/ml of  calcein AM (Invitrogen, Carlsbad, CA) was 
added to each well. Cells were then incubated for 45 min at 37°C, 5% CO2 before fluorescence measurement using an 
Analyst GT multimode reader (Molecular Devices,  Sunnyvale, CA).  Percent cytotoxicity  was expressed relative to 
wells  containing cells treated with DMSO only  (100%). A detailed description of  the protocol used at the SRIMSC is 
available at the PubChem website (http://pubchem.ncbi.nlm.nih.gov/; PubChem AIDs 1259).
Gel Mobility Shift Analysis (EMSA). Electrophoretic mobility  shift  analysis was performed using a 32P-labeled probe 
containing the proximal heat shock element from the human Hsp70.1 gene promoter. The whole cell extract-labeled 
probe mixtures were incubated room temperature for 20 minutes and analyzed by  native electrophoresis on 4% 
polyacrylamide gels.  The intensities of  the shifted bands were quantified on a PhosphorImager (Molecular Dynamics, 
Sunnyvale, CA). For competition experiments, a 200-fold molar excess of  the same unlabeled double stranded 
oligonucleotide was used. Supershifts were performed by  incubating 1 µl of  polyclonal antibodies specific for HSF-15 
with the whole cell extracts for 20 minutes at room temperature prior to the HSF-1-heat shock element binding 
reaction.
Chromatin Immunoprecipitation Assays (ChIP). Nuclear cell extracts obtained from about  3 × 107 HeLa cells were 
used for each tested condition, cross-linked for 10 minutes at room temperature with a 37% formaldehyde solution and 
sonicated for 30 sec at  4°C. Samples were immunoprecipitated with 10 µl of  a rabbit polyclonal HSF-1 #471 at  4°C 
overnight. Primers used for the human Hsp70.1, Hsp40, Hsp27 and dihydrofolate reductase promoters were the 
following:
(forward) 5′-GGCGAAACCCCTGGAATATTCCCGA-3′  and (reverse) 5′- AGCCTTGGGACAACGGGAG-3’; (forward) 5′-
GTGGTACCCTCCTCCGACCTGTG-3’ and (reverse) 5’-TACTCGAGACCCCCTCCTGCG-3’; (forward) 5′- 
CTATCTCACACGCGTGTGGTTCC-3′ and (reverse) 5′- TTAAGGAGGACAGAGCCAGACAG-3’. 
Primers used for the human dihydrofolate reductase promoter were: 
5′-GGCCTCGCCTGCACAAATAGGG-3′ (forward) and 5′- GGGCAGAAATCAGCAACGGGC-3′ (reverse).
Multiplex Gene Expression Analysis. WT and hsf-1-/- MEFs were seeded at a density  of  12,000 cells/well in 96-well 
plates with an overnight incubation at 37°C, 5% CO2. Cells were treated with serially  diluted compounds in a 7-point 
dose dependent manner. Cell lysis with 50% [v/v] Panomics Lysis Mixture (Lysis Mixture + 10 µl/ml Proteinase K) was 
performed 6 hours post-compound treatment. Lysed cells  were heated at 50°C to ensure appropriate lysing and the 
plates were then frozen at -80°C. Cell lysates,  thawed at room temperature on the day  of  the assay, were pooled with 
mouse 8-gene multiplex probe sets  and with 8 different sets of  magnetic capture beads (Luminex Technology, Austin, 
TX) in a 100 µl/well volume. Biomek FX was used at every  liquid transfer step to reduce variability  by  human error. The 
eight plates containing lysate-probe-bead mixtures were incubated at 54°C ± 1°C on a shaking platform for an 
overnight  incubation in the dark (18-20 hours). The following day  the hybridization plates were compressed by 
transferring the hybridized lysates into a single magnetic capture plate. The plate was kept on a magnet to hold the 
beads and then washed with Panomics Wash Buffer 2.0 on a BioTek ELx405 select plate washer to remove any 
unbound sample. This step was followed by  serial hybridizations and washings of  the bDNA pre-amplifier (1 hour, 
50°C), bDNA amplifier (1 hour,  50°C), label probe (1 hour, 50°C), and streptavidin-phycoerythrin (SAPE, 30 minutes, 
room temperature)6. The plate was then washed with SAPE wash buffer to remove unbound SAPE and each well was 
analyzed with the Luminex FlexMap3D (Luminex,  Austin,  TX). SAPE fluorescence measured from each bead was 
proportional to the number of  mRNA transcripts captured by  the beads7. Fold changes in gene expression were 
obtained for each gene per well by  normalizing the raw data first to the DMSO control and then to a housekeeping 
gene (TBP).
HeLa cell transfection with wild type and mutant HSE-luc. HeLa cells were plated in a white 96-well plate and 
transfected with a wild type and mutant HSE-luc plasmid using FuGENE HD transfection reagent (Roche, Indianapolis, 
IN). Cells were treated with PRs A1, A3, C1, D1, and F1 (10 µM) and then luciferase activity was measured 24 h later.
Cytoprotection and Apoptosis Analysis. HeLa cells were plated in black 96-well plates at  a density  of  10,000 cells/
well.  The cells  were treated with DMSO or the PRs A1, A3, C1, D1 and F1 (10 µM) for 1 h and then recovered for 8 h 
before a 45°C heat shock treatment for 35 min. As a control, the cells were pretreated with a 42°C heat shock for 1 h. 
Cell death was assessed 24 h later by  using the Calcein AM dye. Assessment of  apoptotic and necrotic events was 
performed using the Annexin V- FLUOS/PI Staining Kit (Roche, Indianapolis,  IN) accordingly  to the manufacturer’s 
protocol. In brief, cells were washed twice with ice-cold PBS, resuspended in binding buffer,  and incubated for 15 min 
in the dark at room temperature with Annexin V-fluorescein and PI labeling solution. Fluorescence images were 
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acquired using an Axiovert S100 TV fluorescence microscope (Carl Zeiss,  Germany) equipped with a 40x objective 
and a CoolSNAP HQ camera system (Photometrics, Tucson, AZ). All image processing and analysis was performed 
using functions in the MetaMorph software (Molecular Devices, Inc., Sunnyvale, CA). For quantification of  Annexin V-
stained cells, approximately 200 cells were counted for each treatment.
Filter  Trap Assay and Immunoblotting. The filter trap assay  was performed accordingly  to Wanker et al.8. In brief, 
cells  were lysed on ice for 30 min in filter trap lysis buffer [50 mM Tris-HCl, pH 8.8; 100 mM NaCl; 5 mM MgCl2; 0.5% 
(v/v) Nonidet P-40; and 1 mM EDTA] in presence of  protease inhibitors. Insoluble material was pelleted by 
centrifugation and resuspended in 100 µl of  20 mM Tris-HCl, 15 mM MgCl2, 0.5 mg/ml DNase I for 2 h at 37°C. Protein 
concentration of  total, soluble and insoluble fractions was determined by  the protein dotMetric assay  (G-Biosciences, 
St.  Louis, MO). 20 µg of  soluble and insoluble material was diluted into 2% SDS, boiled and added to a 48-well blot 
apparatus (Bio-Rad Laboratories, Hercules, CA) containing either a nitrocellulose or cellulose acetate membrane.  For 
western blotting, protein samples were electrophoresed by  SDS-PAGE and transferred to PVDF membranes using a 
semi-dry  apparatus. Membranes were then blocked in 5% milk for 1 h and then probed with the following primary 
antibodies: a goat monoclonal anti-GFP IR dye 800 (Rockland Immunochemicals, Gilbertsville,  PA) at 1:4,000 and a 
mouse monoclonal anti-tubulin at 1:5,000 (Sigma, St.  Louis, MO). The secondary  antibody  was an Alexa Fluor 680 
goat anti mouse IgG diluted 1:5,000 (Invitrogen, Carlsbad,  CA). Western analysis was performed with the Odyssey 
system (Li-COR, Lincoln, NE).
ΔF508-CFTR YFP Quenching Assay. Human bronchial epithelial cells (CFBE41o-) stably  expressing ΔF508-CFTR 
as well as H148Q/I152L-YFP (CFBE41o- -YFP) were added to a 96-well black walled plate and grown to confluency  in 
growth media (α-MEM containing 100 U/ml penicillin, 100 U/ml streptomycin,  10% v/v  FBS, 2mM L-glutamine, 2 µg/ml 
puromycin and 0.75 µg/ml G418).  Cells were treated with the indicated concentration of  compounds in complete 
growth media and incubated at 37°C, 5% CO2 for 24 h. Cells were subsequently  washed three times with 200 µl of 
PBS pH 7.4 (137 mM NaCl, 2.7 mM KCl, 0.7 mM CaCl2, 1.1 mM MgCl2, 1.5 mM KH2PO4, 8.1 mM Na2HPO4) and 
equilibrated in 40 µl of  PBS pH 7.4 and maintained at  37°C throughout. Cells were stimulated with a final concentration 
of  10 µM forskolin (fsk) and 50 µM genistein (gen) for 15 min prior to addition of  PBS + NaI (replacement of  NaCl with 
137 mM NaI). Fluorescence was monitored every  second for a total of  30 seconds (3 seconds prior to addition of  NaI 
and 27 seconds after addition of  NaI). Data were normalized to the initial fluorescence to account for variations in the 
overall starting fluorescence. To ensure that the observed H148Q/I152L-YFP fluorescence quenching was the result of 
ΔF508-CFTR activation and not the action of  additional halide channels, the CFTR specific inhibitor (CFInh-172) was 
used.
ΔF508-CFTR Transport Assay. CFBE41o- cells stably  expressing ΔF508-CFTR were plated in 12-well dishes and 
grown to confluence in growth media (α-MEM containing 100 U/ml penicillin,  100 U/ml streptomycin, 10% v/v  FBS, 2 
mM L-glutamine and 2 µg/ml puromycin). Cells  were treated with the indicated concentration of  compound in complete 
growth media and maintained at 37°C, 5% CO2 for 24 hrs. Cells were lysed on ice in 50 µl of  TBS (50 mM Tris-HCl pH 
7.4,  150 mM NaCl) + 1% (v/v) Triton X-100 containing 2 mg/ml of  complete protease inhibitor cocktail (Roche, 
Switzerland) for 30 min. The lysates were harvested and cleared at 20,000xg for 20 min (4°C) and the supernatant 
was collected for analysis. Equal amount of  total protein (15 µg) was separated by  SDS-PAGE (8% gel) and 
transferred to nitrocellulose. The blot was probed overnight at 4oC for CFTR (3G11 rat monoclonal antibody  at 1:500 
dilution) and indicated chaperone proteins.
C. elegans Strains.  Worms were maintained according to standard methods, at 20°C on nematode growth media 
(NGM) with OP50 E. coli (Brenner 1974).  The following strains were obtained from the C. elegans Genetic Center 
(CGC): wild-type (wt) Bristol strain N2, HSF-1 mutant hsf-1(sy441) (PS3551), temperature sensitive strains unc-52
(e669su250) and unc-45(e286) (HE250 and CB286, respectively). The polyglutamine strain expressing 35 CAG-
repeats fused with YFP (Q35::YFP) was described elsewhere (AM140 in CGC)9.
C. elegans Assays for Aggregation and Motility Defects. The treatment with chemical compounds was performed 
in a 96-well plate format, in liquid culture10. Each well contained a final volume of  60 µL, comprising 20 to 25 L2 (larval 
2 stage) age- synchronized animals, compound at  the appropriate concentration, and OP50 bacteria to a final 
OD595nm of  0.8 in the microtiter plate. Animals and bacteria were resuspended in S-medium supplemented with 
streptomycin, penicillin, and nystatin (Sigma, St.  Louis,  MO). To obtain the age synchronized population of  L2 larvae, 
gravid adults  were bleached with a NaOCl solution [250 mM NaOH and 1:4 (v/v) dilution of  commercial bleach] and the 
eggs were allowed to hatch in M9 buffer overnight at 20°C. The first larval stage (L1) animals were transferred to 
OP50 plates to allow them to develop into L2 stage (20°C). The animals were then washed with M9 buffer, 
resuspended in S- medium to the appropriate concentration, and transferred into the 96-well plates. The compounds 
were dissolved and diluted in 100% DMSO, and the animals were incubated at a maximum concentration of  1.5% 
DMSO to avoid solvent-specific developmental defects and toxicity. The range of  concentrations tested was 0, 1, 5, 10 
and 15 µM (final concentration in the well). OP50-only  and DMSO-only  controls were used. In addition, the compound 
17-(allylamino)-17-demethoxygeldanamycin (17-AAG, Biomol, Plymouth Meeting, PA) (at  the concentrations 0.5, 1, 5 
and 50 µM) was utilized as positive control for induction of  the HSR. The plates were incubated at  20°C for 4 days. 
The animals were scored for changes in aggregation (number of  fluorescent foci) using the stereomicroscope Leica 
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MZ16FA equipped for epifluorescence (Leica Microsystems, Switzerland). Suppression of  aggregation was scored 
positive when ≥50% of  the worms had a reduction in fluorescent foci number, without  loss of  body-wall fluorescence, 
compared to the DMSO control (experiments done at least in triplicate). Other phenotypes such as thrashing in liquid, 
body  size and progeny  number were also taken into account, as indicative of  animal health. Simultaneous treatment 
with RNA interference (RNAi) and compounds was also performed in liquid culture (commercial RNAi library 
GeneServiceTM, USA). RNAi for hsf-1 or the empty-vector (EV) control L4440 bacterial cultures were grown over-
night in LB-ampicillin 50 µg/ml at  37°C, and induced with 0.7 mM isopropyl β-D-thiogalatoside (IPTG) for 2.5 hours at 
37°C. Bacteria was then pelleted and resuspended in supplemented S-medium to a final OD595nm of  0.8 in the 
microtiter plate. Assay  plates were setup as before, with L2 age synchronized animals and 4 days incubation at  20°C. 
Fluorescent  microscopy images were taken using an Axiovert 200 microscope with a Hamamatsu digital camera 
C4742-98 (Carl Zeiss, Germany). For the motility  assay, animals were incubated in liquid culture with the chemical 
compounds as described above. Six days old animals were transferred from the liquid culture onto a NGM plate 
seeded with OP50 bacteria (equilibrated at 20°C) and allowed to acclimate for 1 h. At this point the animals’ movement 
was digitally  recorded using a Leica M205 FA microscope with a Hamamatsu digital camera C10600-10B (Orca-R2, 
Leica Microsystems, Switzerland), and the Hamamatsu Simple PCI Imaging software.  Movies of  45 sec were captured 
at 5 frames/s, for each condition, for a minimum of  50 animals,  and the experiment was done at least in triplicate 
(n≥150). Captured frames were merged into *.avi format and were imported directly  into ImageJ11. Using the LOCI bio-
formats plugin and a custom stack deflicker plugin (http://www.loci.wisc.edu/bio- formats/imagej), light average 
intensity  was normalized for each frame. To enhance the definition of  the animals in the movies, the difference 
between each frame and the constant  background was calculated, using the Maximum Z stack projection. The 
resulting movie was converted to binary  format using Otsu Thresholding 2. Binary  objects representing the animals 
were tracked using custom ImageJ plugin, wrMTrck (based on “MTrack2” by  Nico Stuurman)12.  The average speed of 
each animal was calculated by  dividing its body  length by  the duration of  each track (body  length per second, or 
BLPS). Motility  measurements are given as a percentage of  the wild type control strain motility, N2. Statistically 
significant  changes in motility  were obtained with **p-value < 0.01 and ***p-value<0.001 (Student’s T-test). The 
wrMTrck plugin and scripts for automated analysis are open-source and publicly  available at http://www.phage.dk/
plugins.
Semi-quantitative RT-PCR (qPCR). The small molecule treatment,  with or without RNAi, was performed at least  in 
triplicate for either N2(wt),  Q35 or hsf-1(sy441) animals. Animals were collected from the liquid cultures (96-well plates) 
into eppendorf  tubes, washed with M9 buffer,  pelleted at 3,000xg (Eppendorf  centrifuge 5424, Eppendorf) and re-
suspended in Trizol (Invitrogen, Carlsbad,  CA).  Samples were homogenized by  vortexing and incubated on ice for 10 
min.  50µl of  chloroform were added to each sample, followed by  vortexing and centrifugation at 13,500g for 15 min 
(4°C). A volume of  150µl of  2-propanol was added to each aqueous layer (10 min incubation) and total RNA was spun-
down at 18,000g (4°C) for 10 min. The pellets were washed with 75% (v/v) ethanol, air-dried and re-suspended in 
nuclease free water at  60°C for 10 min.  RNA aliquots of  10µg were used for DNase treatment (Applied Biosystems, 
Carlsbad, CA). 1µg of  purified RNA was used for cDNA synthesis (Bio-Rad,  Hercules, CA). cDNA samples were 
diluted to a final volume of  500µl in water and 1.5 µl (~10 ng) were used for real-time PCR amplification.  PCR 
measurements were performed for HSP-70 (C12C8.1, F44E5.4 and C30C11.4), small HSPs (hsp-16.1 and hsp-16.49) 
mRNA, ER HSP-70 (hsp-4), oxidative stress sod-1,  HSP-90 chaperone and co-chaperone (daf-21 and ZC395.10) and 
ubiquitin protein (ubq-2) with the following primers: 
C12C8.1.fw 5’-ACTCATGTGTCGGTATTTATCA-3’; C12C8.1.rev 5’-ACGGGCTTTCCTTGTTTT-3’; 
C30C11.4.fw 5’-GCTTCGTACTATTGTGGAATCTC-3’; C30C11.4.rev 5’-GGAGATCTTGCTTGTAGATTCC-3’; 
F44E5.4.fw 5’-GTCTTCATGCAAAGCTATTGGTATC-3’; F44E5.4.rev 5’-CGTCGTCCAATCAATCCTTTTGCATC-3’; 
hsp-16.1.fw 5’-ACTTTACCACTATTTCCGTCCAGC-3’; hsp-16.1.rev 5’-GATAATGTATGTCCATCCAAATTA-3’; 
hsp-16.49 fw 5’-CCATATTGGAGAAATGCTGATCAC-3’; hsp-16.49 rev 5’-CTTCTGGTAGAAGAATCATTTTTG-3’; 
hsp-4.fw 5’-GCAGATGATCAAGCCCAAAAAG-3’ hsp-4.rev 5’-GGAGACGATTGGTTGAACAACAG-3’; 
sod-1.fw 5’-GGACTTACTCCCGGTCTTCATG-3’; sod-1.rev 5’-GTAAAGCGTGACGAGCGTGTCG-3’; 
daf-21.fw 5’-CTTGACAAGATTCGCTACCAG-3’; daf-21.rev 5’-GCTTGAAGAGCCTCCATGAAGG-3’; 
ZC395.10.fw 5’-CTTGTCTATCTGACCATCGAGG-3’; ZC395.10.rev 5’-GGGTCTTCTTCTGAACTGTGATC-3’; 
ubq-2.fw 5’-GAATCCCACCAGATCAGCAAAG-3’; ubq-2.rev 5’-GTCGCAGTTGTACTTCTGGG-3’; 
mtl-1 fw 5’-GGCTTGCAAGTGTGACTGCAAAAACAAGC-3’; mtl-1 rev 5’-TTAATGAGCCGCAGCAGTTCCCTGGTGTTGATGG-3’ 
sod-3 fw 5’-GCTTCAAAGCTTGTTCAACCGGTTGCG-3’; sod-3 rev 5’-CAGCGCTGGTTGGAGAGCAATTGC-3’ 
gcs-1 fw 5’-GTGCAAGTGTCGACGATCGTAC-3’; gcs-1 rev 5’-GCGAATATGTTTTGCCAGTGGCTC-3’ 
gst-4 fw 5’-CGACTCCATTTGGCCAGC-3’; gst-4 rev 5’-GATCAGCGTCACTTCTAG-3’ 
pcm-1 fw 5’-CGGTTTCTGCACCTCACATG-3’;  pcm-1 rev 5’-CACGTTCCAATTGTTCACTG-3’ 
nduf-7 fw 5’-GAG GTT CAA TTT GGC CAC TGA C-3’;  nduf-7 rev 5’-CAT ATA TGC GGC GAA GTG CAG-3 
dnj-7 fw 5’-GAGCACGGATAGTACGGAC-3’; dnj-7 rev 5’-GAGGCAAGCCATCCAGTC-3’ 
ero-1 fw 5’-CGACGAAATGCAGTGAATATG-3’; ero-1 rev 5’-GTGTAGCGTTCCGGATTCTTCG-3’ 
hsp-6 fw 5’-CAGGCCGTTACCAACTCTGC-3’;  hsp-6 rev 5’-GCAGTTTCCTTCATCTTCATC-3’ 
rpn-2 fw 5’-GCC TGC AGA TTT GAC CAT CAA G-3’; rpn-2 rev 5’-CTC GTA ATC GTG TCA GCA GC-3’ 
As an internal control, we amplified mRNA of act-1 (actin) with the primers: 
act-1.fw 5’-ATCACCGCTCTTGCCCCATC-3’; act-1.rev 5’-GGCCGGACTCGTCGTATTCTTG.
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Assay for TS Phenotypes. The temperature sensitive mutant (TS) animals were age-synchronized to L1 stage, and 
grown in liquid media with or without compounds, as described before13,14. Plates were either incubated at the 
permissive temperature 15°C, or incubated at 15°C until animals reached L4 stage and then transferred to the 
restrictive temperature,  25°C. TS phenotypes were scored 2 days post-transfer to 25°C 13,14.  For abnormal body  shape 
(or stiff  paralysis) in the unc-52(e669su250), partially  paralyzed animals with moving heads and stick-like bodies were 
scored. For the egg laying defect in the unc-45(e286) animals were scored for accumulation of  eggs in the gonad and 
enlargement  of  the animal belly. For control conditions, L1 animals were grown on OP50 bacteria and DMSO at either 
15°C or 25°C and scored 2 days later for the TS phenotype. Experiment was performed in triplicate.
Proteasome Inhibition Assay.  The assay  was essentially  performed as described by  Kisselev  et al.15. In brief, HeLa 
cells  were incubated with either DMSO (negative control),  the positive controls  MG132 (10 µM) and lactacystin (6 µM) 
or the PRs A1, A3 and F1 for 3 and 6 hours and then harvested. Cells were lysed in homogenization buffer (50 mM 
Tris-HCl, pH7.5, 250 mM sucrose, 5 mM MgCl2, 2 mM ATP, 1 mM DTT, 0.5 mM EDTA, 0.025% digitonin) for 5 min on 
ice,  and total protein concentration of  whole cell extract was determined by  Bradford assay. 3 µg of  whole cell extracts 
were combined with assay  buffer (50 mM Tris-HCl, pH 7.5, 40 mM KCl, 5 mM MgCl2,  0.5 mM ATP, 1 mM DTT, 0.05 
mg/ml BSA) in a black 96-well plate and the reaction was initiated by  the addition of  a 2x (200 µM) fluorogenic peptide 
substrate Suc-LLVY-AMC (EMD Chemicals Inc., Gibbstown, NJ). Fluorescence was measured every  10 min using a 
Synergy H4 multi-mode microplate reader (BioTek, Winooski, VT).
Hsp90 Client Protein Degradation. Analysis of  Hsp90 client protein degradation was carried out using HeLa cells 
that  were treated with the indicated compounds for 6,  16 and 24 h. The same procedure described for the Western 
Blot analysis was followed. The following primary  antibodies were used: a mouse monoclonal Cdk-4 (DCS-31, Santa 
Cruz Biotechnology, Inc., Santa Cruz, CA),  a rabbit polyclonal Raf-1 (C-12, Santa Cruz Biotechnology,  Inc.,  Santa 
Cruz, CA), a rabbit polyclonal Akt (Cell Signaling Technology, Inc., Danvers,  MA) and a mouse monoclonal GAPDH 
(AbCam, Cambridge, MA). The primary  antibodies were used at the following dilutions: Cdk-4,  1:200; Raf-1, 1:500; 
Akt, 1:1,000; and GAPDH, 1:5,000.
Luciferase Renaturation Assay in Rabbit Reticulocyte Lysate. The luciferase renaturation assay  was performed 
essentially  as described previously16,17. Diluted RRL was pre-incubated with either DMSO (0.2%), 17-AAG (2 µM) or 
PR A1 (10 µM) for 30 minutes at RT before addition of denatured luciferase.
Geldanamycin Competition Assay. Human recombinant Hsp90β (2 µg) in Hsp90 binding buffer (10 mM Tris, 50 mM 
KCl,  5 mM MgCl2, 20 mM NaMoO4, 0.01% NP40) was preincubated with either DMSO, 17-AAG (1 µM) or PRs A1, A3 
and F1 (10 and 100 µM) for 30 min at 4°C before the addition of  1 µM geldanamycin-biotin (Enzo Life Sciences, 
Farmingdale, NY). Bound Hsp90 was then captured with neutravidin-agarose beads for 30 min at 4°C. The beads 
were washed with Hsp90 binding buffer, and Hsp90 was eluted from the beads by  incubating in Laemmli sample buffer 
at 95°C for 5 min.
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